US20190152974A1 - Substituted pteridines useful for the treatment and prevention of viral infections - Google Patents
Substituted pteridines useful for the treatment and prevention of viral infections Download PDFInfo
- Publication number
- US20190152974A1 US20190152974A1 US16/162,887 US201816162887A US2019152974A1 US 20190152974 A1 US20190152974 A1 US 20190152974A1 US 201816162887 A US201816162887 A US 201816162887A US 2019152974 A1 US2019152974 A1 US 2019152974A1
- Authority
- US
- United States
- Prior art keywords
- ylamine
- pteridin
- ethoxy
- morpholino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 21
- 230000009385 viral infection Effects 0.000 title claims abstract description 21
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 150000003195 pteridines Chemical class 0.000 title claims 6
- -1 2,4,6-tri-substituted pteridine Chemical class 0.000 claims abstract description 562
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000003282 alkyl amino group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 13
- 125000001769 aryl amino group Chemical group 0.000 claims description 12
- 239000003443 antiviral agent Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 10
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 229960000329 ribavirin Drugs 0.000 claims description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 9
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 9
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 8
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000005276 alkyl hydrazino group Chemical group 0.000 claims description 6
- 125000006319 alkynyl amino group Chemical group 0.000 claims description 6
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 150000007970 thio esters Chemical class 0.000 claims description 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 241000710778 Pestivirus Species 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 4
- HPQBNSNQPZYGED-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)benzonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C#N)=C1 HPQBNSNQPZYGED-UHFFFAOYSA-N 0.000 claims description 4
- IXLMMNVPRYEJNC-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzonitrile Chemical compound C=12N=C(C=3C=C(C=CC=3)C#N)C=NC2=NC(N)=NC=1N1CCOCC1 IXLMMNVPRYEJNC-UHFFFAOYSA-N 0.000 claims description 4
- JVKTXRURWOBLJS-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzonitrile Chemical compound C=12N=C(C=3C=CC(=CC=3)C#N)C=NC2=NC(N)=NC=1N1CCOCC1 JVKTXRURWOBLJS-UHFFFAOYSA-N 0.000 claims description 4
- JURKLJNTOAXTQR-UHFFFAOYSA-N 4-ethoxy-6-(1h-pyrazol-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NNC=1 JURKLJNTOAXTQR-UHFFFAOYSA-N 0.000 claims description 4
- CNTRUIBFEXHRCG-UHFFFAOYSA-N 4-ethoxy-6-(2,3,4-trifluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C(F)=C1F CNTRUIBFEXHRCG-UHFFFAOYSA-N 0.000 claims description 4
- WTGIVBAGHOAHGY-UHFFFAOYSA-N 4-ethoxy-6-(6-methoxypyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)N=C1 WTGIVBAGHOAHGY-UHFFFAOYSA-N 0.000 claims description 4
- SMTIGAWQYOYTPG-UHFFFAOYSA-N 4-ethoxy-6-(furan-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CO1 SMTIGAWQYOYTPG-UHFFFAOYSA-N 0.000 claims description 4
- WKGQDQDHXJJLMJ-UHFFFAOYSA-N 4-ethoxy-6-pyridin-4-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC=C1 WKGQDQDHXJJLMJ-UHFFFAOYSA-N 0.000 claims description 4
- XCVQXXRZFLSEGD-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1h-pyrazol-4-yl)pteridin-2-amine Chemical compound C=12N=C(C3=CNN=C3)C=NC2=NC(N)=NC=1N1CCOCC1 XCVQXXRZFLSEGD-UHFFFAOYSA-N 0.000 claims description 4
- YIDSPBGTWNGXNG-UHFFFAOYSA-N 4-morpholin-4-yl-6-pyridin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CN=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 YIDSPBGTWNGXNG-UHFFFAOYSA-N 0.000 claims description 4
- ATJWZYXETKCGJV-UHFFFAOYSA-N 6-(2,6-dimethoxypyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)N=C1OC ATJWZYXETKCGJV-UHFFFAOYSA-N 0.000 claims description 4
- BQSOFDRRDCTSHW-UHFFFAOYSA-N 6-(2,6-dimethoxypyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=NC(OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 BQSOFDRRDCTSHW-UHFFFAOYSA-N 0.000 claims description 4
- JNYPXMXHIINKJA-UHFFFAOYSA-N 6-(6-methoxypyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 JNYPXMXHIINKJA-UHFFFAOYSA-N 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 150000003556 thioamides Chemical class 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 241000711557 Hepacivirus Species 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 3
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical class 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 3
- 125000005000 thioaryl group Chemical group 0.000 claims description 3
- 150000003566 thiocarboxylic acids Chemical class 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- VQJYYAYBKBRRDJ-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-1,3-dihydro-[1,3]thiazolo[3,4-a]benzimidazole 2-oxide Chemical compound FC1=CC=CC(F)=C1C1S(=O)CC2=NC3=CC=CC=C3N12 VQJYYAYBKBRRDJ-UHFFFAOYSA-N 0.000 claims description 2
- PLXATZUIACEWPC-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)-4-methoxybenzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(OC)=CC=C1C=O PLXATZUIACEWPC-UHFFFAOYSA-N 0.000 claims description 2
- KWTVRZZEKJTEER-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)-4-methylbenzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=CC=C1C=O KWTVRZZEKJTEER-UHFFFAOYSA-N 0.000 claims description 2
- JRENBLICRYMRMG-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)-6-(2-hydroxyethyl)benzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(CCO)=C1C(N)=O JRENBLICRYMRMG-UHFFFAOYSA-N 0.000 claims description 2
- QWESGQOCXFFNJU-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)benzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C=O QWESGQOCXFFNJU-UHFFFAOYSA-N 0.000 claims description 2
- NEIRRTGZPDKWLW-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)benzenesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1S(N)(=O)=O NEIRRTGZPDKWLW-UHFFFAOYSA-N 0.000 claims description 2
- FJXYOFQRGXKTPV-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)benzonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C#N FJXYOFQRGXKTPV-UHFFFAOYSA-N 0.000 claims description 2
- QKBLLHWWZZWIKH-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 QKBLLHWWZZWIKH-UHFFFAOYSA-N 0.000 claims description 2
- QKMBWNCOIBRHRO-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 QKMBWNCOIBRHRO-UHFFFAOYSA-N 0.000 claims description 2
- FGDMEQZIKKVYQY-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)-6-(2-hydroxyethyl)benzamide Chemical compound NC(=O)C1=C(CCO)C=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 FGDMEQZIKKVYQY-UHFFFAOYSA-N 0.000 claims description 2
- IRODBUFUKTUREE-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzaldehyde Chemical compound C=12N=C(C=3C(=CC=CC=3)C=O)C=NC2=NC(N)=NC=1N1CCOCC1 IRODBUFUKTUREE-UHFFFAOYSA-N 0.000 claims description 2
- UFUFCXLDUGHGFE-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzenesulfonamide Chemical compound C=12N=C(C=3C(=CC=CC=3)S(N)(=O)=O)C=NC2=NC(N)=NC=1N1CCOCC1 UFUFCXLDUGHGFE-UHFFFAOYSA-N 0.000 claims description 2
- WVAFLTAAPWGDSI-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzonitrile Chemical compound C=12N=C(C=3C(=CC=CC=3)C#N)C=NC2=NC(N)=NC=1N1CCOCC1 WVAFLTAAPWGDSI-UHFFFAOYSA-N 0.000 claims description 2
- YHFZLKSFVRDXEA-UHFFFAOYSA-N 2-[2-(2-amino-4-ethoxypteridin-6-yl)phenoxy]acetonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1OCC#N YHFZLKSFVRDXEA-UHFFFAOYSA-N 0.000 claims description 2
- CKMDDJXGPQHYRW-UHFFFAOYSA-N 2-[2-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]acetonitrile Chemical compound C=12N=C(C=3C(=CC=CC=3)OCC#N)C=NC2=NC(N)=NC=1N1CCOCC1 CKMDDJXGPQHYRW-UHFFFAOYSA-N 0.000 claims description 2
- UBWVFGCKTRUURE-UHFFFAOYSA-N 2-[3-(2-amino-4-ethoxypteridin-6-yl)phenoxy]acetonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(OCC#N)=C1 UBWVFGCKTRUURE-UHFFFAOYSA-N 0.000 claims description 2
- LBGCJGQBRRLBBS-UHFFFAOYSA-N 2-[3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]acetonitrile Chemical compound C=12N=C(C=3C=C(OCC#N)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 LBGCJGQBRRLBBS-UHFFFAOYSA-N 0.000 claims description 2
- DFVYTQJNQDQHRI-UHFFFAOYSA-N 2-[4-(2-amino-4-ethoxypteridin-6-yl)phenoxy]acetonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OCC#N)C=C1 DFVYTQJNQDQHRI-UHFFFAOYSA-N 0.000 claims description 2
- QABVWSKJEZYWIZ-UHFFFAOYSA-N 2-[4-(2-amino-4-ethoxypteridin-6-yl)phenoxy]ethanol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OCCO)C=C1 QABVWSKJEZYWIZ-UHFFFAOYSA-N 0.000 claims description 2
- ODUPIKHRIKRJBM-UHFFFAOYSA-N 2-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]acetonitrile Chemical compound C=12N=C(C=3C=CC(OCC#N)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 ODUPIKHRIKRJBM-UHFFFAOYSA-N 0.000 claims description 2
- XYHJHCABPNVUTG-UHFFFAOYSA-N 2-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]ethanol Chemical compound C=12N=C(C=3C=CC(OCCO)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XYHJHCABPNVUTG-UHFFFAOYSA-N 0.000 claims description 2
- FMZCQBRXFMFIBX-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)-4-methoxybenzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C=O)=CC=C1OC FMZCQBRXFMFIBX-UHFFFAOYSA-N 0.000 claims description 2
- ATBHVEIMPHJWGQ-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)-n,n-diethylbenzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(=O)N(CC)CC)=C1 ATBHVEIMPHJWGQ-UHFFFAOYSA-N 0.000 claims description 2
- IYQSDRGCSMDKGU-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)-n,n-dimethylbenzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(=O)N(C)C)=C1 IYQSDRGCSMDKGU-UHFFFAOYSA-N 0.000 claims description 2
- ALGUFTKPGUNTDO-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)-n-cyclopropylbenzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=CC=1C(=O)NC1CC1 ALGUFTKPGUNTDO-UHFFFAOYSA-N 0.000 claims description 2
- YFNIPGJUZDNFHD-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)benzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C=O)=C1 YFNIPGJUZDNFHD-UHFFFAOYSA-N 0.000 claims description 2
- MAGOAFCOXZTJII-UHFFFAOYSA-N 3-(2-amino-4-ethoxypteridin-6-yl)benzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(N)=O)=C1 MAGOAFCOXZTJII-UHFFFAOYSA-N 0.000 claims description 2
- NQWRRTZPHZBNBD-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 NQWRRTZPHZBNBD-UHFFFAOYSA-N 0.000 claims description 2
- DTINQZPXTLPYSP-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 DTINQZPXTLPYSP-UHFFFAOYSA-N 0.000 claims description 2
- DYHLRKNLYJWSEC-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 DYHLRKNLYJWSEC-UHFFFAOYSA-N 0.000 claims description 2
- GNQJUEKPUGWXQV-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)-n-cyclopropylbenzamide Chemical compound C=12N=C(C=3C=C(C=CC=3)C(=O)NC3CC3)C=NC2=NC(N)=NC=1N1CCOCC1 GNQJUEKPUGWXQV-UHFFFAOYSA-N 0.000 claims description 2
- AOFDOPMJFIARSJ-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzaldehyde Chemical compound C=12N=C(C=3C=C(C=O)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 AOFDOPMJFIARSJ-UHFFFAOYSA-N 0.000 claims description 2
- WGKXQWRTLJBVSR-UHFFFAOYSA-N 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 WGKXQWRTLJBVSR-UHFFFAOYSA-N 0.000 claims description 2
- CQLZCVPZTWXLBV-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-2,6-dimethylphenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=C(O)C(C)=C1 CQLZCVPZTWXLBV-UHFFFAOYSA-N 0.000 claims description 2
- KJEWSNBISHJEHU-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-2-chloro-6-methoxyphenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Cl)=C(O)C(OC)=C1 KJEWSNBISHJEHU-UHFFFAOYSA-N 0.000 claims description 2
- GCKSBRSWUABFSF-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-2-fluorobenzoic acid Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(O)=O)C(F)=C1 GCKSBRSWUABFSF-UHFFFAOYSA-N 0.000 claims description 2
- OUUREBZGDZDGLN-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-2-methoxyphenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(O)C(OC)=C1 OUUREBZGDZDGLN-UHFFFAOYSA-N 0.000 claims description 2
- GXBKXXXASDCXDP-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-2-nitrophenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(O)C([N+]([O-])=O)=C1 GXBKXXXASDCXDP-UHFFFAOYSA-N 0.000 claims description 2
- ZMBFXKJFGUSUEU-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)benzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C=O)C=C1 ZMBFXKJFGUSUEU-UHFFFAOYSA-N 0.000 claims description 2
- IYKNWPLWJGDMBL-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)benzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(N)=O)C=C1 IYKNWPLWJGDMBL-UHFFFAOYSA-N 0.000 claims description 2
- YNRWPNFLIHKBPC-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)benzonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C#N)C=C1 YNRWPNFLIHKBPC-UHFFFAOYSA-N 0.000 claims description 2
- XBLFVSRRTOAWAV-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 XBLFVSRRTOAWAV-UHFFFAOYSA-N 0.000 claims description 2
- VSCUQJDBHXJWTK-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-chloro-6-methoxyphenol Chemical compound ClC1=C(O)C(OC)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 VSCUQJDBHXJWTK-UHFFFAOYSA-N 0.000 claims description 2
- IMAACOBVEATDFU-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-fluorobenzoic acid Chemical compound C=12N=C(C=3C=C(F)C(C(O)=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IMAACOBVEATDFU-UHFFFAOYSA-N 0.000 claims description 2
- MGHYURJFGDACAG-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 MGHYURJFGDACAG-UHFFFAOYSA-N 0.000 claims description 2
- BWSYCIDGBMQSEA-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-nitrophenol Chemical compound C=12N=C(C=3C=C(C(O)=CC=3)[N+]([O-])=O)C=NC2=NC(N)=NC=1N1CCOCC1 BWSYCIDGBMQSEA-UHFFFAOYSA-N 0.000 claims description 2
- FFNHXAGFNMAPLN-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzaldehyde Chemical compound C=12N=C(C=3C=CC(C=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 FFNHXAGFNMAPLN-UHFFFAOYSA-N 0.000 claims description 2
- TYZNSXUGQXOJBC-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 TYZNSXUGQXOJBC-UHFFFAOYSA-N 0.000 claims description 2
- STYBZBNTYOHSIF-UHFFFAOYSA-N 4-[3-(2-amino-4-ethoxypteridin-6-yl)anilino]-4-oxobutanoic acid Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(NC(=O)CCC(O)=O)=C1 STYBZBNTYOHSIF-UHFFFAOYSA-N 0.000 claims description 2
- GUNNUQXKXMGAKB-UHFFFAOYSA-N 4-[3-(2-amino-4-morpholin-4-ylpteridin-6-yl)anilino]-4-oxobutanoic acid Chemical compound C=12N=C(C=3C=C(NC(=O)CCC(O)=O)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 GUNNUQXKXMGAKB-UHFFFAOYSA-N 0.000 claims description 2
- PWYRZFPOYWUWSM-UHFFFAOYSA-N 4-[4-(2-amino-4-ethoxypteridin-6-yl)anilino]-4-oxobutanoic acid Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC(=O)CCC(O)=O)C=C1 PWYRZFPOYWUWSM-UHFFFAOYSA-N 0.000 claims description 2
- VQCAGMLKRZSCBE-UHFFFAOYSA-N 4-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)anilino]-4-oxobutanoic acid Chemical compound C=12N=C(C=3C=CC(NC(=O)CCC(O)=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 VQCAGMLKRZSCBE-UHFFFAOYSA-N 0.000 claims description 2
- BPXYJMUKHOTXBH-UHFFFAOYSA-N 4-ethoxy-6-(1,3,5-trimethylpyrazol-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C(C)=NN(C)C=1C BPXYJMUKHOTXBH-UHFFFAOYSA-N 0.000 claims description 2
- JGKWJCMWNCNCJV-UHFFFAOYSA-N 4-ethoxy-6-(1-methylindol-5-yl)pteridin-2-amine Chemical compound C1=C2N(C)C=CC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 JGKWJCMWNCNCJV-UHFFFAOYSA-N 0.000 claims description 2
- MRGPXJWFLUKZSH-UHFFFAOYSA-N 4-ethoxy-6-(1-methylpyrazol-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NN(C)C=1 MRGPXJWFLUKZSH-UHFFFAOYSA-N 0.000 claims description 2
- QNXNWHGFPLSGAE-UHFFFAOYSA-N 4-ethoxy-6-(1-phenylcyclohexa-2,4-dien-1-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1(C=2C=CC=CC=2)CC=CC=C1 QNXNWHGFPLSGAE-UHFFFAOYSA-N 0.000 claims description 2
- IFEMBJVRFRYJAQ-UHFFFAOYSA-N 4-ethoxy-6-(1-propylpyrazol-4-yl)pteridin-2-amine Chemical compound C1=NN(CCC)C=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 IFEMBJVRFRYJAQ-UHFFFAOYSA-N 0.000 claims description 2
- SBTDJDYNSKOHRJ-UHFFFAOYSA-N 4-ethoxy-6-(2,4,6-trimethylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=C(C)C=C(C)C=C1C SBTDJDYNSKOHRJ-UHFFFAOYSA-N 0.000 claims description 2
- PRUDWLWKEMKXAO-UHFFFAOYSA-N 4-ethoxy-6-(2-ethoxypyridin-3-yl)pteridin-2-amine Chemical compound CCOC1=NC=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 PRUDWLWKEMKXAO-UHFFFAOYSA-N 0.000 claims description 2
- CMELFQWLJDWEAK-UHFFFAOYSA-N 4-ethoxy-6-(2-methoxy-5-methylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=CC=C1OC CMELFQWLJDWEAK-UHFFFAOYSA-N 0.000 claims description 2
- NRFJSTQQVUVJHJ-UHFFFAOYSA-N 4-ethoxy-6-(2-methoxypyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CN=C1OC NRFJSTQQVUVJHJ-UHFFFAOYSA-N 0.000 claims description 2
- WHQOGSBYDIUQPK-UHFFFAOYSA-N 4-ethoxy-6-(2-methoxypyrimidin-5-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(OC)N=C1 WHQOGSBYDIUQPK-UHFFFAOYSA-N 0.000 claims description 2
- VBLJVYDIYUQCOI-UHFFFAOYSA-N 4-ethoxy-6-(2-methylsulfanylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1SC VBLJVYDIYUQCOI-UHFFFAOYSA-N 0.000 claims description 2
- FOYPFSRPWGMMOG-UHFFFAOYSA-N 4-ethoxy-6-(2-nitrophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1[N+]([O-])=O FOYPFSRPWGMMOG-UHFFFAOYSA-N 0.000 claims description 2
- UFXLUPBYJQRAKB-UHFFFAOYSA-N 4-ethoxy-6-(2-phenylmethoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1OCC1=CC=CC=C1 UFXLUPBYJQRAKB-UHFFFAOYSA-N 0.000 claims description 2
- FZCNKBUQFKOOOD-UHFFFAOYSA-N 4-ethoxy-6-(2-piperazin-1-ylpyridin-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=NC=1N1CCNCC1 FZCNKBUQFKOOOD-UHFFFAOYSA-N 0.000 claims description 2
- UJTSZYCGVFUPFV-UHFFFAOYSA-N 4-ethoxy-6-(3,4,5-trimethoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(OC)=C(OC)C(OC)=C1 UJTSZYCGVFUPFV-UHFFFAOYSA-N 0.000 claims description 2
- CJUFDHZUXOKCBK-UHFFFAOYSA-N 4-ethoxy-6-(3-methoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(OC)=C1 CJUFDHZUXOKCBK-UHFFFAOYSA-N 0.000 claims description 2
- UWHYVFKTKDOCEG-UHFFFAOYSA-N 4-ethoxy-6-(3-methylpyridin-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=NC=CC=C1C UWHYVFKTKDOCEG-UHFFFAOYSA-N 0.000 claims description 2
- FNEKOEORZNBLGR-UHFFFAOYSA-N 4-ethoxy-6-(3-methylsulfanylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(SC)=C1 FNEKOEORZNBLGR-UHFFFAOYSA-N 0.000 claims description 2
- OTICOKPVCUPXOC-UHFFFAOYSA-N 4-ethoxy-6-(3-nitrophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC([N+]([O-])=O)=C1 OTICOKPVCUPXOC-UHFFFAOYSA-N 0.000 claims description 2
- PHDXMGHOPZCWSB-UHFFFAOYSA-N 4-ethoxy-6-(4-methoxy-3-nitrophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)C([N+]([O-])=O)=C1 PHDXMGHOPZCWSB-UHFFFAOYSA-N 0.000 claims description 2
- RMJKOBCEYDIBEL-UHFFFAOYSA-N 4-ethoxy-6-(4-methoxy-3-phenylmethoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=C(OC)C=1OCC1=CC=CC=C1 RMJKOBCEYDIBEL-UHFFFAOYSA-N 0.000 claims description 2
- QIHCDIUPLBDLML-UHFFFAOYSA-N 4-ethoxy-6-(4-methoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)C=C1 QIHCDIUPLBDLML-UHFFFAOYSA-N 0.000 claims description 2
- KSDAGBAFHVRWOM-UHFFFAOYSA-N 4-ethoxy-6-(4-methylsulfanylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(SC)C=C1 KSDAGBAFHVRWOM-UHFFFAOYSA-N 0.000 claims description 2
- OXVRKRXUPYWXHU-UHFFFAOYSA-N 4-ethoxy-6-(4-methylthiophen-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=CS1 OXVRKRXUPYWXHU-UHFFFAOYSA-N 0.000 claims description 2
- GUDNMMRZIXHCNK-UHFFFAOYSA-N 4-ethoxy-6-(4-morpholin-4-ylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1N1CCOCC1 GUDNMMRZIXHCNK-UHFFFAOYSA-N 0.000 claims description 2
- HSFCQYUQLADIJK-UHFFFAOYSA-N 4-ethoxy-6-(4-nitrophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C([N+]([O-])=O)C=C1 HSFCQYUQLADIJK-UHFFFAOYSA-N 0.000 claims description 2
- XAOLTBVDVDVJFF-UHFFFAOYSA-N 4-ethoxy-6-(4-phenoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XAOLTBVDVDVJFF-UHFFFAOYSA-N 0.000 claims description 2
- FAYPLVNUXNKDPF-UHFFFAOYSA-N 4-ethoxy-6-(4-piperazin-1-ylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1N1CCNCC1 FAYPLVNUXNKDPF-UHFFFAOYSA-N 0.000 claims description 2
- OVGBIYHUSSUTEO-UHFFFAOYSA-N 4-ethoxy-6-(4-propan-2-yloxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC(C)C)C=C1 OVGBIYHUSSUTEO-UHFFFAOYSA-N 0.000 claims description 2
- KQXXYRFPSPBRHC-UHFFFAOYSA-N 4-ethoxy-6-(4-propan-2-ylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(C)C)C=C1 KQXXYRFPSPBRHC-UHFFFAOYSA-N 0.000 claims description 2
- XIMVUQJXHZWUPY-UHFFFAOYSA-N 4-ethoxy-6-(4-thiophen-2-ylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C1=CC=CS1 XIMVUQJXHZWUPY-UHFFFAOYSA-N 0.000 claims description 2
- WGSKNJNBIKBCGX-UHFFFAOYSA-N 4-ethoxy-6-(5-methyl-1-benzothiophen-2-yl)pteridin-2-amine Chemical compound CC1=CC=C2SC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC2=C1 WGSKNJNBIKBCGX-UHFFFAOYSA-N 0.000 claims description 2
- CCYUZNSBEKAWOQ-UHFFFAOYSA-N 4-ethoxy-6-(5-methyl-3-phenyl-1,2-oxazol-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=C(C)ON=C1C1=CC=CC=C1 CCYUZNSBEKAWOQ-UHFFFAOYSA-N 0.000 claims description 2
- MIXFBYOYZHOQBI-UHFFFAOYSA-N 4-ethoxy-6-(5-methylfuran-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C)O1 MIXFBYOYZHOQBI-UHFFFAOYSA-N 0.000 claims description 2
- OICRTFARRNECMX-UHFFFAOYSA-N 4-ethoxy-6-(5-methylpyridin-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C)C=N1 OICRTFARRNECMX-UHFFFAOYSA-N 0.000 claims description 2
- INEJHQRQHRSISI-UHFFFAOYSA-N 4-ethoxy-6-(5-methylpyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=CC(C)=C1 INEJHQRQHRSISI-UHFFFAOYSA-N 0.000 claims description 2
- DJRNVSIFLZARFO-UHFFFAOYSA-N 4-ethoxy-6-(5-methylsulfanylthiophen-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(SC)S1 DJRNVSIFLZARFO-UHFFFAOYSA-N 0.000 claims description 2
- WFAIKSBQSKRNKK-UHFFFAOYSA-N 4-ethoxy-6-(5-methylthiophen-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C)S1 WFAIKSBQSKRNKK-UHFFFAOYSA-N 0.000 claims description 2
- KWLNXSOWGFFGGD-UHFFFAOYSA-N 4-ethoxy-6-(5-phenylthiophen-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(S1)=CC=C1C1=CC=CC=C1 KWLNXSOWGFFGGD-UHFFFAOYSA-N 0.000 claims description 2
- JDZXGDNSRJJXJT-UHFFFAOYSA-N 4-ethoxy-6-(6-fluoro-5-methylpyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(F)C(C)=C1 JDZXGDNSRJJXJT-UHFFFAOYSA-N 0.000 claims description 2
- ZZTSHTUPYAXSFW-UHFFFAOYSA-N 4-ethoxy-6-(6-fluoropyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)N=C1 ZZTSHTUPYAXSFW-UHFFFAOYSA-N 0.000 claims description 2
- KEJCGHWWGGHPDZ-UHFFFAOYSA-N 4-ethoxy-6-(6-phenylmethoxynaphthalen-2-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1C=C2)=CC=C1C=C2OCC1=CC=CC=C1 KEJCGHWWGGHPDZ-UHFFFAOYSA-N 0.000 claims description 2
- LUUMJJZUIQCGSN-UHFFFAOYSA-N 4-ethoxy-6-(6-phenylmethoxypyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=N1)=CC=C1OCC1=CC=CC=C1 LUUMJJZUIQCGSN-UHFFFAOYSA-N 0.000 claims description 2
- UJISFKDZGMZKQN-UHFFFAOYSA-N 4-ethoxy-6-(6-piperazin-1-ylpyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=N1)=CC=C1N1CCNCC1 UJISFKDZGMZKQN-UHFFFAOYSA-N 0.000 claims description 2
- ASEQDAOHQRCVKC-UHFFFAOYSA-N 4-ethoxy-6-[1-(2-methylpropyl)pyrazol-4-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NN(CC(C)C)C=1 ASEQDAOHQRCVKC-UHFFFAOYSA-N 0.000 claims description 2
- GQOCITMSRWPYIQ-UHFFFAOYSA-N 4-ethoxy-6-[1-(3-methylbutyl)pyrazol-4-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NN(CCC(C)C)C=1 GQOCITMSRWPYIQ-UHFFFAOYSA-N 0.000 claims description 2
- TUDFMPHDEUAIOH-UHFFFAOYSA-N 4-ethoxy-6-[2-(2-morpholin-4-ylethyl)-1,3-dihydropyrazol-4-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C1)=CNN1CCN1CCOCC1 TUDFMPHDEUAIOH-UHFFFAOYSA-N 0.000 claims description 2
- KTSKXJNWWHDUFR-UHFFFAOYSA-N 4-ethoxy-6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=NC=1N1CCN(C)CC1 KTSKXJNWWHDUFR-UHFFFAOYSA-N 0.000 claims description 2
- XCZGRRIKIXDLSY-UHFFFAOYSA-N 4-ethoxy-6-[2-(morpholin-4-ylmethyl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1CN1CCOCC1 XCZGRRIKIXDLSY-UHFFFAOYSA-N 0.000 claims description 2
- HZMOMIMMUYHLCJ-UHFFFAOYSA-N 4-ethoxy-6-[4-(2-methylpropyl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(CC(C)C)C=C1 HZMOMIMMUYHLCJ-UHFFFAOYSA-N 0.000 claims description 2
- RRXHKCALRIQOHY-UHFFFAOYSA-N 4-ethoxy-6-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1N1CCN(C(C)C)CC1 RRXHKCALRIQOHY-UHFFFAOYSA-N 0.000 claims description 2
- IGIHRNXFMCSAQM-UHFFFAOYSA-N 4-ethoxy-6-[4-(methylamino)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC)C=C1 IGIHRNXFMCSAQM-UHFFFAOYSA-N 0.000 claims description 2
- VEODFQVLJPXGKR-UHFFFAOYSA-N 4-ethoxy-6-[4-(oxan-2-yloxy)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1OC1CCCCO1 VEODFQVLJPXGKR-UHFFFAOYSA-N 0.000 claims description 2
- WSPYPXXVGURBOS-UHFFFAOYSA-N 4-ethoxy-6-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=N1)=CC=C1NCCN1CCOCC1 WSPYPXXVGURBOS-UHFFFAOYSA-N 0.000 claims description 2
- LBNPEEPIYOJIIN-UHFFFAOYSA-N 4-ethoxy-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=N1)=CC=C1N1CCN(C)CC1 LBNPEEPIYOJIIN-UHFFFAOYSA-N 0.000 claims description 2
- FNZUAULTUGFWGW-UHFFFAOYSA-N 4-ethoxy-6-isoquinolin-4-ylpteridin-2-amine Chemical compound C1=CC=C2C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CN=CC2=C1 FNZUAULTUGFWGW-UHFFFAOYSA-N 0.000 claims description 2
- UZUKDUFDAPTOBY-UHFFFAOYSA-N 4-ethoxy-6-naphthalen-1-ylpteridin-2-amine Chemical compound C1=CC=C2C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC=CC2=C1 UZUKDUFDAPTOBY-UHFFFAOYSA-N 0.000 claims description 2
- QCDFINCLQKZDDC-UHFFFAOYSA-N 4-ethoxy-6-naphthalen-2-ylpteridin-2-amine Chemical compound C1=CC=CC2=CC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC=C21 QCDFINCLQKZDDC-UHFFFAOYSA-N 0.000 claims description 2
- DVKDQBIHJSFOCI-UHFFFAOYSA-N 4-ethoxy-6-phenoxathiin-4-ylpteridin-2-amine Chemical compound S1C2=CC=CC=C2OC2=C1C=CC=C2C1=CN=C2N=C(N)N=C(OCC)C2=N1 DVKDQBIHJSFOCI-UHFFFAOYSA-N 0.000 claims description 2
- MKIVZSJBUIDLLL-UHFFFAOYSA-N 4-ethoxy-6-quinolin-3-ylpteridin-2-amine Chemical compound C1=CC=CC2=CC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CN=C21 MKIVZSJBUIDLLL-UHFFFAOYSA-N 0.000 claims description 2
- RQBGCMKIYFRKFJ-UHFFFAOYSA-N 4-ethoxy-6-quinolin-8-ylpteridin-2-amine Chemical compound C1=CN=C2C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC=CC2=C1 RQBGCMKIYFRKFJ-UHFFFAOYSA-N 0.000 claims description 2
- BLNNJZNYXSOOBK-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1,3,5-trimethylpyrazol-4-yl)pteridin-2-amine Chemical compound CC1=NN(C)C(C)=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 BLNNJZNYXSOOBK-UHFFFAOYSA-N 0.000 claims description 2
- VHAWQXTXGJWBBA-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1-phenylcyclohexa-2,4-dien-1-yl)pteridin-2-amine Chemical compound C=12N=C(C3(C=CC=CC3)C=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 VHAWQXTXGJWBBA-UHFFFAOYSA-N 0.000 claims description 2
- KRRAYMMLBWECOA-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1-propylpyrazol-4-yl)pteridin-2-amine Chemical compound C1=NN(CCC)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 KRRAYMMLBWECOA-UHFFFAOYSA-N 0.000 claims description 2
- BRQNNYABWIGHQJ-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2,3,4-trifluorophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C(=C(F)C(F)=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 BRQNNYABWIGHQJ-UHFFFAOYSA-N 0.000 claims description 2
- OHGLMVRDKGSFCM-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2,4,6-trimethylphenyl)pteridin-2-amine Chemical compound CC1=CC(C)=CC(C)=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 OHGLMVRDKGSFCM-UHFFFAOYSA-N 0.000 claims description 2
- IOJQDLRERLCGKW-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2-nitrophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)[N+]([O-])=O)C=NC2=NC(N)=NC=1N1CCOCC1 IOJQDLRERLCGKW-UHFFFAOYSA-N 0.000 claims description 2
- XWFILXOEXCSOMF-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2-phenylmethoxyphenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)OCC=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XWFILXOEXCSOMF-UHFFFAOYSA-N 0.000 claims description 2
- WMPOTEJUMFCIFJ-UHFFFAOYSA-N 4-morpholin-4-yl-6-(2-piperazin-1-ylpyridin-4-yl)pteridin-2-amine Chemical compound C=12N=C(C=3C=C(N=CC=3)N3CCNCC3)C=NC2=NC(N)=NC=1N1CCOCC1 WMPOTEJUMFCIFJ-UHFFFAOYSA-N 0.000 claims description 2
- ZPGQIQBTVOIMMH-UHFFFAOYSA-N 4-morpholin-4-yl-6-(3,4,5-trimethoxyphenyl)pteridin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 ZPGQIQBTVOIMMH-UHFFFAOYSA-N 0.000 claims description 2
- JJNXJWCKHLVSDO-UHFFFAOYSA-N 4-morpholin-4-yl-6-(3-nitrophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=C(C=CC=3)[N+]([O-])=O)C=NC2=NC(N)=NC=1N1CCOCC1 JJNXJWCKHLVSDO-UHFFFAOYSA-N 0.000 claims description 2
- IQUUSTYURBEVGC-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-morpholin-4-ylphenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(=CC=3)N3CCOCC3)C=NC2=NC(N)=NC=1N1CCOCC1 IQUUSTYURBEVGC-UHFFFAOYSA-N 0.000 claims description 2
- ZFYHADWNQPJWOB-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-nitrophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(=CC=3)[N+]([O-])=O)C=NC2=NC(N)=NC=1N1CCOCC1 ZFYHADWNQPJWOB-UHFFFAOYSA-N 0.000 claims description 2
- IGBGIXBLMZZLID-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-phenoxyphenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IGBGIXBLMZZLID-UHFFFAOYSA-N 0.000 claims description 2
- HMHFZIINGDDPMH-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-piperazin-1-ylphenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(=CC=3)N3CCNCC3)C=NC2=NC(N)=NC=1N1CCOCC1 HMHFZIINGDDPMH-UHFFFAOYSA-N 0.000 claims description 2
- CDSXNFHEAGNIBO-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-propan-2-yloxyphenyl)pteridin-2-amine Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 CDSXNFHEAGNIBO-UHFFFAOYSA-N 0.000 claims description 2
- DCXNXLPNBOVMKN-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-propan-2-ylphenyl)pteridin-2-amine Chemical compound C1=CC(C(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 DCXNXLPNBOVMKN-UHFFFAOYSA-N 0.000 claims description 2
- ZTFQXOCJPQJMDE-UHFFFAOYSA-N 4-morpholin-4-yl-6-(4-thiophen-2-ylphenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(=CC=3)C=3SC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 ZTFQXOCJPQJMDE-UHFFFAOYSA-N 0.000 claims description 2
- LBGZSHMHMZJKIZ-UHFFFAOYSA-N 4-morpholin-4-yl-6-(5-phenylthiophen-2-yl)pteridin-2-amine Chemical compound C=12N=C(C=3SC(=CC=3)C=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 LBGZSHMHMZJKIZ-UHFFFAOYSA-N 0.000 claims description 2
- LSJVZXFIXSHIGB-UHFFFAOYSA-N 4-morpholin-4-yl-6-(6-phenylmethoxynaphthalen-2-yl)pteridin-2-amine Chemical compound C=12N=C(C=3C=C4C=CC(OCC=5C=CC=CC=5)=CC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 LSJVZXFIXSHIGB-UHFFFAOYSA-N 0.000 claims description 2
- IIAQVRSOUQLIBD-UHFFFAOYSA-N 4-morpholin-4-yl-6-(6-phenylmethoxypyridin-3-yl)pteridin-2-amine Chemical compound C=12N=C(C=3C=NC(OCC=4C=CC=CC=4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IIAQVRSOUQLIBD-UHFFFAOYSA-N 0.000 claims description 2
- NWMNLRYLMVICPA-UHFFFAOYSA-N 4-morpholin-4-yl-6-(6-piperazin-1-ylpyridin-3-yl)pteridin-2-amine Chemical compound C=12N=C(C=3C=NC(=CC=3)N3CCNCC3)C=NC2=NC(N)=NC=1N1CCOCC1 NWMNLRYLMVICPA-UHFFFAOYSA-N 0.000 claims description 2
- OZOWSNQSTWWGDT-UHFFFAOYSA-N 4-morpholin-4-yl-6-[2-(2-morpholin-4-ylethyl)-1,3-dihydropyrazol-4-yl]pteridin-2-amine Chemical compound C=12N=C(C=3CN(CCN4CCOCC4)NC=3)C=NC2=NC(N)=NC=1N1CCOCC1 OZOWSNQSTWWGDT-UHFFFAOYSA-N 0.000 claims description 2
- NKMXUQVXIILNRH-UHFFFAOYSA-N 4-morpholin-4-yl-6-[2-(morpholin-4-ylmethyl)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)CN3CCOCC3)C=NC2=NC(N)=NC=1N1CCOCC1 NKMXUQVXIILNRH-UHFFFAOYSA-N 0.000 claims description 2
- SSRJFKZXBZPJEZ-UHFFFAOYSA-N 4-morpholin-4-yl-6-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]pteridin-2-amine Chemical compound C1CN(C(C)C)CCN1C1=CC=C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)C=C1 SSRJFKZXBZPJEZ-UHFFFAOYSA-N 0.000 claims description 2
- KGSGQUHDZWWSST-UHFFFAOYSA-N 4-morpholin-4-yl-6-[4-(oxan-2-yloxy)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(OC4OCCCC4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 KGSGQUHDZWWSST-UHFFFAOYSA-N 0.000 claims description 2
- KIFLEQHDBXWJPH-UHFFFAOYSA-N 4-morpholin-4-yl-6-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]pteridin-2-amine Chemical compound C=12N=C(C=3C=NC(NCCN4CCOCC4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 KIFLEQHDBXWJPH-UHFFFAOYSA-N 0.000 claims description 2
- PSUUZCOKOMHCBI-UHFFFAOYSA-N 4-morpholin-4-yl-6-naphthalen-1-ylpteridin-2-amine Chemical compound C=12N=C(C=3C4=CC=CC=C4C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 PSUUZCOKOMHCBI-UHFFFAOYSA-N 0.000 claims description 2
- HCGZTXNSWIMZKZ-UHFFFAOYSA-N 4-morpholin-4-yl-6-naphthalen-2-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4C=CC=CC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 HCGZTXNSWIMZKZ-UHFFFAOYSA-N 0.000 claims description 2
- WETRRCHPXVNNGQ-UHFFFAOYSA-N 4-morpholin-4-yl-6-phenoxathiin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=4OC5=CC=CC=C5SC=4C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 WETRRCHPXVNNGQ-UHFFFAOYSA-N 0.000 claims description 2
- XPMBQPWYJAQIQE-UHFFFAOYSA-N 4-morpholin-4-yl-6-quinolin-3-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4C=CC=CC4=NC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XPMBQPWYJAQIQE-UHFFFAOYSA-N 0.000 claims description 2
- WBNZQHVKVWFZCP-UHFFFAOYSA-N 4-morpholin-4-yl-6-quinolin-8-ylpteridin-2-amine Chemical compound C=12N=C(C=3C4=NC=CC=C4C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 WBNZQHVKVWFZCP-UHFFFAOYSA-N 0.000 claims description 2
- ZKHZFIPDZNFTGR-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)-1h-pyridin-2-one Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(O)N=C1 ZKHZFIPDZNFTGR-UHFFFAOYSA-N 0.000 claims description 2
- ATYOUOPMOFYYPQ-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)-1h-pyrimidine-2,4-dione Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CNC(=O)NC1=O ATYOUOPMOFYYPQ-UHFFFAOYSA-N 0.000 claims description 2
- JVIZMSALFVRNNT-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)-2,3-dihydroinden-1-one Chemical compound C1=C2C(=O)CCC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 JVIZMSALFVRNNT-UHFFFAOYSA-N 0.000 claims description 2
- SAQFIJBEUQWACX-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)-2-methoxybenzaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)C(C=O)=C1 SAQFIJBEUQWACX-UHFFFAOYSA-N 0.000 claims description 2
- ATWMZTKEWLJWFT-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)furan-2-carbaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C=O)O1 ATWMZTKEWLJWFT-UHFFFAOYSA-N 0.000 claims description 2
- ZYXCIIFQYYSCPD-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)thiophene-2-carbaldehyde Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C=O)S1 ZYXCIIFQYYSCPD-UHFFFAOYSA-N 0.000 claims description 2
- XHFRXIZJNYOVBK-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)-1h-pyridin-2-one Chemical compound C=12N=C(C=3C=NC(O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XHFRXIZJNYOVBK-UHFFFAOYSA-N 0.000 claims description 2
- BAAGSLHTPUUVAW-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)-1h-pyrimidine-2,4-dione Chemical compound C=12N=C(C=3C(NC(=O)NC=3)=O)C=NC2=NC(N)=NC=1N1CCOCC1 BAAGSLHTPUUVAW-UHFFFAOYSA-N 0.000 claims description 2
- UKMUYHRWINLNHC-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2,3-dihydroinden-1-one Chemical compound C=12N=C(C=3C=C4CCC(=O)C4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 UKMUYHRWINLNHC-UHFFFAOYSA-N 0.000 claims description 2
- XWXTYYYDCVYGAF-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-methoxybenzaldehyde Chemical compound C1=C(C=O)C(OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XWXTYYYDCVYGAF-UHFFFAOYSA-N 0.000 claims description 2
- QBIUABYZKRNTIA-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)furan-2-carbaldehyde Chemical compound C=12N=C(C=3OC(C=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 QBIUABYZKRNTIA-UHFFFAOYSA-N 0.000 claims description 2
- GFXACWPKOPAAST-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)thiophene-2-carbaldehyde Chemical compound C=12N=C(C=3SC(C=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 GFXACWPKOPAAST-UHFFFAOYSA-N 0.000 claims description 2
- HLJRKBMUHJMURR-UHFFFAOYSA-N 6-(1,3-benzodioxol-2-yl)-4-ethoxypteridin-2-amine Chemical compound O1C2=CC=CC=C2OC1C1=CN=C2N=C(N)N=C(OCC)C2=N1 HLJRKBMUHJMURR-UHFFFAOYSA-N 0.000 claims description 2
- AIPYNVWJFGJHLS-UHFFFAOYSA-N 6-(1,3-benzodioxol-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C3OC4=CC=CC=C4O3)C=NC2=NC(N)=NC=1N1CCOCC1 AIPYNVWJFGJHLS-UHFFFAOYSA-N 0.000 claims description 2
- BHPMHBLZHRJKKV-UHFFFAOYSA-N 6-(1-benzothiophen-3-yl)-4-ethoxypteridin-2-amine Chemical compound C1=CC=C2C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CSC2=C1 BHPMHBLZHRJKKV-UHFFFAOYSA-N 0.000 claims description 2
- MWUNYKMAMIGPIL-UHFFFAOYSA-N 6-(1-benzothiophen-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C4=CC=CC=C4SC=3)C=NC2=NC(N)=NC=1N1CCOCC1 MWUNYKMAMIGPIL-UHFFFAOYSA-N 0.000 claims description 2
- XVPWJBVGQKJYKK-UHFFFAOYSA-N 6-(1-benzylpyrazol-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(=C1)C=NN1CC1=CC=CC=C1 XVPWJBVGQKJYKK-UHFFFAOYSA-N 0.000 claims description 2
- OHPKEZVWTHPSQZ-UHFFFAOYSA-N 6-(1-benzylpyrazol-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C3=CN(CC=4C=CC=CC=4)N=C3)C=NC2=NC(N)=NC=1N1CCOCC1 OHPKEZVWTHPSQZ-UHFFFAOYSA-N 0.000 claims description 2
- IEGCZJMEXMVUKQ-UHFFFAOYSA-N 6-(1-methylindol-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=1C=C2N(C)C=CC2=CC=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 IEGCZJMEXMVUKQ-UHFFFAOYSA-N 0.000 claims description 2
- YPJPDBUFHCTZPH-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NN(C)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 YPJPDBUFHCTZPH-UHFFFAOYSA-N 0.000 claims description 2
- OTUFHLHIFHOPSM-UHFFFAOYSA-N 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-ethoxypteridin-2-amine Chemical compound O1CCOC2=CC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC=C21 OTUFHLHIFHOPSM-UHFFFAOYSA-N 0.000 claims description 2
- GOIRUISXKKTAKX-UHFFFAOYSA-N 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4OCCOC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 GOIRUISXKKTAKX-UHFFFAOYSA-N 0.000 claims description 2
- VLGGSZYTTPWIRS-UHFFFAOYSA-N 6-(2,3-dihydro-1-benzofuran-5-yl)-4-ethoxypteridin-2-amine Chemical compound C1=C2OCCC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 VLGGSZYTTPWIRS-UHFFFAOYSA-N 0.000 claims description 2
- BMMWBMNWWXGBFD-UHFFFAOYSA-N 6-(2,3-dihydro-1-benzofuran-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4CCOC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 BMMWBMNWWXGBFD-UHFFFAOYSA-N 0.000 claims description 2
- HCPPYDJQPRRYJZ-UHFFFAOYSA-N 6-(2,4-dimethoxypyrimidin-5-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(OC)N=C1OC HCPPYDJQPRRYJZ-UHFFFAOYSA-N 0.000 claims description 2
- REDKSYJCVHJBID-UHFFFAOYSA-N 6-(2,4-dimethoxypyrimidin-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=NC(OC)=NC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 REDKSYJCVHJBID-UHFFFAOYSA-N 0.000 claims description 2
- DHEGCTFLNSUVOI-UHFFFAOYSA-N 6-(2,5-dibromopyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Br)=CN=C1Br DHEGCTFLNSUVOI-UHFFFAOYSA-N 0.000 claims description 2
- ZBQWLFXMLZSDLJ-UHFFFAOYSA-N 6-(2,5-dibromopyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=NC=C(Br)C=3)Br)C=NC2=NC(N)=NC=1N1CCOCC1 ZBQWLFXMLZSDLJ-UHFFFAOYSA-N 0.000 claims description 2
- VIKQHOQNMDBDJD-UHFFFAOYSA-N 6-(2,6-dichloropyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)N=C1Cl VIKQHOQNMDBDJD-UHFFFAOYSA-N 0.000 claims description 2
- SIBGHERPALWOMH-UHFFFAOYSA-N 6-(2,6-dichloropyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=NC(Cl)=CC=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 SIBGHERPALWOMH-UHFFFAOYSA-N 0.000 claims description 2
- COMUTVWYEMVVCP-UHFFFAOYSA-N 6-(2-amino-4-methylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C)C=C1N COMUTVWYEMVVCP-UHFFFAOYSA-N 0.000 claims description 2
- UBPPBDXQOFIBDD-UHFFFAOYSA-N 6-(2-amino-4-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound NC1=CC(C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 UBPPBDXQOFIBDD-UHFFFAOYSA-N 0.000 claims description 2
- FOVKTPNJGYNSAO-UHFFFAOYSA-N 6-(2-amino-5-chlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Cl)=CC=C1N FOVKTPNJGYNSAO-UHFFFAOYSA-N 0.000 claims description 2
- UDTJBOSSZOBLBN-UHFFFAOYSA-N 6-(2-amino-5-chlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=C(Cl)C=3)N)C=NC2=NC(N)=NC=1N1CCOCC1 UDTJBOSSZOBLBN-UHFFFAOYSA-N 0.000 claims description 2
- SAVCQNCOLCMVIK-UHFFFAOYSA-N 6-(2-amino-5-methylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=CC=C1N SAVCQNCOLCMVIK-UHFFFAOYSA-N 0.000 claims description 2
- OYSMNIXNLKNKIY-UHFFFAOYSA-N 6-(2-amino-5-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC=C(N)C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 OYSMNIXNLKNKIY-UHFFFAOYSA-N 0.000 claims description 2
- JUCCFDBPMOPNNZ-UHFFFAOYSA-N 6-(2-aminopyrimidin-5-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(N)N=C1 JUCCFDBPMOPNNZ-UHFFFAOYSA-N 0.000 claims description 2
- KXCZMOUZTOVQAT-UHFFFAOYSA-N 6-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NC(N)=NC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 KXCZMOUZTOVQAT-UHFFFAOYSA-N 0.000 claims description 2
- VXWUHVDBJHBUQF-UHFFFAOYSA-N 6-(2-bromo-3-chloropyridin-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC(Br)=C1Cl VXWUHVDBJHBUQF-UHFFFAOYSA-N 0.000 claims description 2
- MUXGMXRDDYAMMA-UHFFFAOYSA-N 6-(2-bromo-3-chloropyridin-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=C(Br)N=CC=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 MUXGMXRDDYAMMA-UHFFFAOYSA-N 0.000 claims description 2
- HLSNEPNMMYLGDD-UHFFFAOYSA-N 6-(2-chloro-3-fluoropyridin-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC(Cl)=C1F HLSNEPNMMYLGDD-UHFFFAOYSA-N 0.000 claims description 2
- WTKNNZIDGAYQQL-UHFFFAOYSA-N 6-(2-chloro-3-fluoropyridin-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=C(Cl)N=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 WTKNNZIDGAYQQL-UHFFFAOYSA-N 0.000 claims description 2
- JMBSCCCQJYKQQP-UHFFFAOYSA-N 6-(2-chloro-6-propan-2-ylpyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(C)C)N=C1Cl JMBSCCCQJYKQQP-UHFFFAOYSA-N 0.000 claims description 2
- UWZSAUQNTCADAQ-UHFFFAOYSA-N 6-(2-chloro-6-propan-2-ylpyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound ClC1=NC(C(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 UWZSAUQNTCADAQ-UHFFFAOYSA-N 0.000 claims description 2
- HMFXNLQRQHLPRC-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC(Cl)=C1 HMFXNLQRQHLPRC-UHFFFAOYSA-N 0.000 claims description 2
- VFKQXCHEHAPCNV-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Cl)N=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 VFKQXCHEHAPCNV-UHFFFAOYSA-N 0.000 claims description 2
- OZSGBLXWKKEELP-UHFFFAOYSA-N 6-(2-ethoxypyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CCOC1=NC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 OZSGBLXWKKEELP-UHFFFAOYSA-N 0.000 claims description 2
- UAIPWZZNCKQMMQ-UHFFFAOYSA-N 6-(2-methoxy-5-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=CC=C(C)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 UAIPWZZNCKQMMQ-UHFFFAOYSA-N 0.000 claims description 2
- XBYRWWCICDYEKL-UHFFFAOYSA-N 6-(2-methoxypyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=NC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XBYRWWCICDYEKL-UHFFFAOYSA-N 0.000 claims description 2
- FUBZDVQDHYPUMV-UHFFFAOYSA-N 6-(2-methoxypyrimidin-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NC(OC)=NC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 FUBZDVQDHYPUMV-UHFFFAOYSA-N 0.000 claims description 2
- DZTHJHJLGLRWCC-UHFFFAOYSA-N 6-(2-methylsulfanylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CSC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 DZTHJHJLGLRWCC-UHFFFAOYSA-N 0.000 claims description 2
- PDEXDIHPDPHCBA-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)-4-ethoxypteridin-2-amine Chemical compound O1CCCOC2=CC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC=C21 PDEXDIHPDPHCBA-UHFFFAOYSA-N 0.000 claims description 2
- XLXRHIDVVPYXBZ-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4OCCCOC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XLXRHIDVVPYXBZ-UHFFFAOYSA-N 0.000 claims description 2
- HTAFJGXCIQNHGX-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C(C)=NOC=1C HTAFJGXCIQNHGX-UHFFFAOYSA-N 0.000 claims description 2
- DFAWADCIZACSEO-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=NOC(C)=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 DFAWADCIZACSEO-UHFFFAOYSA-N 0.000 claims description 2
- LQDINWMQFGJUID-UHFFFAOYSA-N 6-(3,5-dimethyl-1h-pyrazol-4-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C(C)=NNC=1C LQDINWMQFGJUID-UHFFFAOYSA-N 0.000 claims description 2
- IDGGWNOWAZHUBW-UHFFFAOYSA-N 6-(3,5-dimethyl-1h-pyrazol-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=NNC(C)=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 IDGGWNOWAZHUBW-UHFFFAOYSA-N 0.000 claims description 2
- GTTLNAMJDOARFB-UHFFFAOYSA-N 6-(3-methoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 GTTLNAMJDOARFB-UHFFFAOYSA-N 0.000 claims description 2
- HVDYUPLXTVYSBM-UHFFFAOYSA-N 6-(3-methylpyridin-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC=CN=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 HVDYUPLXTVYSBM-UHFFFAOYSA-N 0.000 claims description 2
- ZDMZNMWJLUIWLD-UHFFFAOYSA-N 6-(3-methylsulfanylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CSC1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 ZDMZNMWJLUIWLD-UHFFFAOYSA-N 0.000 claims description 2
- WBNYJPZQBJMISE-UHFFFAOYSA-N 6-(4-amino-2-methylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N)C=C1C WBNYJPZQBJMISE-UHFFFAOYSA-N 0.000 claims description 2
- LGQIZDUECUNZTF-UHFFFAOYSA-N 6-(4-amino-2-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC(N)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 LGQIZDUECUNZTF-UHFFFAOYSA-N 0.000 claims description 2
- DERKKFNSRSBJTR-UHFFFAOYSA-N 6-(4-amino-3-methoxyphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N)C(OC)=C1 DERKKFNSRSBJTR-UHFFFAOYSA-N 0.000 claims description 2
- VTPVJVYLSHHXGB-UHFFFAOYSA-N 6-(4-amino-3-methoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=C(N)C(OC)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 VTPVJVYLSHHXGB-UHFFFAOYSA-N 0.000 claims description 2
- RLSNUCRPYNMYGG-UHFFFAOYSA-N 6-(4-amino-3-nitrophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N)C([N+]([O-])=O)=C1 RLSNUCRPYNMYGG-UHFFFAOYSA-N 0.000 claims description 2
- YYDPZHBHUWIIIQ-UHFFFAOYSA-N 6-(4-amino-3-nitrophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(C(N)=CC=3)[N+]([O-])=O)C=NC2=NC(N)=NC=1N1CCOCC1 YYDPZHBHUWIIIQ-UHFFFAOYSA-N 0.000 claims description 2
- LUJHIIWCUXWMFV-UHFFFAOYSA-N 6-(4-butylphenyl)-4-ethoxypteridin-2-amine Chemical compound C1=CC(CCCC)=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 LUJHIIWCUXWMFV-UHFFFAOYSA-N 0.000 claims description 2
- KUPKMWQWPRNSNR-UHFFFAOYSA-N 6-(4-butylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(CCCC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 KUPKMWQWPRNSNR-UHFFFAOYSA-N 0.000 claims description 2
- XVAWJRAPKVQENP-UHFFFAOYSA-N 6-(4-ethenylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C=C)C=C1 XVAWJRAPKVQENP-UHFFFAOYSA-N 0.000 claims description 2
- QKUYZYJQTVBXRL-UHFFFAOYSA-N 6-(4-ethenylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CC(C=C)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 QKUYZYJQTVBXRL-UHFFFAOYSA-N 0.000 claims description 2
- HLSOUIGLAUAMSV-UHFFFAOYSA-N 6-(4-methoxy-3-nitrophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 HLSOUIGLAUAMSV-UHFFFAOYSA-N 0.000 claims description 2
- QHENZLDSWGQHGH-UHFFFAOYSA-N 6-(4-methoxy-3-phenylmethoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=CC=C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)C=C1OCC1=CC=CC=C1 QHENZLDSWGQHGH-UHFFFAOYSA-N 0.000 claims description 2
- UMIKXAFNBRZUCM-UHFFFAOYSA-N 6-(4-methoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 UMIKXAFNBRZUCM-UHFFFAOYSA-N 0.000 claims description 2
- IHIUGXYZTQAYSV-UHFFFAOYSA-N 6-(4-methylsulfanylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(SC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 IHIUGXYZTQAYSV-UHFFFAOYSA-N 0.000 claims description 2
- OZRXWYMPTVNADH-UHFFFAOYSA-N 6-(4-methylthiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CSC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 OZRXWYMPTVNADH-UHFFFAOYSA-N 0.000 claims description 2
- PNSWPPOQCWFLPN-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(C)(C)C)C=C1 PNSWPPOQCWFLPN-UHFFFAOYSA-N 0.000 claims description 2
- MAUPVJDKJOJNOU-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 MAUPVJDKJOJNOU-UHFFFAOYSA-N 0.000 claims description 2
- HLTPSRNTVWCNOL-UHFFFAOYSA-N 6-(5-amino-2-methylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(N)=CC=C1C HLTPSRNTVWCNOL-UHFFFAOYSA-N 0.000 claims description 2
- URFPASPPVGSMJK-UHFFFAOYSA-N 6-(5-amino-2-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC=C(N)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 URFPASPPVGSMJK-UHFFFAOYSA-N 0.000 claims description 2
- IONJBWUKHVSMAL-UHFFFAOYSA-N 6-(5-bromo-2,3-dihydro-1-benzofuran-7-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Br)=CC2=C1OCC2 IONJBWUKHVSMAL-UHFFFAOYSA-N 0.000 claims description 2
- RVNFYJSIUXLGFX-UHFFFAOYSA-N 6-(5-bromo-2,3-dihydro-1-benzofuran-7-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=4OCCC=4C=C(Br)C=3)C=NC2=NC(N)=NC=1N1CCOCC1 RVNFYJSIUXLGFX-UHFFFAOYSA-N 0.000 claims description 2
- RJXHFZVEDDUTPE-UHFFFAOYSA-N 6-(5-bromopyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=CC(Br)=C1 RJXHFZVEDDUTPE-UHFFFAOYSA-N 0.000 claims description 2
- STNYXOCYENYOTA-UHFFFAOYSA-N 6-(5-bromopyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Br)C=NC=3)C=NC2=NC(N)=NC=1N1CCOCC1 STNYXOCYENYOTA-UHFFFAOYSA-N 0.000 claims description 2
- CCMFMLWBMNSCQA-UHFFFAOYSA-N 6-(5-bromothiophen-2-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Br)S1 CCMFMLWBMNSCQA-UHFFFAOYSA-N 0.000 claims description 2
- PMDWOSLKJFUSDU-UHFFFAOYSA-N 6-(5-bromothiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3SC(Br)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 PMDWOSLKJFUSDU-UHFFFAOYSA-N 0.000 claims description 2
- KEILUMFXFRIPPU-UHFFFAOYSA-N 6-(5-methyl-1-benzothiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=1C2=CC(C)=CC=C2SC=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 KEILUMFXFRIPPU-UHFFFAOYSA-N 0.000 claims description 2
- ZJWKLFBQEJSPRZ-UHFFFAOYSA-N 6-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 ZJWKLFBQEJSPRZ-UHFFFAOYSA-N 0.000 claims description 2
- NYKUQOPLRQFGJB-UHFFFAOYSA-N 6-(5-methylfuran-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound O1C(C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 NYKUQOPLRQFGJB-UHFFFAOYSA-N 0.000 claims description 2
- RDMKQYICWAGUMF-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound N1=CC(C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 RDMKQYICWAGUMF-UHFFFAOYSA-N 0.000 claims description 2
- MZXFIJZTGMFAPL-UHFFFAOYSA-N 6-(5-methylpyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CN=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 MZXFIJZTGMFAPL-UHFFFAOYSA-N 0.000 claims description 2
- PYLPUPHEIDPQKM-UHFFFAOYSA-N 6-(5-methylsulfanylthiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound S1C(SC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 PYLPUPHEIDPQKM-UHFFFAOYSA-N 0.000 claims description 2
- WWGKACXEYOXWNG-UHFFFAOYSA-N 6-(5-methylthiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound S1C(C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 WWGKACXEYOXWNG-UHFFFAOYSA-N 0.000 claims description 2
- INISBMRISVNGQU-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N)N=C1 INISBMRISVNGQU-UHFFFAOYSA-N 0.000 claims description 2
- SECHRNXJEBQJLX-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 SECHRNXJEBQJLX-UHFFFAOYSA-N 0.000 claims description 2
- RAMWRTUCPNHDMM-UHFFFAOYSA-N 6-(6-bromo-5-methylpyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(Br)C(C)=C1 RAMWRTUCPNHDMM-UHFFFAOYSA-N 0.000 claims description 2
- LXIFPTHWPBZEJG-UHFFFAOYSA-N 6-(6-bromo-5-methylpyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound N1=C(Br)C(C)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 LXIFPTHWPBZEJG-UHFFFAOYSA-N 0.000 claims description 2
- SAPLZFDMOCSPBX-UHFFFAOYSA-N 6-(6-bromopyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Br)N=C1 SAPLZFDMOCSPBX-UHFFFAOYSA-N 0.000 claims description 2
- RZUOPBPYVWEVKY-UHFFFAOYSA-N 6-(6-bromopyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC(Br)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 RZUOPBPYVWEVKY-UHFFFAOYSA-N 0.000 claims description 2
- JEZABJMRNOYVQL-UHFFFAOYSA-N 6-(6-chloro-5-methylpyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(Cl)C(C)=C1 JEZABJMRNOYVQL-UHFFFAOYSA-N 0.000 claims description 2
- IRCPTSVZLOJXRY-UHFFFAOYSA-N 6-(6-chloro-5-methylpyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound N1=C(Cl)C(C)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 IRCPTSVZLOJXRY-UHFFFAOYSA-N 0.000 claims description 2
- AIFVXDMJBUBXIE-UHFFFAOYSA-N 6-(6-chloropyridin-3-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)N=C1 AIFVXDMJBUBXIE-UHFFFAOYSA-N 0.000 claims description 2
- KOEXDTSNKXNHPU-UHFFFAOYSA-N 6-(6-chloropyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC(Cl)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 KOEXDTSNKXNHPU-UHFFFAOYSA-N 0.000 claims description 2
- XSWDCPPPDSPOBL-UHFFFAOYSA-N 6-(6-fluoropyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC(F)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XSWDCPPPDSPOBL-UHFFFAOYSA-N 0.000 claims description 2
- CYJRFCGZNYQWRC-UHFFFAOYSA-N 6-(furan-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3OC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 CYJRFCGZNYQWRC-UHFFFAOYSA-N 0.000 claims description 2
- KXWYQSGQHGVKPB-UHFFFAOYSA-N 6-[1-(1,3-dioxolan-2-ylmethyl)pyrazol-4-yl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(=C1)C=NN1CC1OCCO1 KXWYQSGQHGVKPB-UHFFFAOYSA-N 0.000 claims description 2
- QIXUHHBBKGXZBO-UHFFFAOYSA-N 6-[1-(1,3-dioxolan-2-ylmethyl)pyrazol-4-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C3=CN(CC4OCCO4)N=C3)C=NC2=NC(N)=NC=1N1CCOCC1 QIXUHHBBKGXZBO-UHFFFAOYSA-N 0.000 claims description 2
- JGUGCHQXJLWTHC-UHFFFAOYSA-N 6-[1-(2-methylpropyl)pyrazol-4-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NN(CC(C)C)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 JGUGCHQXJLWTHC-UHFFFAOYSA-N 0.000 claims description 2
- XLENGHOCRXROCU-UHFFFAOYSA-N 6-[1-(3-methylbutyl)pyrazol-4-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=NN(CCC(C)C)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XLENGHOCRXROCU-UHFFFAOYSA-N 0.000 claims description 2
- MKVWFZRIAKEAFM-UHFFFAOYSA-N 6-[1-(benzenesulfonyl)indol-3-yl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C1=CC=CC=C11)=CN1S(=O)(=O)C1=CC=CC=C1 MKVWFZRIAKEAFM-UHFFFAOYSA-N 0.000 claims description 2
- ALXYESMCTWBVES-UHFFFAOYSA-N 6-[1-(benzenesulfonyl)indol-3-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C4=CC=CC=C4N(C=3)S(=O)(=O)C=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 ALXYESMCTWBVES-UHFFFAOYSA-N 0.000 claims description 2
- SRDQVLPASQVQND-UHFFFAOYSA-N 6-[2,4-bis[(2-methylpropan-2-yl)oxy]pyrimidin-5-yl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=C(OC(C)(C)C)N=C1OC(C)(C)C SRDQVLPASQVQND-UHFFFAOYSA-N 0.000 claims description 2
- WIKDGSNQLPAPDJ-UHFFFAOYSA-N 6-[2,4-bis[(2-methylpropan-2-yl)oxy]pyrimidin-5-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound CC(C)(C)OC1=NC(OC(C)(C)C)=NC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 WIKDGSNQLPAPDJ-UHFFFAOYSA-N 0.000 claims description 2
- YYMDXCWIPHRFLH-UHFFFAOYSA-N 6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1CN(C)CCN1C1=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=CC=N1 YYMDXCWIPHRFLH-UHFFFAOYSA-N 0.000 claims description 2
- VDKPIXPNHIBYHV-UHFFFAOYSA-N 6-[2-(dimethylamino)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1N(C)C VDKPIXPNHIBYHV-UHFFFAOYSA-N 0.000 claims description 2
- OLKQDABWSRZVPE-UHFFFAOYSA-N 6-[3-(1,3-dioxolan-2-ylmethoxy)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=CC=1OCC1OCCO1 OLKQDABWSRZVPE-UHFFFAOYSA-N 0.000 claims description 2
- VZPOSTPXYXYHPS-UHFFFAOYSA-N 6-[3-(1,3-dioxolan-2-ylmethoxy)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(OCC4OCCO4)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 VZPOSTPXYXYHPS-UHFFFAOYSA-N 0.000 claims description 2
- OQACBCQWGYBXIU-UHFFFAOYSA-N 6-[3-(dimethylamino)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(N(C)C)=C1 OQACBCQWGYBXIU-UHFFFAOYSA-N 0.000 claims description 2
- JTOOYTVGQJHPCV-UHFFFAOYSA-N 6-[3-(dimethylamino)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound CN(C)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 JTOOYTVGQJHPCV-UHFFFAOYSA-N 0.000 claims description 2
- JQPADLPGMSTVTN-UHFFFAOYSA-N 6-[4-(2-methylpropyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(CC(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 JQPADLPGMSTVTN-UHFFFAOYSA-N 0.000 claims description 2
- KAONRYKQAJDQQJ-UHFFFAOYSA-N 6-[4-(anilinomethyl)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1CNC1=CC=CC=C1 KAONRYKQAJDQQJ-UHFFFAOYSA-N 0.000 claims description 2
- SFLGQGSTFLCVOY-UHFFFAOYSA-N 6-[4-(anilinomethyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CC(CNC=4C=CC=CC=4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 SFLGQGSTFLCVOY-UHFFFAOYSA-N 0.000 claims description 2
- AVMIAYGMPXPAHS-UHFFFAOYSA-N 6-[4-(methylamino)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(NC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 AVMIAYGMPXPAHS-UHFFFAOYSA-N 0.000 claims description 2
- WXATWGWLRVUBNW-UHFFFAOYSA-N 6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)C=N1 WXATWGWLRVUBNW-UHFFFAOYSA-N 0.000 claims description 2
- SIQXOVXBPOVSAT-UHFFFAOYSA-N 6-[6-[4-(4-chlorophenyl)sulfonylpiperazin-1-yl]pyridin-3-yl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=N1)=CC=C1N(CC1)CCN1S(=O)(=O)C1=CC=C(Cl)C=C1 SIQXOVXBPOVSAT-UHFFFAOYSA-N 0.000 claims description 2
- SWWPWEQICONGFL-UHFFFAOYSA-N 6-[6-[4-(4-chlorophenyl)sulfonylpiperazin-1-yl]pyridin-3-yl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC(=CC=3)N3CCN(CC3)S(=O)(=O)C=3C=CC(Cl)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 SWWPWEQICONGFL-UHFFFAOYSA-N 0.000 claims description 2
- OAWQNDOEDKYWFN-UHFFFAOYSA-N 6-dibenzofuran-4-yl-4-ethoxypteridin-2-amine Chemical compound C12=CC=CC=C2OC2=C1C=CC=C2C1=CN=C2N=C(N)N=C(OCC)C2=N1 OAWQNDOEDKYWFN-UHFFFAOYSA-N 0.000 claims description 2
- SIVLOGIKZKTVEZ-UHFFFAOYSA-N 6-dibenzofuran-4-yl-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=4OC5=CC=CC=C5C=4C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 SIVLOGIKZKTVEZ-UHFFFAOYSA-N 0.000 claims description 2
- MFKVOOKVSATKGH-UHFFFAOYSA-N 6-dibenzothiophen-4-yl-4-ethoxypteridin-2-amine Chemical compound C12=CC=CC=C2SC2=C1C=CC=C2C1=CN=C2N=C(N)N=C(OCC)C2=N1 MFKVOOKVSATKGH-UHFFFAOYSA-N 0.000 claims description 2
- YUNMYGJSYSHOOD-UHFFFAOYSA-N 6-dibenzothiophen-4-yl-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=4SC5=CC=CC=C5C=4C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 YUNMYGJSYSHOOD-UHFFFAOYSA-N 0.000 claims description 2
- CAUGSOKQMKSAGT-UHFFFAOYSA-N 6-isoquinolin-4-yl-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C4=CC=CC=C4C=NC=3)C=NC2=NC(N)=NC=1N1CCOCC1 CAUGSOKQMKSAGT-UHFFFAOYSA-N 0.000 claims description 2
- WDWNCCONMFUIFF-UHFFFAOYSA-N CCOC1=NC(N)=NC2=NC=C(C(C=C3)=C[S+]3C3=CC=CC4=C3SC3=CC=CC=C3S4)N=C12 Chemical compound CCOC1=NC(N)=NC2=NC=C(C(C=C3)=C[S+]3C3=CC=CC4=C3SC3=CC=CC=C3S4)N=C12 WDWNCCONMFUIFF-UHFFFAOYSA-N 0.000 claims description 2
- POOMTUWUKOBKHA-UHFFFAOYSA-N NC(N=C1N=C2)=NC(N3CCOCC3)=C1N=C2C(C=C1)=C[S+]1C1=CC=CC2=C1SC1=CC=CC=C1S2 Chemical compound NC(N=C1N=C2)=NC(N3CCOCC3)=C1N=C2C(C=C1)=C[S+]1C1=CC=CC2=C1SC1=CC=CC=C1S2 POOMTUWUKOBKHA-UHFFFAOYSA-N 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- ZBCHBONXTGHXCM-UHFFFAOYSA-N [(hydroxyamino)-nitrosulfanylamino] cyanoformate Chemical class [N+](=O)([O-])SN(OC(=O)C#N)NO ZBCHBONXTGHXCM-UHFFFAOYSA-N 0.000 claims description 2
- VVTJGHROSDJGNP-UHFFFAOYSA-N [3-(2-amino-4-ethoxypteridin-6-yl)-4-chlorophenyl]methanol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(CO)=CC=C1Cl VVTJGHROSDJGNP-UHFFFAOYSA-N 0.000 claims description 2
- PRGXPXOEWJKBPE-UHFFFAOYSA-N [3-(2-amino-4-ethoxypteridin-6-yl)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 PRGXPXOEWJKBPE-UHFFFAOYSA-N 0.000 claims description 2
- MLPGOPKJTGAPGA-UHFFFAOYSA-N [3-(2-amino-4-ethoxypteridin-6-yl)phenyl]methanol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(CO)=C1 MLPGOPKJTGAPGA-UHFFFAOYSA-N 0.000 claims description 2
- WIGOHZIPDQFNDV-UHFFFAOYSA-N [3-(2-amino-4-morpholin-4-ylpteridin-6-yl)-4-chlorophenyl]methanol Chemical compound C=12N=C(C=3C(=CC=C(CO)C=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 WIGOHZIPDQFNDV-UHFFFAOYSA-N 0.000 claims description 2
- HBKIYDFZJCOMEC-UHFFFAOYSA-N [3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 HBKIYDFZJCOMEC-UHFFFAOYSA-N 0.000 claims description 2
- IHTMQFJYABLLOR-UHFFFAOYSA-N [3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]methanol Chemical compound C=12N=C(C=3C=C(CO)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IHTMQFJYABLLOR-UHFFFAOYSA-N 0.000 claims description 2
- KFLQUUJALIKFFB-UHFFFAOYSA-N [4-(2-amino-4-ethoxypteridin-6-yl)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 KFLQUUJALIKFFB-UHFFFAOYSA-N 0.000 claims description 2
- UNGOOYCKDNGTNE-UHFFFAOYSA-N [4-(2-amino-4-ethoxypteridin-6-yl)phenyl]-morpholin-4-ylmethanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(=O)N1CCOCC1 UNGOOYCKDNGTNE-UHFFFAOYSA-N 0.000 claims description 2
- OCOFMVRNEFYHOO-UHFFFAOYSA-N [4-(2-amino-4-ethoxypteridin-6-yl)phenyl]-phenylmethanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 OCOFMVRNEFYHOO-UHFFFAOYSA-N 0.000 claims description 2
- ORWVDGMEMGCQNF-UHFFFAOYSA-N [4-(2-amino-4-ethoxypteridin-6-yl)phenyl]-piperazin-1-ylmethanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(=O)N1CCNCC1 ORWVDGMEMGCQNF-UHFFFAOYSA-N 0.000 claims description 2
- YUQMCAGSFFVAAQ-UHFFFAOYSA-N [4-(2-amino-4-ethoxypteridin-6-yl)phenyl]methanol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(CO)C=C1 YUQMCAGSFFVAAQ-UHFFFAOYSA-N 0.000 claims description 2
- OLFOGMTUCDBDTL-UHFFFAOYSA-N [4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)C=C1 OLFOGMTUCDBDTL-UHFFFAOYSA-N 0.000 claims description 2
- AFECKDKDORPZBL-UHFFFAOYSA-N [4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-morpholin-4-ylmethanone Chemical compound C=12N=C(C=3C=CC(=CC=3)C(=O)N3CCOCC3)C=NC2=NC(N)=NC=1N1CCOCC1 AFECKDKDORPZBL-UHFFFAOYSA-N 0.000 claims description 2
- ZXCVIBIMSZLONX-UHFFFAOYSA-N [4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-phenylmethanone Chemical compound C=12N=C(C=3C=CC(=CC=3)C(=O)C=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 ZXCVIBIMSZLONX-UHFFFAOYSA-N 0.000 claims description 2
- GPVLLHXUFBAYAN-UHFFFAOYSA-N [4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-piperazin-1-ylmethanone Chemical compound C=12N=C(C=3C=CC(=CC=3)C(=O)N3CCNCC3)C=NC2=NC(N)=NC=1N1CCOCC1 GPVLLHXUFBAYAN-UHFFFAOYSA-N 0.000 claims description 2
- QEAHADKHTAOVEL-UHFFFAOYSA-N [4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]methanol Chemical compound C=12N=C(C=3C=CC(CO)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 QEAHADKHTAOVEL-UHFFFAOYSA-N 0.000 claims description 2
- OVWWLUUCEXWKMU-UHFFFAOYSA-N [4-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]phenyl]-phenylmethanone Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 OVWWLUUCEXWKMU-UHFFFAOYSA-N 0.000 claims description 2
- HAWWHUXNLNAMQJ-UHFFFAOYSA-N [4-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]phenyl]-phenylmethanone Chemical compound C=12N=C(C=3C=CC(=CC=3)C=3C=CC(=CC=3)C(=O)C=3C=CC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 HAWWHUXNLNAMQJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005362 aryl sulfone group Chemical group 0.000 claims description 2
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 125000005026 carboxyaryl group Chemical group 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- NFCHWLLMZQFMBS-UHFFFAOYSA-N ethyl 2-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 NFCHWLLMZQFMBS-UHFFFAOYSA-N 0.000 claims description 2
- DOCQOSYIKBOUAC-UHFFFAOYSA-N ethyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 DOCQOSYIKBOUAC-UHFFFAOYSA-N 0.000 claims description 2
- MFOUQKCHAUDXPP-UHFFFAOYSA-N ethyl 2-[3-(2-amino-4-ethoxypteridin-6-yl)phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC(C=2N=C3C(OCC)=NC(N)=NC3=NC=2)=C1 MFOUQKCHAUDXPP-UHFFFAOYSA-N 0.000 claims description 2
- DHZYIGVQONVMAI-UHFFFAOYSA-N ethyl 2-[3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 DHZYIGVQONVMAI-UHFFFAOYSA-N 0.000 claims description 2
- TYIVXFDRCYLHCR-UHFFFAOYSA-N ethyl 2-[4-(2-amino-4-ethoxypteridin-6-yl)phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 TYIVXFDRCYLHCR-UHFFFAOYSA-N 0.000 claims description 2
- HGTKHBKFWJJDAJ-UHFFFAOYSA-N ethyl 2-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 HGTKHBKFWJJDAJ-UHFFFAOYSA-N 0.000 claims description 2
- YWSYAHVTWVCSOV-UHFFFAOYSA-N ethyl 3-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C3C(OCC)=NC(N)=NC3=NC=2)=C1 YWSYAHVTWVCSOV-UHFFFAOYSA-N 0.000 claims description 2
- MNFIZMAPWDXVSC-UHFFFAOYSA-N ethyl 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 MNFIZMAPWDXVSC-UHFFFAOYSA-N 0.000 claims description 2
- AWNPBGLBPMJGEM-UHFFFAOYSA-N ethyl 4-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 AWNPBGLBPMJGEM-UHFFFAOYSA-N 0.000 claims description 2
- QBPOLZPPMSXZBT-UHFFFAOYSA-N ethyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 QBPOLZPPMSXZBT-UHFFFAOYSA-N 0.000 claims description 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 2
- VCCHOUMXWMFOLU-UHFFFAOYSA-N methyl 2-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C(=O)OC VCCHOUMXWMFOLU-UHFFFAOYSA-N 0.000 claims description 2
- MOGPIDINKTYUCM-UHFFFAOYSA-N methyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 MOGPIDINKTYUCM-UHFFFAOYSA-N 0.000 claims description 2
- IXEWTFUEHJLCOP-UHFFFAOYSA-N methyl 3-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(=O)OC)=C1 IXEWTFUEHJLCOP-UHFFFAOYSA-N 0.000 claims description 2
- QFKWNAWSIKJOJT-UHFFFAOYSA-N methyl 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 QFKWNAWSIKJOJT-UHFFFAOYSA-N 0.000 claims description 2
- ZWRISYFIPXSNIW-UHFFFAOYSA-N methyl 4-(2-amino-4-ethoxypteridin-6-yl)-2-hydroxybenzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(=O)OC)C(O)=C1 ZWRISYFIPXSNIW-UHFFFAOYSA-N 0.000 claims description 2
- HYATUZNOWYUXQG-UHFFFAOYSA-N methyl 4-(2-amino-4-ethoxypteridin-6-yl)-2-methoxybenzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(=O)OC)C(OC)=C1 HYATUZNOWYUXQG-UHFFFAOYSA-N 0.000 claims description 2
- SWJXVJKBGOKGFB-UHFFFAOYSA-N methyl 4-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(=O)OC)C=C1 SWJXVJKBGOKGFB-UHFFFAOYSA-N 0.000 claims description 2
- LKLFVAIKLADFQX-UHFFFAOYSA-N methyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 LKLFVAIKLADFQX-UHFFFAOYSA-N 0.000 claims description 2
- VVECVRVNXRVRNP-UHFFFAOYSA-N methyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-methoxybenzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 VVECVRVNXRVRNP-UHFFFAOYSA-N 0.000 claims description 2
- ARPRIBRKFUSCRY-UHFFFAOYSA-N methyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 ARPRIBRKFUSCRY-UHFFFAOYSA-N 0.000 claims description 2
- NERIMRLYCBVVJT-UHFFFAOYSA-N n-[2-(2-amino-4-ethoxypteridin-6-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 NERIMRLYCBVVJT-UHFFFAOYSA-N 0.000 claims description 2
- NICOGCBTKIGUOF-UHFFFAOYSA-N n-[2-(2-amino-4-ethoxypteridin-6-yl)phenyl]formamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1NC=O NICOGCBTKIGUOF-UHFFFAOYSA-N 0.000 claims description 2
- XPVGBADUUMPRAQ-UHFFFAOYSA-N n-[2-(2-amino-4-ethoxypteridin-6-yl)phenyl]methanesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1NS(C)(=O)=O XPVGBADUUMPRAQ-UHFFFAOYSA-N 0.000 claims description 2
- ODSKIMZHSRMOMO-UHFFFAOYSA-N n-[2-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 ODSKIMZHSRMOMO-UHFFFAOYSA-N 0.000 claims description 2
- ZWRBLUVJJSIZFQ-UHFFFAOYSA-N n-[2-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]formamide Chemical compound C=12N=C(C=3C(=CC=CC=3)NC=O)C=NC2=NC(N)=NC=1N1CCOCC1 ZWRBLUVJJSIZFQ-UHFFFAOYSA-N 0.000 claims description 2
- IJXHANQVLCKIHA-UHFFFAOYSA-N n-[2-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 IJXHANQVLCKIHA-UHFFFAOYSA-N 0.000 claims description 2
- PYNIVFVOZVWARW-UHFFFAOYSA-N n-[3-(2-amino-4-ethoxypteridin-6-yl)phenyl]formamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(NC=O)=C1 PYNIVFVOZVWARW-UHFFFAOYSA-N 0.000 claims description 2
- QECMXAPXKXXRGV-UHFFFAOYSA-N n-[3-(2-amino-4-ethoxypteridin-6-yl)phenyl]methanesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(NS(C)(=O)=O)=C1 QECMXAPXKXXRGV-UHFFFAOYSA-N 0.000 claims description 2
- BYEISEZBSSUDRU-UHFFFAOYSA-N n-[3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]formamide Chemical compound C=12N=C(C=3C=C(NC=O)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 BYEISEZBSSUDRU-UHFFFAOYSA-N 0.000 claims description 2
- XPYGDBRUJPXUKE-UHFFFAOYSA-N n-[3-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 XPYGDBRUJPXUKE-UHFFFAOYSA-N 0.000 claims description 2
- KOWTZJLYXDWLBS-UHFFFAOYSA-N n-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 KOWTZJLYXDWLBS-UHFFFAOYSA-N 0.000 claims description 2
- OBDCCTADXASHHQ-UHFFFAOYSA-N n-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]formamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC=O)C=C1 OBDCCTADXASHHQ-UHFFFAOYSA-N 0.000 claims description 2
- LELFOYVHYYLMOO-UHFFFAOYSA-N n-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]methanesulfonamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NS(C)(=O)=O)C=C1 LELFOYVHYYLMOO-UHFFFAOYSA-N 0.000 claims description 2
- AJALYSPILHNWSF-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)C=C1 AJALYSPILHNWSF-UHFFFAOYSA-N 0.000 claims description 2
- WYKRUHYFTZUHFU-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]formamide Chemical compound C=12N=C(C=3C=CC(NC=O)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 WYKRUHYFTZUHFU-UHFFFAOYSA-N 0.000 claims description 2
- NLDCLFUGDWHJKR-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 NLDCLFUGDWHJKR-UHFFFAOYSA-N 0.000 claims description 2
- WUARKXMODHLTJX-UHFFFAOYSA-N n-[5-(2-amino-4-ethoxypteridin-6-yl)pyridin-2-yl]acetamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC(C)=O)N=C1 WUARKXMODHLTJX-UHFFFAOYSA-N 0.000 claims description 2
- XERHDLCXKHASEP-UHFFFAOYSA-N n-[5-(2-amino-4-morpholin-4-ylpteridin-6-yl)pyridin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XERHDLCXKHASEP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- CRXIVTALPJFIKX-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-ethoxypteridin-6-yl)-5-bromoindole-1-carboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC2=C1 CRXIVTALPJFIKX-UHFFFAOYSA-N 0.000 claims description 2
- MNWQPHODVFIUJP-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-ethoxypteridin-6-yl)-5-methoxyindole-1-carboxylate Chemical compound COC1=CC=C2N(C(=O)OC(C)(C)C)C(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC2=C1 MNWQPHODVFIUJP-UHFFFAOYSA-N 0.000 claims description 2
- JZXORXQEMKHYOS-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C(=O)OC(C)(C)C JZXORXQEMKHYOS-UHFFFAOYSA-N 0.000 claims description 2
- UHFFOGCEDDRBKV-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-ethoxypteridin-6-yl)pyrrole-1-carboxylate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CN1C(=O)OC(C)(C)C UHFFOGCEDDRBKV-UHFFFAOYSA-N 0.000 claims description 2
- PLNOAMAPHZIGFY-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)-5-bromoindole-1-carboxylate Chemical compound C=1C2=CC(Br)=CC=C2N(C(=O)OC(C)(C)C)C=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 PLNOAMAPHZIGFY-UHFFFAOYSA-N 0.000 claims description 2
- PFNBVWCPPUSZMD-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)-5-methoxyindole-1-carboxylate Chemical compound C=1C2=CC(OC)=CC=C2N(C(=O)OC(C)(C)C)C=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 PFNBVWCPPUSZMD-UHFFFAOYSA-N 0.000 claims description 2
- WOCKXNLKOOAUIZ-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 WOCKXNLKOOAUIZ-UHFFFAOYSA-N 0.000 claims description 2
- ITENVLQTJAXLKC-UHFFFAOYSA-N tert-butyl 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 ITENVLQTJAXLKC-UHFFFAOYSA-N 0.000 claims description 2
- OEBVBZDGSIIQQF-UHFFFAOYSA-N tert-butyl 3-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(=O)OC(C)(C)C)=C1 OEBVBZDGSIIQQF-UHFFFAOYSA-N 0.000 claims description 2
- HEIBQAQMXPILEF-UHFFFAOYSA-N tert-butyl 3-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 HEIBQAQMXPILEF-UHFFFAOYSA-N 0.000 claims description 2
- XAKHSGPNRGMTHU-UHFFFAOYSA-N tert-butyl 4-(2-amino-4-ethoxypteridin-6-yl)benzoate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(=O)OC(C)(C)C)C=C1 XAKHSGPNRGMTHU-UHFFFAOYSA-N 0.000 claims description 2
- NYPSDXHVXGQSRH-UHFFFAOYSA-N tert-butyl 4-(2-amino-4-ethoxypteridin-6-yl)pyrazole-1-carboxylate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NN(C(=O)OC(C)(C)C)C=1 NYPSDXHVXGQSRH-UHFFFAOYSA-N 0.000 claims description 2
- XDGDRBGLMWKFGD-UHFFFAOYSA-N tert-butyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XDGDRBGLMWKFGD-UHFFFAOYSA-N 0.000 claims description 2
- PWZZVUUOIUCXNW-UHFFFAOYSA-N tert-butyl 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 PWZZVUUOIUCXNW-UHFFFAOYSA-N 0.000 claims description 2
- WWCJIUJRDHTTGM-UHFFFAOYSA-N tert-butyl 4-[4-(2-amino-4-ethoxypteridin-6-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=1)=CC=NC=1N1CCN(C(=O)OC(C)(C)C)CC1 WWCJIUJRDHTTGM-UHFFFAOYSA-N 0.000 claims description 2
- VFLGKANJCBGVLP-UHFFFAOYSA-N tert-butyl 4-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=CC=N1 VFLGKANJCBGVLP-UHFFFAOYSA-N 0.000 claims description 2
- HQIXKBKBDQREFS-UHFFFAOYSA-N tert-butyl 5-(2-amino-4-ethoxypteridin-6-yl)indole-1-carboxylate Chemical compound C1=C2N(C(=O)OC(C)(C)C)C=CC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 HQIXKBKBDQREFS-UHFFFAOYSA-N 0.000 claims description 2
- WXYHWXVXDMAYAV-UHFFFAOYSA-N tert-butyl 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)indole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)C=CC2=CC=1C(N=C12)=CN=C1N=C(N)N=C2N1CCOCC1 WXYHWXVXDMAYAV-UHFFFAOYSA-N 0.000 claims description 2
- MGQAVSIMIZNJRR-UHFFFAOYSA-N tert-butyl n-[4-(2-amino-4-ethoxypteridin-6-yl)-2-methoxyphenyl]carbamate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC(=O)OC(C)(C)C)C(OC)=C1 MGQAVSIMIZNJRR-UHFFFAOYSA-N 0.000 claims description 2
- JFWZBTSTNRPFFO-UHFFFAOYSA-N tert-butyl n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-2-methoxyphenyl]carbamate Chemical compound C1=C(NC(=O)OC(C)(C)C)C(OC)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 JFWZBTSTNRPFFO-UHFFFAOYSA-N 0.000 claims description 2
- OEEFANGZSGUSKH-UHFFFAOYSA-N 6-(6-fluoro-5-methylpyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound N1=C(F)C(C)=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 OEEFANGZSGUSKH-UHFFFAOYSA-N 0.000 claims 1
- WALDUTSBRCWROA-UHFFFAOYSA-N 6-[2-(dimethylamino)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound CN(C)C1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 WALDUTSBRCWROA-UHFFFAOYSA-N 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000010076 replication Effects 0.000 abstract description 8
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 150000003254 radicals Chemical group 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 21
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 0 [1*]CC1=C2N=C([3*])C([4*])=NC2=NC([2*])=N1 Chemical compound [1*]CC1=C2N=C([3*])C([4*])=NC2=NC([2*])=N1 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229930195733 hydrocarbon Natural products 0.000 description 12
- 238000004949 mass spectrometry Methods 0.000 description 12
- HYCZDWGCJOEHBO-UHFFFAOYSA-N pteridin-2-amine Chemical compound N1=CC=NC2=NC(N)=NC=C21 HYCZDWGCJOEHBO-UHFFFAOYSA-N 0.000 description 12
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical group N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 239000004215 Carbon black (E152) Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 208000005176 Hepatitis C Diseases 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 150000002367 halogens Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 238000013207 serial dilution Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- AVDABTIRTZHAPD-UHFFFAOYSA-N 6-(2,3-difluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=C(F)C=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 AVDABTIRTZHAPD-UHFFFAOYSA-N 0.000 description 4
- HKYRDJSVJNRYJK-UHFFFAOYSA-N 6-(4-fluorophenyl)-n-(4-methylcyclohexyl)pteridin-4-amine Chemical compound C1CC(C)CCC1NC1=NC=NC2=NC=C(C=3C=CC(F)=CC=3)N=C12 HKYRDJSVJNRYJK-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WYHBENDEZDFJNU-UHFFFAOYSA-N CC1=C(C)C=C(F)C=C1 Chemical compound CC1=C(C)C=C(F)C=C1 WYHBENDEZDFJNU-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- JDTAUEUMSABGRL-UHFFFAOYSA-N n-[6-(4-fluorophenyl)-4-(1h-1,2,4-triazol-5-yl)pteridin-2-yl]acetamide Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(NC(=O)C)=NC=1C=1N=CNN=1 JDTAUEUMSABGRL-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 description 3
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 3
- QJKQXGALSQCRJG-UHFFFAOYSA-N 4-ethoxy-6-(2-fluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1F QJKQXGALSQCRJG-UHFFFAOYSA-N 0.000 description 3
- NVGRNODFTBUMRG-UHFFFAOYSA-N 4-ethylsulfanyl-6-(4-fluorophenyl)pteridin-2-amine Chemical compound N1=C2C(SCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 NVGRNODFTBUMRG-UHFFFAOYSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- DTWWSUWMOIJRSW-UHFFFAOYSA-N 4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=CC=NC2=NC(N)=NC=1N1CCOCC1 DTWWSUWMOIJRSW-UHFFFAOYSA-N 0.000 description 3
- RKJWJWUSERYAGE-UHFFFAOYSA-N 6-(2,3-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(F)=C1F RKJWJWUSERYAGE-UHFFFAOYSA-N 0.000 description 3
- RNKPEIAFFFKDGO-UHFFFAOYSA-N 6-(4-fluorophenyl)-1h-pteridin-4-one Chemical compound C1=CC(F)=CC=C1C1=CN=C(N=CNC2=O)C2=N1 RNKPEIAFFFKDGO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DVFVNJHIVAPTMS-UHFFFAOYSA-N CC1=C(C(F)(F)F)C=CC=C1 Chemical compound CC1=C(C(F)(F)F)C=CC=C1 DVFVNJHIVAPTMS-UHFFFAOYSA-N 0.000 description 3
- GWLKCPXYBLCEKC-UHFFFAOYSA-N CC1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=C(Cl)C(Cl)=CC=C1 GWLKCPXYBLCEKC-UHFFFAOYSA-N 0.000 description 3
- ZNEHIDGAPGVZSA-UHFFFAOYSA-N CC1=C(F)C(F)=CC=C1 Chemical compound CC1=C(F)C(F)=CC=C1 ZNEHIDGAPGVZSA-UHFFFAOYSA-N 0.000 description 3
- QWVGKYWNOKOFNN-UHFFFAOYSA-N CC1=C(O)C=CC=C1 Chemical compound CC1=C(O)C=CC=C1 QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 3
- BOHCMQZJWOGWTA-UHFFFAOYSA-N CC1=CC(C#N)=CC=C1 Chemical compound CC1=CC(C#N)=CC=C1 BOHCMQZJWOGWTA-UHFFFAOYSA-N 0.000 description 3
- GBGPVUAOTCNZPT-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)O1 Chemical compound CC1=CC2=C(C=CC=C2)O1 GBGPVUAOTCNZPT-UHFFFAOYSA-N 0.000 description 3
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 3
- GYVGXEWAOAAJEU-UHFFFAOYSA-N CC1=CC=C(N(C)C)C=C1 Chemical compound CC1=CC=C(N(C)C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 3
- ORPHOKOVVUFNKE-UHFFFAOYSA-N CC1=CC=C(N2CCCC2=O)C=C1 Chemical compound CC1=CC=C(N2CCCC2=O)C=C1 ORPHOKOVVUFNKE-UHFFFAOYSA-N 0.000 description 3
- NFQGQMBFMIIIOR-UHFFFAOYSA-N COC1=NC=C(C)C=C1 Chemical compound COC1=NC=C(C)C=C1 NFQGQMBFMIIIOR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UCVLQSOHXLVBRX-UHFFFAOYSA-N n-[6-(4-aminophenyl)-4-morpholin-4-ylpteridin-2-yl]acetamide Chemical compound C=12N=C(C=3C=CC(N)=CC=3)C=NC2=NC(NC(=O)C)=NC=1N1CCOCC1 UCVLQSOHXLVBRX-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- PYOLTUBGDWTLGH-ZDUSSCGKSA-N (2s)-2-amino-n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-3-hydroxypropanamide Chemical compound C1=CC(NC(=O)[C@H](CO)N)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 PYOLTUBGDWTLGH-ZDUSSCGKSA-N 0.000 description 2
- XMQKNKOCQDPXSS-NSHDSACASA-N (2s)-2-amino-n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]propanamide Chemical compound C1=CC(NC(=O)[C@@H](N)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 XMQKNKOCQDPXSS-NSHDSACASA-N 0.000 description 2
- IIQMDXZITNWTSQ-UHFFFAOYSA-N 1-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]pyrrolidin-2-one Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1N1CCCC1=O IIQMDXZITNWTSQ-UHFFFAOYSA-N 0.000 description 2
- XISCQTLKJGSQLC-UHFFFAOYSA-N 1-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]pyrrolidin-2-one Chemical compound C=12N=C(C=3C=CC(=CC=3)N3C(CCC3)=O)C=NC2=NC(N)=NC=1N1CCOCC1 XISCQTLKJGSQLC-UHFFFAOYSA-N 0.000 description 2
- LSFUQSZDSYRXNT-UHFFFAOYSA-N 2-(2-amino-4-ethoxypteridin-6-yl)phenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1O LSFUQSZDSYRXNT-UHFFFAOYSA-N 0.000 description 2
- KCNYQMQJPFLKLY-UHFFFAOYSA-N 2-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenol Chemical compound C=12N=C(C=3C(=CC=CC=3)O)C=NC2=NC(N)=NC=1N1CCOCC1 KCNYQMQJPFLKLY-UHFFFAOYSA-N 0.000 description 2
- LQVXACIJRYTKSU-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(1,2,4-triazol-1-yl)pteridine Chemical compound C1=CC(F)=CC=C1C1=NC(N2N=CN=C2)=C(N=CC=N2)C2=N1 LQVXACIJRYTKSU-UHFFFAOYSA-N 0.000 description 2
- OAPKFNQPDNASHY-UHFFFAOYSA-N 2-amino-6-(4-fluorophenyl)-1h-pteridin-4-one Chemical compound C1=NC2=NC(N)=NC(O)=C2N=C1C1=CC=C(F)C=C1 OAPKFNQPDNASHY-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- QCXKSAYMPGLELC-UHFFFAOYSA-N 2-n-cyclohexyl-6-(4-fluorophenyl)pteridine-2,4-diamine Chemical compound N=1C2=NC=C(C=3C=CC(F)=CC=3)N=C2C(N)=NC=1NC1CCCCC1 QCXKSAYMPGLELC-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- AQWPMIPLDIXGTN-UHFFFAOYSA-N 4-(2,6-dimethylmorpholin-4-yl)-6-(4-fluorophenyl)pteridin-2-amine Chemical compound C1C(C)OC(C)CN1C1=NC(N)=NC2=NC=C(C=3C=CC(F)=CC=3)N=C12 AQWPMIPLDIXGTN-UHFFFAOYSA-N 0.000 description 2
- SWYFWTDUKZOEOD-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-n-cyclopropylbenzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C(C=C1)=CC=C1C(=O)NC1CC1 SWYFWTDUKZOEOD-UHFFFAOYSA-N 0.000 description 2
- LZTXTQDNVQQIOV-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)phenol Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(O)C=C1 LZTXTQDNVQQIOV-UHFFFAOYSA-N 0.000 description 2
- ZNBRORGUWGROHY-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-n-cyclopropylbenzamide Chemical compound C=12N=C(C=3C=CC(=CC=3)C(=O)NC3CC3)C=NC2=NC(N)=NC=1N1CCOCC1 ZNBRORGUWGROHY-UHFFFAOYSA-N 0.000 description 2
- OFPGDNPKCWETKG-UHFFFAOYSA-N 4-(2-amino-4-morpholin-4-ylpteridin-6-yl)-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 OFPGDNPKCWETKG-UHFFFAOYSA-N 0.000 description 2
- XTHACNVNAZZMMS-UHFFFAOYSA-N 4-(cyclobutylmethoxy)-6-(4-fluorophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OCC1CCC1 XTHACNVNAZZMMS-UHFFFAOYSA-N 0.000 description 2
- HDGBYRKEAHZDBV-UHFFFAOYSA-N 4-[2-amino-6-(4-fluorophenyl)pteridin-4-yl]oxy-2-methylbutan-2-ol Chemical compound N1=C2C(OCCC(C)(O)C)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 HDGBYRKEAHZDBV-UHFFFAOYSA-N 0.000 description 2
- AXPCIHVYUDEYNY-UHFFFAOYSA-N 4-[6-(4-fluorophenyl)pteridin-4-yl]morpholine Chemical compound C1=CC(F)=CC=C1C1=CN=C(N=CN=C2N3CCOCC3)C2=N1 AXPCIHVYUDEYNY-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- FHKKALWGXQTDDM-UHFFFAOYSA-N 4-ethoxy-6-(1,2-oxazol-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=NOC=1 FHKKALWGXQTDDM-UHFFFAOYSA-N 0.000 description 2
- AKYHZQOBNYDWFI-UHFFFAOYSA-N 4-ethoxy-6-(1h-indol-5-yl)pteridin-2-amine Chemical compound C1=C2NC=CC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 AKYHZQOBNYDWFI-UHFFFAOYSA-N 0.000 description 2
- FYQYPAUIMMORIA-UHFFFAOYSA-N 4-ethoxy-6-(1h-pyrazol-5-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NN1 FYQYPAUIMMORIA-UHFFFAOYSA-N 0.000 description 2
- NLEVDGGYXWEWSW-UHFFFAOYSA-N 4-ethoxy-6-(2,4,5-trifluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(F)=C(F)C=C1F NLEVDGGYXWEWSW-UHFFFAOYSA-N 0.000 description 2
- PVUFOGPGHGFESW-UHFFFAOYSA-N 4-ethoxy-6-(2-ethoxyphenyl)pteridin-2-amine Chemical compound CCOC1=CC=CC=C1C1=CN=C(N=C(N)N=C2OCC)C2=N1 PVUFOGPGHGFESW-UHFFFAOYSA-N 0.000 description 2
- JVIRFGYIHKQRKX-UHFFFAOYSA-N 4-ethoxy-6-(2-fluoropyridin-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CN=C1F JVIRFGYIHKQRKX-UHFFFAOYSA-N 0.000 description 2
- PBMCKXFOQUNQGH-UHFFFAOYSA-N 4-ethoxy-6-(2-methoxypyridin-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC(OC)=C1 PBMCKXFOQUNQGH-UHFFFAOYSA-N 0.000 description 2
- VFDWIJVKWWZACH-UHFFFAOYSA-N 4-ethoxy-6-(2-methylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C VFDWIJVKWWZACH-UHFFFAOYSA-N 0.000 description 2
- VCQGYUCEEZQONE-UHFFFAOYSA-N 4-ethoxy-6-(3-fluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(F)=C1 VCQGYUCEEZQONE-UHFFFAOYSA-N 0.000 description 2
- MSAAFVZYVQTFTL-UHFFFAOYSA-N 4-ethoxy-6-(3-methylpyridin-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC=C1C MSAAFVZYVQTFTL-UHFFFAOYSA-N 0.000 description 2
- QVJHHQYZMIJYTP-UHFFFAOYSA-N 4-ethoxy-6-(4-fluoro-2-methylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1C QVJHHQYZMIJYTP-UHFFFAOYSA-N 0.000 description 2
- GSBPPLKWMANLLZ-UHFFFAOYSA-N 4-ethoxy-6-(4-methylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C)C=C1 GSBPPLKWMANLLZ-UHFFFAOYSA-N 0.000 description 2
- BXYOYISHTBDFTD-UHFFFAOYSA-N 4-ethoxy-6-(5-fluoro-2-methoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(F)=CC=C1OC BXYOYISHTBDFTD-UHFFFAOYSA-N 0.000 description 2
- ICKHJOYAYSFMDT-UHFFFAOYSA-N 4-ethoxy-6-(furan-3-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=COC=1 ICKHJOYAYSFMDT-UHFFFAOYSA-N 0.000 description 2
- GMMFCIVXDJGUED-UHFFFAOYSA-N 4-ethoxy-6-[3-(trifluoromethoxy)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(OC(F)(F)F)=C1 GMMFCIVXDJGUED-UHFFFAOYSA-N 0.000 description 2
- JWDCHJVPGZEBOU-UHFFFAOYSA-N 4-ethoxy-6-morpholin-4-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1N1CCOCC1 JWDCHJVPGZEBOU-UHFFFAOYSA-N 0.000 description 2
- ZGFAYLGWBQYFIG-UHFFFAOYSA-N 4-ethoxy-6-pyridin-2-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=N1 ZGFAYLGWBQYFIG-UHFFFAOYSA-N 0.000 description 2
- IKOONOXEQYZGEN-UHFFFAOYSA-N 4-ethoxy-6-pyridin-3-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CN=C1 IKOONOXEQYZGEN-UHFFFAOYSA-N 0.000 description 2
- BPUICYYTRHLZDH-UHFFFAOYSA-N 4-ethoxy-6-pyrimidin-5-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CN=CN=C1 BPUICYYTRHLZDH-UHFFFAOYSA-N 0.000 description 2
- VIPCGCMUCBFPSP-UHFFFAOYSA-N 4-ethoxy-6-thiophen-3-ylpteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C=1C=CSC=1 VIPCGCMUCBFPSP-UHFFFAOYSA-N 0.000 description 2
- LKYWOPOQERTAIJ-UHFFFAOYSA-N 4-ethylsulfanyl-6-(4-fluorophenyl)pteridine Chemical compound N1=C2C(SCC)=NC=NC2=NC=C1C1=CC=C(F)C=C1 LKYWOPOQERTAIJ-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- BHKOLCBBUHXEIQ-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1,2-oxazol-4-yl)pteridin-2-amine Chemical compound C=12N=C(C3=CON=C3)C=NC2=NC(N)=NC=1N1CCOCC1 BHKOLCBBUHXEIQ-UHFFFAOYSA-N 0.000 description 2
- NCXPEZXLWSOPOI-UHFFFAOYSA-N 4-morpholin-4-yl-6-(1h-pyrazol-5-yl)pteridin-2-amine Chemical compound C=12N=C(C=3NN=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 NCXPEZXLWSOPOI-UHFFFAOYSA-N 0.000 description 2
- KNUUSGYFRUCESA-UHFFFAOYSA-N 4-morpholin-4-yl-6-(3,4,5-trifluorophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=C(F)C(F)=C(F)C=3)C=NC2=NC(N)=NC=1N1CCOCC1 KNUUSGYFRUCESA-UHFFFAOYSA-N 0.000 description 2
- MPGIXWANZLODDA-UHFFFAOYSA-N 4-morpholin-4-yl-6-[3-(trifluoromethoxy)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=C(OC(F)(F)F)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 MPGIXWANZLODDA-UHFFFAOYSA-N 0.000 description 2
- DAIPLTJOYWAVBI-UHFFFAOYSA-N 4-morpholin-4-yl-6-[4-(morpholin-4-ylmethyl)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(CN4CCOCC4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 DAIPLTJOYWAVBI-UHFFFAOYSA-N 0.000 description 2
- VCQQOGQFWZFRGZ-UHFFFAOYSA-N 4-morpholin-4-yl-6-pyridin-3-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 VCQQOGQFWZFRGZ-UHFFFAOYSA-N 0.000 description 2
- QXTRHSSZMPKWJE-UHFFFAOYSA-N 4-morpholin-4-yl-6-pyrimidin-5-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=NC=NC=3)C=NC2=NC(N)=NC=1N1CCOCC1 QXTRHSSZMPKWJE-UHFFFAOYSA-N 0.000 description 2
- IAKNYVSOQKTNPR-UHFFFAOYSA-N 4-morpholin-4-yl-6-thiophen-3-ylpteridin-2-amine Chemical compound C=12N=C(C3=CSC=C3)C=NC2=NC(N)=NC=1N1CCOCC1 IAKNYVSOQKTNPR-UHFFFAOYSA-N 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- JNFWUNXHMFREGO-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)thiophene-2-carbonitrile Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C#N)S1 JNFWUNXHMFREGO-UHFFFAOYSA-N 0.000 description 2
- IUHGOMAZSUDRBF-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)-1,3-dihydroindol-2-one Chemical compound C=12N=C(C=3C=C4CC(=O)NC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IUHGOMAZSUDRBF-UHFFFAOYSA-N 0.000 description 2
- BAIHWSMLBMNORL-UHFFFAOYSA-N 5-(2-amino-4-morpholin-4-ylpteridin-6-yl)thiophene-2-carbonitrile Chemical compound C=12N=C(C=3SC(=CC=3)C#N)C=NC2=NC(N)=NC=1N1CCOCC1 BAIHWSMLBMNORL-UHFFFAOYSA-N 0.000 description 2
- FWQZDCFUXIUFSY-UHFFFAOYSA-N 6-(1-benzofuran-2-yl)-4-ethoxypteridin-2-amine Chemical compound C1=CC=C2OC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC2=C1 FWQZDCFUXIUFSY-UHFFFAOYSA-N 0.000 description 2
- PUPDJGLRBNBPIJ-UHFFFAOYSA-N 6-(1-benzofuran-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3OC4=CC=CC=C4C=3)C=NC2=NC(N)=NC=1N1CCOCC1 PUPDJGLRBNBPIJ-UHFFFAOYSA-N 0.000 description 2
- YZSGPDFFSKGCNQ-UHFFFAOYSA-N 6-(1-benzothiophen-2-yl)-4-ethoxypteridin-2-amine Chemical compound C1=CC=C2SC(C3=CN=C4N=C(N)N=C(C4=N3)OCC)=CC2=C1 YZSGPDFFSKGCNQ-UHFFFAOYSA-N 0.000 description 2
- QAMRXZXXAMYMCF-UHFFFAOYSA-N 6-(1-benzothiophen-2-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3SC4=CC=CC=C4C=3)C=NC2=NC(N)=NC=1N1CCOCC1 QAMRXZXXAMYMCF-UHFFFAOYSA-N 0.000 description 2
- DURVLPQMEQWDTE-UHFFFAOYSA-N 6-(1h-indol-5-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C4C=CNC4=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 DURVLPQMEQWDTE-UHFFFAOYSA-N 0.000 description 2
- CKMYEYWTCCUKFE-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=C(Cl)C=CC=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 CKMYEYWTCCUKFE-UHFFFAOYSA-N 0.000 description 2
- NGWDXRBNEKOPFQ-UHFFFAOYSA-N 6-(2,3-difluorophenyl)pteridine-2,4-diamine Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(F)=C1F NGWDXRBNEKOPFQ-UHFFFAOYSA-N 0.000 description 2
- USUXNTAUZGTLBK-UHFFFAOYSA-N 6-(2,4-difluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC(F)=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 USUXNTAUZGTLBK-UHFFFAOYSA-N 0.000 description 2
- CWXHKZRAKATOQT-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Cl)=CC=C1Cl CWXHKZRAKATOQT-UHFFFAOYSA-N 0.000 description 2
- PFVZZSOWYRCBRP-UHFFFAOYSA-N 6-(2,5-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(F)=CC=C1F PFVZZSOWYRCBRP-UHFFFAOYSA-N 0.000 description 2
- QXSXILLTEXJGNO-UHFFFAOYSA-N 6-(2,5-difluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=C(F)C=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 QXSXILLTEXJGNO-UHFFFAOYSA-N 0.000 description 2
- WBVPMUCNWCRXEF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=C(Cl)C=CC=C1Cl WBVPMUCNWCRXEF-UHFFFAOYSA-N 0.000 description 2
- IKCHRBVYDYOAFK-UHFFFAOYSA-N 6-(2,6-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=C(F)C=CC=C1F IKCHRBVYDYOAFK-UHFFFAOYSA-N 0.000 description 2
- HBSIFDCLHHUTPE-UHFFFAOYSA-N 6-(2,6-difluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3F)F)C=NC2=NC(N)=NC=1N1CCOCC1 HBSIFDCLHHUTPE-UHFFFAOYSA-N 0.000 description 2
- IKZASRGYBIGYPO-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1Cl IKZASRGYBIGYPO-UHFFFAOYSA-N 0.000 description 2
- WRNJYSAYUPZNLX-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC(F)=CC=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 WRNJYSAYUPZNLX-UHFFFAOYSA-N 0.000 description 2
- AVACODWQCAXAQK-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1Cl AVACODWQCAXAQK-UHFFFAOYSA-N 0.000 description 2
- BWCKVJCFWCZDEJ-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 BWCKVJCFWCZDEJ-UHFFFAOYSA-N 0.000 description 2
- UBLCIOXBSLVSQB-UHFFFAOYSA-N 6-(2-ethoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CCOC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 UBLCIOXBSLVSQB-UHFFFAOYSA-N 0.000 description 2
- LFGMZJPHRNVEEA-UHFFFAOYSA-N 6-(2-fluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 LFGMZJPHRNVEEA-UHFFFAOYSA-N 0.000 description 2
- VBMMTZZBMFKICU-UHFFFAOYSA-N 6-(2-fluoropyridin-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=NC=CC=3)F)C=NC2=NC(N)=NC=1N1CCOCC1 VBMMTZZBMFKICU-UHFFFAOYSA-N 0.000 description 2
- DQXSEUXLEMQQRW-UHFFFAOYSA-N 6-(2-methoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 DQXSEUXLEMQQRW-UHFFFAOYSA-N 0.000 description 2
- BUKJNIQZHNFTME-UHFFFAOYSA-N 6-(2-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 BUKJNIQZHNFTME-UHFFFAOYSA-N 0.000 description 2
- HWNBZVBNBJBMAX-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C(F)=C1 HWNBZVBNBJBMAX-UHFFFAOYSA-N 0.000 description 2
- MAWKMKIDJPYPAI-UHFFFAOYSA-N 6-(3,5-dichlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(Cl)=CC(Cl)=C1 MAWKMKIDJPYPAI-UHFFFAOYSA-N 0.000 description 2
- JWAODGQKLRENHP-UHFFFAOYSA-N 6-(3,5-dichlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Cl)C=C(Cl)C=3)C=NC2=NC(N)=NC=1N1CCOCC1 JWAODGQKLRENHP-UHFFFAOYSA-N 0.000 description 2
- BQHSZWFGFITEFA-UHFFFAOYSA-N 6-(3,5-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(F)=CC(F)=C1 BQHSZWFGFITEFA-UHFFFAOYSA-N 0.000 description 2
- SRQZYUZNNAUARW-UHFFFAOYSA-N 6-(3,5-difluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(F)C=C(F)C=3)C=NC2=NC(N)=NC=1N1CCOCC1 SRQZYUZNNAUARW-UHFFFAOYSA-N 0.000 description 2
- JYQMKOOOIZWADV-UHFFFAOYSA-N 6-(3,5-dimethylphenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C)=CC(C)=C1 JYQMKOOOIZWADV-UHFFFAOYSA-N 0.000 description 2
- HPEMJDWVLBFCTL-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C(Cl)=C1 HPEMJDWVLBFCTL-UHFFFAOYSA-N 0.000 description 2
- PRBMKCFZUUVOOK-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Cl)C(F)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 PRBMKCFZUUVOOK-UHFFFAOYSA-N 0.000 description 2
- UYGYHJITAFDTOY-UHFFFAOYSA-N 6-(3-chlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(Cl)=C1 UYGYHJITAFDTOY-UHFFFAOYSA-N 0.000 description 2
- YTZKZJLMFRFGSU-UHFFFAOYSA-N 6-(3-chlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Cl)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 YTZKZJLMFRFGSU-UHFFFAOYSA-N 0.000 description 2
- NGYGQJNIXJYOLH-UHFFFAOYSA-N 6-(3-ethoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CCOC1=CC=CC(C=2N=C3C(N4CCOCC4)=NC(N)=NC3=NC=2)=C1 NGYGQJNIXJYOLH-UHFFFAOYSA-N 0.000 description 2
- AANOXQXHYMEABW-UHFFFAOYSA-N 6-(3-fluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(F)C=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 AANOXQXHYMEABW-UHFFFAOYSA-N 0.000 description 2
- MHJNXSMVMFOELR-UHFFFAOYSA-N 6-(4-aminophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N)C=C1 MHJNXSMVMFOELR-UHFFFAOYSA-N 0.000 description 2
- IHHNSKVMOHLMOS-UHFFFAOYSA-N 6-(4-chloro-3-fluorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(F)C(Cl)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 IHHNSKVMOHLMOS-UHFFFAOYSA-N 0.000 description 2
- IQUUHHLJBZXZKQ-UHFFFAOYSA-N 6-(4-chlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)C=C1 IQUUHHLJBZXZKQ-UHFFFAOYSA-N 0.000 description 2
- WALNSSRMSWXIBH-UHFFFAOYSA-N 6-(4-fluorophenyl)-1h-pteridine-2,4,4-triamine Chemical compound N1=C2C(N)(N)NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 WALNSSRMSWXIBH-UHFFFAOYSA-N 0.000 description 2
- QWWMCVTYXCCJBI-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(1,2,4-triazol-1-yl)pteridine Chemical compound C1=CC(F)=CC=C1C1=CN=C(N=CN=C2N3N=CN=C3)C2=N1 QWWMCVTYXCCJBI-UHFFFAOYSA-N 0.000 description 2
- OUAZLSLOTRMWCA-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(2,2,2-trifluoroethoxy)pteridin-2-amine Chemical compound C1=NC2=NC(N)=NC(OCC(F)(F)F)=C2N=C1C1=CC=C(F)C=C1 OUAZLSLOTRMWCA-UHFFFAOYSA-N 0.000 description 2
- YYXWJWOPTQYYNM-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(2-methoxyethoxy)pteridin-2-amine Chemical compound N1=C2C(OCCOC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 YYXWJWOPTQYYNM-UHFFFAOYSA-N 0.000 description 2
- STBVVFZJSFJNHS-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(2-morpholin-4-ylethoxy)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OCCN1CCOCC1 STBVVFZJSFJNHS-UHFFFAOYSA-N 0.000 description 2
- SSNZEKVERSBYIH-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(3-morpholin-4-ylpropoxy)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OCCCN1CCOCC1 SSNZEKVERSBYIH-UHFFFAOYSA-N 0.000 description 2
- QPQNZGNRIQSSPG-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)pteridin-2-amine Chemical compound C1CN(C)CCN1C1=NC(N)=NC2=NC=C(C=3C=CC(F)=CC=3)N=C12 QPQNZGNRIQSSPG-UHFFFAOYSA-N 0.000 description 2
- PZPYSKROQMELAH-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(oxolan-3-yloxy)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OC1CCOC1 PZPYSKROQMELAH-UHFFFAOYSA-N 0.000 description 2
- CILMSXJFWZIEEG-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-piperazin-1-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1N1CCNCC1 CILMSXJFWZIEEG-UHFFFAOYSA-N 0.000 description 2
- SMZJHIKIHQKZMC-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-piperidin-1-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1N1CCCCC1 SMZJHIKIHQKZMC-UHFFFAOYSA-N 0.000 description 2
- SSULXMJLTOESOU-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-pyrrolidin-1-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1N1CCCC1 SSULXMJLTOESOU-UHFFFAOYSA-N 0.000 description 2
- SOPCFNSQFFWMAH-UHFFFAOYSA-N 6-(4-fluorophenyl)pteridin-4-amine Chemical class N1=C2C(N)=NC=NC2=NC=C1C1=CC=C(F)C=C1 SOPCFNSQFFWMAH-UHFFFAOYSA-N 0.000 description 2
- ZQSNJLBJZLZBGN-UHFFFAOYSA-N 6-(4-methylsulfonylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 ZQSNJLBJZLZBGN-UHFFFAOYSA-N 0.000 description 2
- DOROZBGNYFTEMG-UHFFFAOYSA-N 6-(5-chlorothiophen-2-yl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)S1 DOROZBGNYFTEMG-UHFFFAOYSA-N 0.000 description 2
- KBNBZNSCLMBMJC-UHFFFAOYSA-N 6-(5-fluoro-2-methoxyphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound COC1=CC=C(F)C=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 KBNBZNSCLMBMJC-UHFFFAOYSA-N 0.000 description 2
- CIXKHQAHPPEDRA-UHFFFAOYSA-N 6-(furan-3-yl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C3=COC=C3)C=NC2=NC(N)=NC=1N1CCOCC1 CIXKHQAHPPEDRA-UHFFFAOYSA-N 0.000 description 2
- HYFRQMVDXDGSIO-UHFFFAOYSA-N 6-[2,4-bis(trifluoromethyl)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(F)(F)F)C=C1C(F)(F)F HYFRQMVDXDGSIO-UHFFFAOYSA-N 0.000 description 2
- WWKVOVUCEQCPAN-UHFFFAOYSA-N 6-[2,4-bis(trifluoromethyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)C=NC2=NC(N)=NC=1N1CCOCC1 WWKVOVUCEQCPAN-UHFFFAOYSA-N 0.000 description 2
- PQGVOWXLVWBXLU-UHFFFAOYSA-N 6-[2-chloro-4-(trifluoromethyl)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(F)(F)F)C=C1Cl PQGVOWXLVWBXLU-UHFFFAOYSA-N 0.000 description 2
- VJPJEPUFJCDPLN-UHFFFAOYSA-N 6-[2-chloro-4-(trifluoromethyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC(=CC=3)C(F)(F)F)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 VJPJEPUFJCDPLN-UHFFFAOYSA-N 0.000 description 2
- NQYYYARIINVLIX-UHFFFAOYSA-N 6-[3,5-bis(trifluoromethyl)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NQYYYARIINVLIX-UHFFFAOYSA-N 0.000 description 2
- RHRZJZJRZXFVJY-UHFFFAOYSA-N 6-[4-(dimethoxyphosphorylmethyl)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(CP(=O)(OC)OC)C=C1 RHRZJZJRZXFVJY-UHFFFAOYSA-N 0.000 description 2
- GNKWIAUTXCLFDQ-UHFFFAOYSA-N 6-[4-(dimethoxyphosphorylmethyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(CP(=O)(OC)OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 GNKWIAUTXCLFDQ-UHFFFAOYSA-N 0.000 description 2
- FEEUBYDJBZLJHM-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(N(C)C)C=C1 FEEUBYDJBZLJHM-UHFFFAOYSA-N 0.000 description 2
- QSRWGQDADNGJJG-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 QSRWGQDADNGJJG-UHFFFAOYSA-N 0.000 description 2
- PQNMRHWTSFOODB-UHFFFAOYSA-N 6-chloro-4-ethoxypteridin-2-amine Chemical compound C1=C(Cl)N=C2C(OCC)=NC(N)=NC2=N1 PQNMRHWTSFOODB-UHFFFAOYSA-N 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZBIUGZLUAUOIRQ-UHFFFAOYSA-N CC1=C(C(F)(F)F)C=C(C(F)(F)F)C=C1 Chemical compound CC1=C(C(F)(F)F)C=C(C(F)(F)F)C=C1 ZBIUGZLUAUOIRQ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N CC1=C(C)C=CC=C1 Chemical compound CC1=C(C)C=CC=C1 CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- DPBMOEZTWZVXLL-UHFFFAOYSA-N CC1=C(Cl)C=C(C(F)(F)F)C=C1 Chemical compound CC1=C(Cl)C=C(C(F)(F)F)C=C1 DPBMOEZTWZVXLL-UHFFFAOYSA-N 0.000 description 2
- CSARJIQZOSVYHA-UHFFFAOYSA-N CC1=C(Cl)C=C(F)C=C1 Chemical compound CC1=C(Cl)C=C(F)C=C1 CSARJIQZOSVYHA-UHFFFAOYSA-N 0.000 description 2
- IBSQPLPBRSHTTG-UHFFFAOYSA-N CC1=C(Cl)C=CC=C1 Chemical compound CC1=C(Cl)C=CC=C1 IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 2
- DMEDNTFWIHCBRK-UHFFFAOYSA-N CC1=C(Cl)C=CC=C1Cl Chemical compound CC1=C(Cl)C=CC=C1Cl DMEDNTFWIHCBRK-UHFFFAOYSA-N 0.000 description 2
- MPXDAIBTYWGBSL-UHFFFAOYSA-N CC1=C(F)C=C(F)C=C1 Chemical compound CC1=C(F)C=C(F)C=C1 MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 2
- MMZYCBHLNZVROM-UHFFFAOYSA-N CC1=C(F)C=CC=C1 Chemical compound CC1=C(F)C=CC=C1 MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 2
- MZLSNIREOQCDED-UHFFFAOYSA-N CC1=C(F)C=CC=C1F Chemical compound CC1=C(F)C=CC=C1F MZLSNIREOQCDED-UHFFFAOYSA-N 0.000 description 2
- PHGXUFPYCAWEHK-UHFFFAOYSA-N CC1=C(F)N=CC=C1 Chemical compound CC1=C(F)N=CC=C1 PHGXUFPYCAWEHK-UHFFFAOYSA-N 0.000 description 2
- WGUXTQDCAZNJIF-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGUXTQDCAZNJIF-UHFFFAOYSA-N 0.000 description 2
- VJYXZJGDFJJDGF-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC=C1 Chemical compound CC1=CC(C(F)(F)F)=CC=C1 VJYXZJGDFJJDGF-UHFFFAOYSA-N 0.000 description 2
- IKNQPNLSEBWZKX-UHFFFAOYSA-N CC1=CC(Cl)=C(F)C=C1 Chemical compound CC1=CC(Cl)=C(F)C=C1 IKNQPNLSEBWZKX-UHFFFAOYSA-N 0.000 description 2
- RYMMNSVHOKXTNN-UHFFFAOYSA-N CC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC1=CC(Cl)=CC(Cl)=C1 RYMMNSVHOKXTNN-UHFFFAOYSA-N 0.000 description 2
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1 Chemical compound CC1=CC(Cl)=CC=C1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 2
- MHXNHUSVBYUTJL-UHFFFAOYSA-N CC1=CC(F)=C(Cl)C=C1 Chemical compound CC1=CC(F)=C(Cl)C=C1 MHXNHUSVBYUTJL-UHFFFAOYSA-N 0.000 description 2
- YISYUYYETHYYMD-UHFFFAOYSA-N CC1=CC(F)=CC(F)=C1 Chemical compound CC1=CC(F)=CC(F)=C1 YISYUYYETHYYMD-UHFFFAOYSA-N 0.000 description 2
- BTQZKHUEUDPRST-UHFFFAOYSA-N CC1=CC(F)=CC=C1 Chemical compound CC1=CC(F)=CC=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 2
- YSNVKDGEALPJGC-UHFFFAOYSA-N CC1=CC(F)=CC=C1F Chemical compound CC1=CC(F)=CC=C1F YSNVKDGEALPJGC-UHFFFAOYSA-N 0.000 description 2
- WRNXOOXIPSTAGJ-UHFFFAOYSA-N CC1=CC(OC(F)(F)F)=CC=C1 Chemical compound CC1=CC(OC(F)(F)F)=CC=C1 WRNXOOXIPSTAGJ-UHFFFAOYSA-N 0.000 description 2
- QLOAMIGYZXLFKF-UHFFFAOYSA-N CC1=CC2=C(C=C1)CC(=O)C2 Chemical compound CC1=CC2=C(C=C1)CC(=O)C2 QLOAMIGYZXLFKF-UHFFFAOYSA-N 0.000 description 2
- YLHSETDFVAXPRB-UHFFFAOYSA-N CC1=CC2=C(C=C1)CC=C2 Chemical compound CC1=CC2=C(C=C1)CC=C2 YLHSETDFVAXPRB-UHFFFAOYSA-N 0.000 description 2
- BLZKSRBAQDZAIX-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)S1 Chemical compound CC1=CC2=C(C=CC=C2)S1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 2
- LRLRAYMYEXQKID-UHFFFAOYSA-N CC1=CC=C(C(F)(F)F)C=C1 Chemical compound CC1=CC=C(C(F)(F)F)C=C1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 2
- JSMMZMYGEVUURX-UHFFFAOYSA-N CC1=CC=C(Cl)S1 Chemical compound CC1=CC=C(Cl)S1 JSMMZMYGEVUURX-UHFFFAOYSA-N 0.000 description 2
- JUXFXYQUXNXVAA-UHFFFAOYSA-N CC1=CC=C(OC(F)(F)F)C=C1 Chemical compound CC1=CC=C(OC(F)(F)F)C=C1 JUXFXYQUXNXVAA-UHFFFAOYSA-N 0.000 description 2
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N CC1=CC=C(S(C)(=O)=O)C=C1 Chemical compound CC1=CC=C(S(C)(=O)=O)C=C1 YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N CC1=CC=NC=C1 Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- XKVUYEYANWFIJX-UHFFFAOYSA-N CC1=CC=NN1 Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N CC1=CN=CC=C1 Chemical compound CC1=CN=CC=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- TWGNOYAGHYUFFR-UHFFFAOYSA-N CC1=CN=CN=C1 Chemical compound CC1=CN=CN=C1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 2
- RIKMMFOAQPJVMX-UHFFFAOYSA-N CC1=CNN=C1 Chemical compound CC1=CNN=C1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 2
- KJRRQXYWFQKJIP-UHFFFAOYSA-N CC1=COC=C1 Chemical compound CC1=COC=C1 KJRRQXYWFQKJIP-UHFFFAOYSA-N 0.000 description 2
- VHWFNFITHSPBSR-UHFFFAOYSA-N CC1=CON=C1 Chemical compound CC1=CON=C1 VHWFNFITHSPBSR-UHFFFAOYSA-N 0.000 description 2
- QENGPZGAWFQWCZ-UHFFFAOYSA-N CC1=CSC=C1 Chemical compound CC1=CSC=C1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 2
- CYISMTMRBPPERU-UHFFFAOYSA-N CCC1CCC(C)CC1 Chemical compound CCC1CCC(C)CC1 CYISMTMRBPPERU-UHFFFAOYSA-N 0.000 description 2
- NMILGIZTAZXMTM-UHFFFAOYSA-N CCCN1CCOCC1 Chemical compound CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 description 2
- JWMKUKRBNODZFA-UHFFFAOYSA-N CCOC1=C(C)C=CC=C1 Chemical compound CCOC1=C(C)C=CC=C1 JWMKUKRBNODZFA-UHFFFAOYSA-N 0.000 description 2
- UALKQROXOHJHFG-UHFFFAOYSA-N CCOC1=CC=CC(C)=C1 Chemical compound CCOC1=CC=CC(C)=C1 UALKQROXOHJHFG-UHFFFAOYSA-N 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- FZIOOTTWDRFBKU-UHFFFAOYSA-N CNC(=O)C1=CC=C(C)C=C1 Chemical compound CNC(=O)C1=CC=C(C)C=C1 FZIOOTTWDRFBKU-UHFFFAOYSA-N 0.000 description 2
- OKBJVCWRESLMMD-UHFFFAOYSA-N COC(=O)NC1=CC=C(C)C=C1 Chemical compound COC(=O)NC1=CC=C(C)C=C1 OKBJVCWRESLMMD-UHFFFAOYSA-N 0.000 description 2
- LJPCNSSTRWGCMZ-RXMQYKEDSA-N C[C@@H]1CCOC1 Chemical compound C[C@@H]1CCOC1 LJPCNSSTRWGCMZ-RXMQYKEDSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000001726 Classical Swine Fever Diseases 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- XGBYBVGZFPRYSK-UHFFFAOYSA-N methyl n-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]carbamate Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC(=O)OC)C=C1 XGBYBVGZFPRYSK-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 150000002763 monocarboxylic acids Chemical class 0.000 description 2
- RTGJINPOYNFZRN-UHFFFAOYSA-N n-(6-chloro-4-morpholin-4-ylpteridin-2-yl)acetamide Chemical compound C=12N=C(Cl)C=NC2=NC(NC(=O)C)=NC=1N1CCOCC1 RTGJINPOYNFZRN-UHFFFAOYSA-N 0.000 description 2
- OQKIZIUYLSUNQC-UHFFFAOYSA-N n-[4-(2-amino-4-ethoxypteridin-6-yl)phenyl]acetamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(NC(C)=O)C=C1 OQKIZIUYLSUNQC-UHFFFAOYSA-N 0.000 description 2
- LFPOJTJRDUDBBK-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1=CC(NC(=O)C(C)(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 LFPOJTJRDUDBBK-UHFFFAOYSA-N 0.000 description 2
- TZDVXSAXPACHOI-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 TZDVXSAXPACHOI-UHFFFAOYSA-N 0.000 description 2
- GWTCZDIFMWIFEC-UHFFFAOYSA-N n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]cyclopropanecarboxamide Chemical compound C=12N=C(C=3C=CC(NC(=O)C4CC4)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 GWTCZDIFMWIFEC-UHFFFAOYSA-N 0.000 description 2
- FYPUKZLHYRYEOZ-UHFFFAOYSA-N n-[6-(4-fluorophenyl)-4-oxo-1h-pteridin-2-yl]acetamide Chemical compound C1=NC2=NC(NC(=O)C)=NC(O)=C2N=C1C1=CC=C(F)C=C1 FYPUKZLHYRYEOZ-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 239000010452 phosphate Chemical group 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- WEFOBSFFNWFDEB-AWEZNQCLSA-N tert-butyl n-[(2s)-1-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)anilino]-1-oxopropan-2-yl]carbamate Chemical compound C1=CC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 WEFOBSFFNWFDEB-AWEZNQCLSA-N 0.000 description 2
- YYHROVTZBYUMPZ-KRWDZBQOSA-N tert-butyl n-[(2s)-1-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)anilino]-3-hydroxy-1-oxopropan-2-yl]carbamate Chemical compound C1=CC(NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 YYHROVTZBYUMPZ-KRWDZBQOSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000009265 virologic response Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- TXCWKZUXQFCWDW-UHFFFAOYSA-N (hydroxyamino) cyanoformate Chemical class ONOC(=O)C#N TXCWKZUXQFCWDW-UHFFFAOYSA-N 0.000 description 1
- KCHIOGFOPPOUJC-UHFFFAOYSA-N (methylpyridazine piperidine ethyloxyphenyl)ethylacetate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 KCHIOGFOPPOUJC-UHFFFAOYSA-N 0.000 description 1
- YRCRRHNVYVFNTM-UHFFFAOYSA-N 1,1-dihydroxy-3-ethoxy-2-butanone Chemical compound CCOC(C)C(=O)C(O)O YRCRRHNVYVFNTM-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- SJBBXFLOLUTGCW-UHFFFAOYSA-N 1,3-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(C(F)(F)F)=C1 SJBBXFLOLUTGCW-UHFFFAOYSA-N 0.000 description 1
- SRGYIOWEOTVTRE-UHFFFAOYSA-N 1,3-oxazinane-2,6-dione Chemical compound O=C1CCNC(=O)O1 SRGYIOWEOTVTRE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OWKXRDQRMTVCEX-UHFFFAOYSA-N 1-(1-adamantyl)-2-methylpropan-2-amine Chemical compound C1C(C2)CC3CC2CC1(CC(C)(N)C)C3 OWKXRDQRMTVCEX-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- NOCSCLPQKGWLDB-UHFFFAOYSA-N 1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline Chemical compound C1=CC(OC)=CC=C1OCC1=NCCC2=CC=CC=C12 NOCSCLPQKGWLDB-UHFFFAOYSA-N 0.000 description 1
- XHQBIYCRFVVHFD-UHFFFAOYSA-N 1-benzothiophen-3-ol Chemical group C1=CC=C2C(O)=CSC2=C1 XHQBIYCRFVVHFD-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical group C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OHZAHWOAMVVGEL-UHFFFAOYSA-N 2,2'-bithiophene Chemical group C1=CSC(C=2SC=CC=2)=C1 OHZAHWOAMVVGEL-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JCRNSBKSAQHNIN-UHFFFAOYSA-N 2,4-dibutylnaphthalene-1-sulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(CCCC)=CC(CCCC)=C21 JCRNSBKSAQHNIN-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- RGALMPOBPCWQJV-UHFFFAOYSA-N 2,5,6-triamino-1h-pyrimidin-4-one;dihydrochloride Chemical compound Cl.Cl.NC1=NC(=O)C(N)=C(N)N1 RGALMPOBPCWQJV-UHFFFAOYSA-N 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- HKEVGRKWUCLEHC-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-hydroxyiminoacetaldehyde Chemical compound ON=C(C=O)C1=CC=C(F)C=C1 HKEVGRKWUCLEHC-UHFFFAOYSA-N 0.000 description 1
- OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical group CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- QDGWHHFJDHIIOS-UHFFFAOYSA-N 2-chloro-1-(6-diethoxyphosphorylhexoxy)-4-methoxybenzene Chemical compound CCOP(=O)(OCC)CCCCCCOC1=CC=C(OC)C=C1Cl QDGWHHFJDHIIOS-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BNBSTIURCCMQAH-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-N-ethylbenzamide Chemical compound NC1=NC2=NC=C(N=C2C(=N1)OCC)C1=CC=C(C(=O)NCC)C=C1 BNBSTIURCCMQAH-UHFFFAOYSA-N 0.000 description 1
- CFDSUQVMLAGNBZ-UHFFFAOYSA-N 4-(2-amino-4-ethoxypteridin-6-yl)-n-methylbenzamide Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(=O)NC)C=C1 CFDSUQVMLAGNBZ-UHFFFAOYSA-N 0.000 description 1
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 1
- YLWHONJGOMLVIE-UHFFFAOYSA-N 4-(cyclopropylmethoxy)-6-(4-fluorophenyl)pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OCC1CC1 YLWHONJGOMLVIE-UHFFFAOYSA-N 0.000 description 1
- BWCVXHATBNNLCB-UHFFFAOYSA-N 4-[2-(5-chlorothiophen-2-yl)morpholin-4-yl]pteridin-2-amine Chemical compound C=12N=CC=NC2=NC(N)=NC=1N(C1)CCOC1C1=CC=C(Cl)S1 BWCVXHATBNNLCB-UHFFFAOYSA-N 0.000 description 1
- BPOMPTVRBWXZBY-UHFFFAOYSA-N 4-[[1-ethoxy-2-oxo-2-(4-phenylphenyl)ethyl]amino]benzoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)C(OCC)NC1=CC=C(C(O)=O)C=C1 BPOMPTVRBWXZBY-UHFFFAOYSA-N 0.000 description 1
- GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- FZFBEWUSDYHFLF-UHFFFAOYSA-N 4-butan-2-yloxy-6-(4-fluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OC(C)CC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 FZFBEWUSDYHFLF-UHFFFAOYSA-N 0.000 description 1
- JBGIFLBOKUSBCS-UHFFFAOYSA-N 4-butoxy-6-(4-fluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCCCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 JBGIFLBOKUSBCS-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- ANIJOPODQXMXJP-UHFFFAOYSA-N 4-ethoxy-6-(2,4,6-trifluorophenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=C(F)C=C(F)C=C1F ANIJOPODQXMXJP-UHFFFAOYSA-N 0.000 description 1
- PWWSBKLYSBUMCQ-UHFFFAOYSA-N 4-ethoxy-6-(2-methylpyridin-4-yl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=NC(C)=C1 PWWSBKLYSBUMCQ-UHFFFAOYSA-N 0.000 description 1
- MVPIEXZQOZNQGE-UHFFFAOYSA-N 4-ethoxy-6-(3-ethoxyphenyl)pteridin-2-amine Chemical compound CCOC1=CC=CC(C=2N=C3C(OCC)=NC(N)=NC3=NC=2)=C1 MVPIEXZQOZNQGE-UHFFFAOYSA-N 0.000 description 1
- SYFZQPPHCCUNRA-UHFFFAOYSA-N 4-ethoxy-6-(3-fluoro-4-methoxyphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC)C(F)=C1 SYFZQPPHCCUNRA-UHFFFAOYSA-N 0.000 description 1
- HKOFZCMWZXJIFV-UHFFFAOYSA-N 4-ethoxy-6-(4-fluorophenyl)pteridine Chemical compound N1=C2C(OCC)=NC=NC2=NC=C1C1=CC=C(F)C=C1 HKOFZCMWZXJIFV-UHFFFAOYSA-N 0.000 description 1
- PWJLBCVRRJVAPN-UHFFFAOYSA-N 4-ethoxy-6-(4-methylsulfonylphenyl)pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(S(C)(=O)=O)C=C1 PWJLBCVRRJVAPN-UHFFFAOYSA-N 0.000 description 1
- LLFNTLOQXHKLTF-UHFFFAOYSA-N 4-ethoxy-6-[2-(trifluoromethoxy)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1OC(F)(F)F LLFNTLOQXHKLTF-UHFFFAOYSA-N 0.000 description 1
- QTZVQZNFCCYNFR-UHFFFAOYSA-N 4-ethoxy-6-[2-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC=C1C(F)(F)F QTZVQZNFCCYNFR-UHFFFAOYSA-N 0.000 description 1
- LWYPFVYINPTTJV-UHFFFAOYSA-N 4-ethoxy-6-[3-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(C(F)(F)F)=C1 LWYPFVYINPTTJV-UHFFFAOYSA-N 0.000 description 1
- IHDBFWKOTXVSAE-UHFFFAOYSA-N 4-ethoxy-6-[4-(trifluoromethoxy)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(OC(F)(F)F)C=C1 IHDBFWKOTXVSAE-UHFFFAOYSA-N 0.000 description 1
- VQGXHBCBFPFOEU-UHFFFAOYSA-N 4-ethoxy-6-[4-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(C(F)(F)F)C=C1 VQGXHBCBFPFOEU-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- DJJDCVQENPOQKZ-UHFFFAOYSA-N 4-morpholin-4-yl-6-[2-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3)C(F)(F)F)C=NC2=NC(N)=NC=1N1CCOCC1 DJJDCVQENPOQKZ-UHFFFAOYSA-N 0.000 description 1
- NBCIKYLMPCIIBR-UHFFFAOYSA-N 4-morpholin-4-yl-6-[3-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=C(C=CC=3)C(F)(F)F)C=NC2=NC(N)=NC=1N1CCOCC1 NBCIKYLMPCIIBR-UHFFFAOYSA-N 0.000 description 1
- SXBZQQFFKCZUPQ-UHFFFAOYSA-N 4-morpholin-4-yl-6-[4-(trifluoromethoxy)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(OC(F)(F)F)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 SXBZQQFFKCZUPQ-UHFFFAOYSA-N 0.000 description 1
- HAWATDHDLDVVQM-UHFFFAOYSA-N 4-morpholin-4-yl-6-[4-(trifluoromethyl)phenyl]pteridin-2-amine Chemical compound C=12N=C(C=3C=CC(=CC=3)C(F)(F)F)C=NC2=NC(N)=NC=1N1CCOCC1 HAWATDHDLDVVQM-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- BMSIGJAYMIHCQP-UHFFFAOYSA-N 5,6-diamino-1h-pyrimidin-4-one;hydrochloride Chemical compound Cl.NC1=NC=NC(O)=C1N BMSIGJAYMIHCQP-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- IJFOPKLYHGSSRS-UHFFFAOYSA-N 5-(2,6-dichlorophenyl)-4-morpholin-4-yl-6H-pteridin-2-amine Chemical compound ClC1=C(C(=CC=C1)Cl)N1C=2C(=NC(=NC=2N=CC1)N)N1CCOCC1 IJFOPKLYHGSSRS-UHFFFAOYSA-N 0.000 description 1
- WTLTZEPLPPCJSK-UHFFFAOYSA-N 5-(2-amino-4-ethoxypteridin-6-yl)-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC(C2=CN=C3N=C(N)N=C(C3=N2)OCC)=C1 WTLTZEPLPPCJSK-UHFFFAOYSA-N 0.000 description 1
- IZSHZLKNFQAAKX-UHFFFAOYSA-N 5-cyclopenta-2,4-dien-1-ylcyclopenta-1,3-diene Chemical group C1=CC=CC1C1C=CC=C1 IZSHZLKNFQAAKX-UHFFFAOYSA-N 0.000 description 1
- POJOGNDIXZPLQP-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=CC(Cl)=C1Cl POJOGNDIXZPLQP-UHFFFAOYSA-N 0.000 description 1
- NOEYBLKSCGKJGV-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)C=C1Cl NOEYBLKSCGKJGV-UHFFFAOYSA-N 0.000 description 1
- HIXIOUQYTXFTNK-UHFFFAOYSA-N 6-(2,4-difluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1F HIXIOUQYTXFTNK-UHFFFAOYSA-N 0.000 description 1
- RRZTZZSHNICLSU-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C(=CC=CC=3Cl)Cl)C=NC2=NC(N)=NC=1N1CCOCC1 RRZTZZSHNICLSU-UHFFFAOYSA-N 0.000 description 1
- XTJGUXZFNVIBLH-UHFFFAOYSA-N 6-(3,4-dichlorophenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(Cl)C(Cl)=CC=3)C=NC2=NC(N)=NC=1N1CCOCC1 XTJGUXZFNVIBLH-UHFFFAOYSA-N 0.000 description 1
- GFZLGGQOVSSSBU-UHFFFAOYSA-N 6-(4-chloro-3-fluorophenyl)-4-ethoxypteridin-2-amine Chemical compound N1=C2C(OCC)=NC(N)=NC2=NC=C1C1=CC=C(Cl)C(F)=C1 GFZLGGQOVSSSBU-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- LBAKFHQBAGMYDJ-UHFFFAOYSA-N 6-(4-fluoro-2-methylphenyl)-4-morpholin-4-ylpteridin-2-amine Chemical compound CC1=CC(F)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 LBAKFHQBAGMYDJ-UHFFFAOYSA-N 0.000 description 1
- FWGWWKGQBHHVOF-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(2-methoxyethoxy)pteridine Chemical compound N1=C2C(OCCOC)=NC=NC2=NC=C1C1=CC=C(F)C=C1 FWGWWKGQBHHVOF-UHFFFAOYSA-N 0.000 description 1
- YURXAWIIKQUGHF-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-(2-methylpropoxy)pteridin-2-amine Chemical compound N1=C2C(OCC(C)C)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 YURXAWIIKQUGHF-UHFFFAOYSA-N 0.000 description 1
- KBDIQXNSFSAGSC-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-methoxypteridin-2-amine Chemical compound N1=C2C(OC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 KBDIQXNSFSAGSC-UHFFFAOYSA-N 0.000 description 1
- BLGJMBKCQSHGJU-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-phenylmethoxypteridin-2-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)C=NC2=NC(N)=NC=1OCC1=CC=CC=C1 BLGJMBKCQSHGJU-UHFFFAOYSA-N 0.000 description 1
- BLWBOWPXNZNKBC-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-propan-2-yloxypteridin-2-amine Chemical compound N1=C2C(OC(C)C)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 BLWBOWPXNZNKBC-UHFFFAOYSA-N 0.000 description 1
- IVPYJVAOTOYLFP-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-propan-2-yloxypteridine Chemical compound N1=C2C(OC(C)C)=NC=NC2=NC=C1C1=CC=C(F)C=C1 IVPYJVAOTOYLFP-UHFFFAOYSA-N 0.000 description 1
- YICXXVUERHRLTR-UHFFFAOYSA-N 6-(4-fluorophenyl)-4-propoxypteridin-2-amine Chemical compound N1=C2C(OCCC)=NC(N)=NC2=NC=C1C1=CC=C(F)C=C1 YICXXVUERHRLTR-UHFFFAOYSA-N 0.000 description 1
- PNKPSBDGNPZDJC-UHFFFAOYSA-N 6-(4-fluorophenyl)pteridin-2-amine Chemical compound C1=NC2=NC(N)=NC=C2N=C1C1=CC=C(F)C=C1 PNKPSBDGNPZDJC-UHFFFAOYSA-N 0.000 description 1
- BFPYUXIFGJJYHU-AYSLTRBKSA-N 6-[(e)-1-phenylprop-1-enyl]-1-propan-2-ylsulfonylbenzimidazol-2-amine Chemical compound C=1C=C2N=C(N)N(S(=O)(=O)C(C)C)C2=CC=1C(=C/C)/C1=CC=CC=C1 BFPYUXIFGJJYHU-AYSLTRBKSA-N 0.000 description 1
- TUZGTRDESCWOLC-UHFFFAOYSA-N 6-[3,5-bis(trifluoromethyl)phenyl]-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)C=NC2=NC(N)=NC=1N1CCOCC1 TUZGTRDESCWOLC-UHFFFAOYSA-N 0.000 description 1
- YUSJWGBURRHBGV-UHFFFAOYSA-N 6-chloro-4-morpholin-4-ylpteridin-2-amine Chemical compound C=12N=C(Cl)C=NC2=NC(N)=NC=1N1CCOCC1 YUSJWGBURRHBGV-UHFFFAOYSA-N 0.000 description 1
- QNJBVYSMCDLEHQ-UHFFFAOYSA-N 6-morpholin-4-ylpyrimidine-2,4,5-triamine;dihydrochloride Chemical compound Cl.Cl.NC1=NC(N)=C(N)C(N2CCOCC2)=N1 QNJBVYSMCDLEHQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NELKDDCAJDVESM-UHFFFAOYSA-N 8-(6-fluoro-5-methylpyridin-3-yl)-4-morpholin-4-yl-7H-pteridin-2-amine Chemical compound O1CCN(CC1)C1=NC(=NC=2N(CC=NC1=2)C=1C=C(C(=NC=1)F)C)N NELKDDCAJDVESM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- ZMCPTLLCBKEMCB-UHFFFAOYSA-N C(C)ON=C1NC2=NC=CN=C2C=N1 Chemical compound C(C)ON=C1NC2=NC=CN=C2C=N1 ZMCPTLLCBKEMCB-UHFFFAOYSA-N 0.000 description 1
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 description 1
- GZAGPXKSUKBUTP-UHFFFAOYSA-N C.CC(=O)NC1=NC2=C(N=C(C3=CC=C(F)C=C3)C=N2)C(N2C=NC=N2)=N1.CC1=NC(N)=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2 Chemical compound C.CC(=O)NC1=NC2=C(N=C(C3=CC=C(F)C=C3)C=N2)C(N2C=NC=N2)=N1.CC1=NC(N)=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2 GZAGPXKSUKBUTP-UHFFFAOYSA-N 0.000 description 1
- CAUDTSDBNWYADX-UHFFFAOYSA-N C.CC1=NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2.FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1 Chemical compound C.CC1=NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2.FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1 CAUDTSDBNWYADX-UHFFFAOYSA-N 0.000 description 1
- ZPUTWYBURPGKMI-UHFFFAOYSA-N C1([ClH]C[ClH]C=C1)C=1N=C2C(=NC(=NC2=NC=1)N)OCC Chemical compound C1([ClH]C[ClH]C=C1)C=1N=C2C(=NC(=NC2=NC=1)N)OCC ZPUTWYBURPGKMI-UHFFFAOYSA-N 0.000 description 1
- SXQMMZOCJHOEGS-JTQLQIEISA-N CB(O)N[C@@H](CO)C(=O)NC1=CC=C(C)C=C1 Chemical compound CB(O)N[C@@H](CO)C(=O)NC1=CC=C(C)C=C1 SXQMMZOCJHOEGS-JTQLQIEISA-N 0.000 description 1
- YICAMJWHIUMFDI-UHFFFAOYSA-N CC(=O)NC1=CC=C(C)C=C1 Chemical compound CC(=O)NC1=CC=C(C)C=C1 YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 description 1
- MSCOTCFFVSXVGB-UHFFFAOYSA-N CC(=O)NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(N)C=C3)C=NC2=N1.CC(=O)NC1=NC(N2CCOCC2)=C2N=C(Cl)C=NC2=N1 Chemical compound CC(=O)NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(N)C=C3)C=NC2=N1.CC(=O)NC1=NC(N2CCOCC2)=C2N=C(Cl)C=NC2=N1 MSCOTCFFVSXVGB-UHFFFAOYSA-N 0.000 description 1
- PYXOLJWGRYSLLJ-UHFFFAOYSA-N CC(=O)NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(N)C=C3)C=NC2=N1.CC(C)C(=O)Cl.NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(CC(=O)C4CC4)C=C3)C=NC2=N1 Chemical compound CC(=O)NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(N)C=C3)C=NC2=N1.CC(C)C(=O)Cl.NC1=NC(N2CCOCC2)=C2N=C(C3=CC=C(CC(=O)C4CC4)C=C3)C=NC2=N1 PYXOLJWGRYSLLJ-UHFFFAOYSA-N 0.000 description 1
- NURQLCJSMXZBPC-UHFFFAOYSA-N CC1=C(C)C=NC=C1 Chemical compound CC1=C(C)C=NC=C1 NURQLCJSMXZBPC-UHFFFAOYSA-N 0.000 description 1
- FUNUTBJJKQIVSY-UHFFFAOYSA-N CC1=C(Cl)C=C(Cl)C=C1 Chemical compound CC1=C(Cl)C=C(Cl)C=C1 FUNUTBJJKQIVSY-UHFFFAOYSA-N 0.000 description 1
- KFAKZJUYBOYVKA-UHFFFAOYSA-N CC1=C(Cl)C=CC(Cl)=C1 Chemical compound CC1=C(Cl)C=CC(Cl)=C1 KFAKZJUYBOYVKA-UHFFFAOYSA-N 0.000 description 1
- LRQPEHJWTXCLQY-UHFFFAOYSA-N CC1=C(F)C(F)=C(F)C=C1 Chemical compound CC1=C(F)C(F)=C(F)C=C1 LRQPEHJWTXCLQY-UHFFFAOYSA-N 0.000 description 1
- ZGEAYXBIJAYBKA-UHFFFAOYSA-N CC1=C(F)C=C(F)C(F)=C1 Chemical compound CC1=C(F)C=C(F)C(F)=C1 ZGEAYXBIJAYBKA-UHFFFAOYSA-N 0.000 description 1
- HZCVONJWZPKKBI-UHFFFAOYSA-N CC1=C(F)C=C(F)C=C1F Chemical compound CC1=C(F)C=C(F)C=C1F HZCVONJWZPKKBI-UHFFFAOYSA-N 0.000 description 1
- YFKPBFKOUVIQTN-UHFFFAOYSA-N CC1=C(OC(F)(F)F)C=CC=C1 Chemical compound CC1=C(OC(F)(F)F)C=CC=C1 YFKPBFKOUVIQTN-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N CC1=CC(C)=CC(C)=C1 Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N CC1=CC(C)=NC=C1 Chemical compound CC1=CC(C)=NC=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
- UHIGHLGTNVYXOP-UHFFFAOYSA-N CC1=CC(F)=C(F)C(F)=C1 Chemical compound CC1=CC(F)=C(F)C(F)=C1 UHIGHLGTNVYXOP-UHFFFAOYSA-N 0.000 description 1
- FZMPLKVGINKUJZ-UHFFFAOYSA-N CC1=CC(F)=C(F)C=C1 Chemical compound CC1=CC(F)=C(F)C=C1 FZMPLKVGINKUJZ-UHFFFAOYSA-N 0.000 description 1
- VCZNNAKNUVJVGX-UHFFFAOYSA-N CC1=CC=C(C#N)C=C1 Chemical compound CC1=CC=C(C#N)C=C1 VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 1
- RBQRZWYCXAXPIN-UHFFFAOYSA-N CC1=CC=C(C#N)S1 Chemical compound CC1=CC=C(C#N)S1 RBQRZWYCXAXPIN-UHFFFAOYSA-N 0.000 description 1
- UJHYJQHCYRQQMI-UHFFFAOYSA-N CC1=CC=C(C=N)S1 Chemical compound CC1=CC=C(C=N)S1 UJHYJQHCYRQQMI-UHFFFAOYSA-N 0.000 description 1
- FWVKDGWFCVUMSI-UHFFFAOYSA-N CC1=CC=C(CC(=O)C(C)(C)C)C=C1 Chemical compound CC1=CC=C(CC(=O)C(C)(C)C)C=C1 FWVKDGWFCVUMSI-UHFFFAOYSA-N 0.000 description 1
- RUTLCLHEAOPMKT-UHFFFAOYSA-N CC1=CC=C(CC(=O)C(C)C)C=C1 Chemical compound CC1=CC=C(CC(=O)C(C)C)C=C1 RUTLCLHEAOPMKT-UHFFFAOYSA-N 0.000 description 1
- JBZFWJJJLREXJO-UHFFFAOYSA-N CC1=CC=C(CN2CCOCC2)C=C1 Chemical compound CC1=CC=C(CN2CCOCC2)C=C1 JBZFWJJJLREXJO-UHFFFAOYSA-N 0.000 description 1
- NPDACUSDTOMAMK-UHFFFAOYSA-N CC1=CC=C(Cl)C=C1 Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N CC1=CC=C(N)C=C1 Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- VPMVBBCZQOSGBS-UHFFFAOYSA-N CC1=CC=C(NC(=O)C(C)C)C=C1 Chemical compound CC1=CC=C(NC(=O)C(C)C)C=C1 VPMVBBCZQOSGBS-UHFFFAOYSA-N 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N CC1=CC=C(O)C=C1 Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N CC1=CC=CO1 Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N CC1=NC=CC=C1 Chemical compound CC1=NC=CC=C1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- APOJIILNJVLCQE-UHFFFAOYSA-N CC1CN(C)CC(C)O1 Chemical compound CC1CN(C)CC(C)O1 APOJIILNJVLCQE-UHFFFAOYSA-N 0.000 description 1
- FOTXAJDDGPYIFU-UHFFFAOYSA-N CCC1CC1 Chemical compound CCC1CC1 FOTXAJDDGPYIFU-UHFFFAOYSA-N 0.000 description 1
- NEZRFXZYPAIZAD-UHFFFAOYSA-N CCC1CCC1 Chemical compound CCC1CCC1 NEZRFXZYPAIZAD-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N CCC1CCCCC1 Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- WFRBDWRZVBPBDO-UHFFFAOYSA-N CCCC(C)(C)O Chemical compound CCCC(C)(C)O WFRBDWRZVBPBDO-UHFFFAOYSA-N 0.000 description 1
- QUEBYVKXYIKVSO-UHFFFAOYSA-N CCCC1=CC(C)=CC=C1 Chemical compound CCCC1=CC(C)=CC=C1 QUEBYVKXYIKVSO-UHFFFAOYSA-N 0.000 description 1
- FBGSJNNMMKJKGE-UHFFFAOYSA-N CCCC1=CC(F)=CC=C1 Chemical compound CCCC1=CC(F)=CC=C1 FBGSJNNMMKJKGE-UHFFFAOYSA-N 0.000 description 1
- ODLMAHJVESYWTB-UHFFFAOYSA-N CCCC1=CC=CC=C1 Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 1
- MWVPQZRIWVPJCA-UHFFFAOYSA-N CCCC1CC1 Chemical compound CCCC1CC1 MWVPQZRIWVPJCA-UHFFFAOYSA-N 0.000 description 1
- LMRKVKPRHROQRR-UHFFFAOYSA-N CCCCN1CCOCC1 Chemical compound CCCCN1CCOCC1 LMRKVKPRHROQRR-UHFFFAOYSA-N 0.000 description 1
- JXLHTTUSANXQJZ-UHFFFAOYSA-N CCOC1=C2N=C(C3=C(F)C(F)=CC=C3)C=NC2=NC(N)=N1.NC1=NC(N)=C2N=C(C3=C(F)C(F)=CC=C3)C=NC2=N1 Chemical compound CCOC1=C2N=C(C3=C(F)C(F)=CC=C3)C=NC2=NC(N)=N1.NC1=NC(N)=C2N=C(C3=C(F)C(F)=CC=C3)C=NC2=N1 JXLHTTUSANXQJZ-UHFFFAOYSA-N 0.000 description 1
- QKGBKPZAXXBLJE-UHFFFAOYSA-N CCOP(=O)(CC1=CC=C(C)C=C1)OCC Chemical compound CCOP(=O)(CC1=CC=C(C)C=C1)OCC QKGBKPZAXXBLJE-UHFFFAOYSA-N 0.000 description 1
- BOEHXXUPIMWPGH-UHFFFAOYSA-M CCSC1=NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2.CCS[Na].FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1 Chemical compound CCSC1=NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2.CCS[Na].FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1 BOEHXXUPIMWPGH-UHFFFAOYSA-M 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- CURITQACYLEMCV-QSMANLJDSA-N CO.Cl.FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1.NC1=C(N)C(=O)NC=N1.O=C(/C=N/O)C1=CC=C(F)C=C1.O=C1NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2 Chemical compound CO.Cl.FC1=CC=C(C2=NC3=C(N=CN=C3N3C=NC=N3)N=C2)C=C1.NC1=C(N)C(=O)NC=N1.O=C(/C=N/O)C1=CC=C(F)C=C1.O=C1NC=NC2=C1N=C(C1=CC=C(F)C=C1)C=N2 CURITQACYLEMCV-QSMANLJDSA-N 0.000 description 1
- DTFKRVXLBCAIOZ-UHFFFAOYSA-N COC1=C(C)C=CC=C1 Chemical compound COC1=C(C)C=CC=C1 DTFKRVXLBCAIOZ-UHFFFAOYSA-N 0.000 description 1
- FOVXANGOLMXKES-UHFFFAOYSA-N COC1=C(F)C=C(C)C=C1 Chemical compound COC1=C(F)C=C(C)C=C1 FOVXANGOLMXKES-UHFFFAOYSA-N 0.000 description 1
- HGRXBKDKSYDWLD-UHFFFAOYSA-N COC1=NC=CC(C)=C1 Chemical compound COC1=NC=CC(C)=C1 HGRXBKDKSYDWLD-UHFFFAOYSA-N 0.000 description 1
- GLCMITCQPZPVDU-UHFFFAOYSA-N COP(=O)(CC1=CC=C(C)C=C1)OC Chemical compound COP(=O)(CC1=CC=C(C)C=C1)OC GLCMITCQPZPVDU-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- UCPOMLWZWRTIAA-UHFFFAOYSA-N [4-[3-(ethylamino)pyridin-2-yl]piperazin-1-yl]-(5-methoxy-1h-indol-2-yl)methanone Chemical compound CCNC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(OC)C=C3C=2)CC1 UCPOMLWZWRTIAA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HXWOWBFXYUFFKS-PSJNWGMYSA-N aranotin Chemical compound C1C2=COC=C[C@H](O)[C@H]2N(C2=O)[C@]31SS[C@]21CC2=COC=C[C@H](OC(=O)C)[C@H]2N1C3=O HXWOWBFXYUFFKS-PSJNWGMYSA-N 0.000 description 1
- 229950001980 aranotin Drugs 0.000 description 1
- HXWOWBFXYUFFKS-UHFFFAOYSA-N aranotin Natural products C1C2=COC=CC(O)C2N(C2=O)C31SSC21CC2=COC=CC(OC(=O)C)C2N1C3=O HXWOWBFXYUFFKS-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- DIXRMZGIJNJUGL-UHFFFAOYSA-N arildone Chemical compound CCC(=O)C(C(=O)CC)CCCCCCOC1=CC=C(OC)C=C1Cl DIXRMZGIJNJUGL-UHFFFAOYSA-N 0.000 description 1
- 229950003470 arildone Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229950006463 atevirdine Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004045 azirinyl group Chemical group 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical compound OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 1
- 229950002405 cipamfylline Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 229950000330 desciclovir Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 229950002098 disoxaril Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950000529 enviradene Drugs 0.000 description 1
- 229950008161 enviroxime Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229950003564 fiacitabine Drugs 0.000 description 1
- 229950008802 fialuridine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950010605 fosarilate Drugs 0.000 description 1
- 229940112424 fosfonet Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229950001103 ketoxal Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 229950005339 lobucavir Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 125000004401 m-toluyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C(*)=O 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229950006938 memotine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- SZORTSQVDWHFHH-UHFFFAOYSA-N methyl n-[4-(2-amino-4-morpholin-4-ylpteridin-6-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=CN=C(N=C(N)N=C2N3CCOCC3)C2=N1 SZORTSQVDWHFHH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960003152 metisazone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
- PUWYTKAKSNINMO-UHFFFAOYSA-N n-[6-(4-fluorophenyl)pteridin-2-yl]acetamide Chemical compound C1=NC2=NC(NC(=O)C)=NC=C2N=C1C1=CC=C(F)C=C1 PUWYTKAKSNINMO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004626 naphthothienyl group Chemical group C1(=CSC2=C1C1=CC=CC=C1C=C2)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000005441 o-toluyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005646 oximino group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000000352 p-cymenyl group Chemical group C1(=C(C=C(C=C1)C)*)C(C)C 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Chemical group 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000001388 picenyl group Chemical group C1(=CC=CC2=CC=C3C4=CC=C5C=CC=CC5=C4C=CC3=C21)* 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical class CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950011136 pirodavir Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- CITCTUNIFJOTHI-UHFFFAOYSA-N pteridine-2,4-diamine Chemical compound N1=CC=NC2=NC(N)=NC(N)=C21 CITCTUNIFJOTHI-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Chemical group 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical group O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950001816 somantadine Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229950009279 sorivudine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008117 stearic acid Chemical class 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000006407 thiazinanyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000004862 thiobutyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical class *C(*)=S 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- MPMFCABZENCRHV-UHFFFAOYSA-N tilorone Chemical compound C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 MPMFCABZENCRHV-UHFFFAOYSA-N 0.000 description 1
- 229950006823 tilorone Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 229950007412 viroxime Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229950004966 xenazoic acid Drugs 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229950007096 zinviroxime Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Definitions
- the present invention relates to a group of novel 4,6-di- and 2,4,6-trisubstituted pteridines and to their use as biologically active ingredients for manufacturing medicaments for the prevention or treatment of viral infections, in particular infections by a virus of the Flaviridae family, more specifically for inhibiting replication of hepatitis C virus.
- the present invention thus also relates to therapeutic and prophylactic methods comprising administration of said specifically 4,6-di- and 2,4,6-trisubstituted pteridine derivatives, or pro-drugs thereof, to mammals, in particular human beings.
- Hepatitis is an inflammation of the liver that is most often caused by infection with one of three viruses known as hepatitis A, B or C.
- Hepatitis A virus (HAV) infection is the most common cause of acute hepatitis, and usually resolves spontaneously after several weeks of acute symptoms.
- Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common viral causes of chronic hepatitis, usually defined as liver inflammation persisting for more than six months.
- HCV is the second most common cause of viral hepatitis in general and most common cause of chronic hepatitis. The World Health Organization estimates that worldwide 170 million people (3% of the world's population) are chronically infected with HCV.
- Pestiviruses may be adopted as a model virus and surrogate for HCV.
- the bovine viral diarrhea virus (BVDV) is closely related to hepatitis C virus (HCV) and may be used as a surrogate virus in drug development for HCV infection.
- HCV is a representative and highly significant member of the Flaviviridae family, a family of positive-strand RNA viruses.
- This family includes the following genera: Genus Flavivirus (type species yellow fever virus, others include west nile virus and dengue fever ), Genus Hepacivirus (type species hepatitis C virus ), and Genus Pestivirus (type species bovine viral diarrhea virus (BVDV), others include classical swine fever or hog cholera ).
- Genus Flavivirus type species yellow fever virus, others include west nile virus and dengue fever
- Genus Hepacivirus type species hepatitis C virus
- Genus Pestivirus type species bovine viral diarrhea virus (BVDV), others include classical swine fever or hog cholera .
- Contrary to other families of positive strand RNA viruses such as human immunodeficiency virus (HIV)
- HCV seems incapable of integrating into the host's genome.
- the primary immune response to HCV is mounted by cytotoxic T lymphocytes
- hepatitis C The diagnosis of hepatitis C is rarely made during the acute phase of the disease because the majority of people infected experience no symptoms during this phase of the disease. Those who do experience acute phase symptoms are rarely ill enough to seek medical attention. The diagnosis of chronic phase hepatitis C is also challenging due to the absence or lack of specificity of symptoms until advanced liver disease develops, which may not occur until decades into the disease.
- Hepatitis C testing begins with serological blood tests used to detect antibodies to HCV.
- Anti-HCV antibodies can be detected in about 80% of patients within 15 weeks after exposure, in more than 90% of patients within 5 months after exposure, and in more than 97% of patients by 6 months after exposure.
- HCV antibody tests have a strong positive predictive value for exposure to the hepatitis C virus, but may miss patients who have not yet developed antibodies (seroconversion), or have an insufficient level of antibodies to detect.
- Anti-HCV antibodies indicate exposure to the virus, but cannot determine if ongoing infection is present. All persons with positive anti-HCV antibody tests must undergo additional testing for the presence of the hepatitis C virus itself to determine whether current infection is present.
- HCV presence of HCV may be tested by using molecular nucleic acid testing methods such as, but not limited to, polymerase chain reaction (PCR), transcription mediated amplification (TMA), or branched DNA amplification. All HCV nucleic acid molecular tests have the capacity to detect not only whether the virus is present, but also to measure the amount of virus present in the blood (the HCV viral load). The HCV viral load is an important factor in determining the probability of response to interferon-base therapy, but does not indicate disease severity nor the likelihood of disease progression.
- PCR polymerase chain reaction
- TMA transcription mediated amplification
- HCV viral load is an important factor in determining the probability of response to interferon-base therapy, but does not indicate disease severity nor the likelihood of disease progression.
- the goal of treatment is to prevent complications of HCV infection. This is principally achieved by eradication of infection. Accordingly, treatment responses are frequently characterized by the results of HCV RNA testing. Infection is considered eradicated when there is a sustained virologic response (SVR), defined as the absence of HCV RNA in serum by a sensitive test at the end of treatment and 6 months later. Persons who achieve an SVR almost always have a dramatic earlier reduction in the HCV RNA level, referred to as an early virologic response (EVR). Continued absence of detectable virus at termination of treatment is referred to as end of treatment response (ETR). A patient is considered relapsed when HCV RNA becomes undetectable on treatment but is detected again after discontinuation of treatment. Persons in whom HCV RNA levels remain stable on treatment are considered as non-responders, while those whose HCV RNA levels decline but remain detectable are referred to as partial responders.
- SVR sustained virologic response
- EMR early virologic response
- Interferons are substances naturally released by cells in the body after viral invasion.
- Interferon alfa-2b and peginterferon alfa-2b are synthetic versions of these substances.
- the protein product is manufactured by recombinant DNA-technology.
- Second generation interferons are further derivatized by binding to inert polyethylene glycol, thereby altering the pharmacokinetic properties.
- Ribavirin is a nucleoside analogue, which disrupts viral replication of hepatitis C virus (HCV).
- the most common side effects of HCV treatment with (pegylated) interferon include: a decrease in white blood cells and platelets, anemia, nausea, diarrhea, fever, chills, muscle and joint pain, difficulty in concentrating, thyroid dysfunction, hair loss, sleeplessness, irritability, mild to serious depression, and rarely, suicidal thoughts.
- Other serious adverse events include bone marrow toxicity, cardiovascular disorders, hypersensitivity, endocrine disorders, pulmonary disorders, colitis, pancreatitis, and ophthalmologic disorders (eye and vision problems).
- (Pegylated) interferon may also cause or make worse fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients with persistently severe or worsening signs or symptoms of these conditions are advised to stop therapy.
- Ribavirin The most common side effect of HCV treatment with ribavirin is anemia, which can be treated with erythropoietin. Other side effects include mood swings, irritability, anxiety, insomnia, abdominal pain, nervousness, breathlessness, rash, hair loss, dry skin, nausea, diarrhea, loss of appetite, dizziness and weight loss. Ribavirin can also cause birth defects. Ribavirin should not be taken in combination with certain HIV drugs such as, but not limited to, didanosine, since lactic acidosis with fatal hepatic steatosis (fatty liver) may occur. Special attention should be taken for treatment with HIV co-infection.
- the liver is the primary target of infection, studies to better define the steps of HCV infection are greatly hampered by the lack of a suitable animal model for such studies.
- the sub-genomic HCV RNA replicon system provides a cell-based assay to evaluate inhibitors of HCV enzymes like the protease, helicase, and RNA-dependant RNA polymerase or to evaluate nucleic acid targeting strategies like antisense RNA arid ribozymes.
- Targets for HCV Drug development include HCV-encoded enzymes, namely, NS2-3 and NS3-4A proteases, NS3 helicase, and NS5B RNA dependant RNA polymerase.
- HCV replication can be inhibited by blocking the conserved RNA elements employing a nucleic acid based approach including antisense oligonucleotides, ribozymes, RNA aptamers, RNA decoys, and RNA interference.
- a major drawback for such nucleic acid based approach is the size and charge of the nucleic acids, and their usually low physiological stability that do not allow for oral administration.
- Another target option for therapy is by blocking viral entry into the cell by obstruction of binding to HCV receptors such as, but not limited to, CD 209L and L-SIGN.
- the present invention is based on the unexpected finding that a number of novel specifically substituted pteridines, in particular 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines, are capable of exhibiting a significant and selective activity against certain types of viral infections, provided that the substituting pattern of such pteridines is suitably selected.
- these selected 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines are capable of selectively inhibiting the replication of the hepatitis C virus.
- the present invention provides pharmaceutical compositions comprising one or more 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines in combination with one or more pharmaceutically acceptable excipients.
- the present invention also provides prophylactic and therapeutic methods of treatment of higher mammals, in particular human beings, through the administration of an effective amount of such selected 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines.
- tri-substituted in relation to the pteridine structure means that three of the carbon atoms being in positions 2, 4 and 6 of the pteridine moiety (according to standard atom numbering for the pteridine moiety) are substituted with an atom or group of atoms other than hydrogen.
- di-substituted in relation to the pteridine structure means that two of the carbon atoms being in positions 4 and 6 of the pteridine moiety (according to standard atom numbering for the pteridine moiety) are substituted with an atom or group of atoms other than hydrogen.
- C 1-7 alkyl means straight and branched chain saturated acyclic hydrocarbon monovalent radicals having from 1 to 7 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methyl-ethyl (isopropyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 2-methyl-butyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, n-heptyl and the like.
- C 1-4 alkyl refers to such radicals having from 1 to 4 carbon atoms, i.e. up to and including butyl
- C 1-12 alkyl refers to such radicals having from 1 to 12 carbon atoms.
- acyl broadly refers to a substituent derived from an acid such as an organic monocarboxylic acid, a carbonic acid, a carbamic acid (resulting into a carbamoyl substituent) or the thioacid or imidic acid (resulting into a carbamidoyl substituent) corresponding to said acids
- sulfonyl refers to a substituent derived from an organic sulfonic acid, wherein said acids comprise an aliphatic, aromatic or heterocyclic group in the molecule.
- acyl within the scope of the above definition refers to a carbonyl (oxo) group adjacent to a C 1-7 alkyl, a C 3-10 cycloalkyl, an aryl, an arylalkyl or a heterocyclic group, all of them being such as herein defined. Suitable examples of acyl groups are to be found below.
- Acyl and sulfonyl groups originating from aliphatic or cycloaliphatic monocarboxylic acids are designated herein as aliphatic or cycloaliphatic acyl and sulfonyl groups and include, but are not limited to, the following:
- Acyl and sulfonyl groups may also originate from aromatic monocarboxylic acids and include, but are not limited to, the following:
- Acyl groups may also originate from an heterocyclic monocarboxylic acids and include, but are not limited to, the following:
- C 1-7 alkylene means the divalent hydrocarbon radical corresponding to the above defined alkyl, such as methylene, bis(methylene), tris(methylene), tetramethylene, hexamethylene and the like.
- C 3-10 cycloalkyl means a mono- or polycyclic saturated hydrocarbon monovalent radical having from 3 to 10 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, or a C 7-10 polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
- C 3-10 cycloalkyl-alkyl refers to an aliphatic saturated hydrocarbon monovalent radical (preferably a C 1-7 alkyl such as defined above) to which a C 3-10 cycloalkyl (such as defined above) is already linked such as, but not limited to, cyclohexylmethyl, cyclopentylmethyl and the like.
- C 3-10 cycloalkylene means the divalent hydrocarbon radical corresponding to the above defined C 3-10 cycloalkyl.
- aryl designates any mono- or polycyclic aromatic monovalent hydrocarbon radical having from 6 up to 30 carbon atoms such as but not limited to phenyl, naphthyl, anthracenyl, phenantracyl, fluoranthenyl, chrysenyl, pyrenyl, biphenylyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like, including fused benzo-C 4-8 cycloalkyl radicals (the latter being as defined above) such as, for instance, indanyl, tetrahydronaphthyl, fluorenyl and the like, all of the said radicals being optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, trifluoromethyl,
- the term “homocyclic” means a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated hydrocarbon radical having from 4 up to 15 carbon atoms but including no heteroatom in the said ring; for instance said combination of substituents may form a C 2-6 alkylene radical, such as tetramethylene, which cyclizes with the carbon atoms in certain positions of the pteridine ring.
- heterocyclic and “heterocyclyl” mean a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated monovalent hydrocarbon radical having from 2 up to 15 carbon atoms and including one or more heteroatoms in one or more heterocyclic rings, each of said rings having from 3 to 10 atoms (and optionally further including one or more heteroatoms attached to one or more carbon atoms of said ring, for instance in the form of a carbonyl or thiocarbonyl or selenocarbonyl group, and/or to one or more heteroatoms of said ring, for instance in the form of a sulfone, sulfoxide, N-oxide, phosphate, phosphonate or selenium oxide group), each of said heteroatoms being
- each carbon atom of said heterocyclic ring may furthermore be independently substituted with a substituent selected from the group consisting of halogen, nitro, C- 1-7 alkyl (optionally containing one or more functions or radicals selected from the group consisting of carbonyl (oxo), alcohol (hydroxyl), ether (alkoxy), acetal, amino, imine, oximino, alkyl
- C 1-7 alkoxy As used herein with respect to a substituting radical, and unless otherwise stated, the terms “C 1-7 alkoxy”, “C 3-10 cycloalkoxy”, “aryloxy”, “arylalkoxy”, “oxyheterocyclic”, “heterocyclic-substituted alkoxy”, “thio C 1-7 alkyl”, “thio C 3-10 cycloalkyl”, “arylthio”, “arylalkylthio” and “thioheterocyclic” refer to substituents wherein a carbon atom of a C 1-7 alkyl, respectively a C 3-10 cycloalkyl, aryl, arylalkyl, heterocyclic radical or heterocyclic-substituted alkyl (each of them such as defined herein), is attached to an oxygen atom or a divalent sulfur atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isoprop
- halogen means any atom selected from the group consisting of fluorine, chlorine, bromine and iodine.
- halo C 1-7 alkyl means a C 1-7 alkyl radical (such as above defined) in which one or more hydrogen atoms are independently replaced by one or more halogens (preferably fluorine, chlorine or bromine), such as but not limited to difluoromethyl, trifluoromethyl, trifluoroethyl, octafluoropentyl, dodecafluoro-heptyl, dichloromethyl and the like.
- C 2-7 alkenyl designate a straight and branched acyclic hydrocarbon monovalent radical having one or more ethylenic unsaturations and having from 2 to 7 carbon atoms such as, for example, vinyl, 1-propenyl, 2-propenyl (allyl), 1-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl, 2-hexenyl, 2-heptenyl, 1,3-butadienyl, pentadienyl, hexadienyl, heptadienyl, heptatrienyl and the like, including all possible isomers thereof.
- C 3-10 cycloalkenyl means a monocyclic mono- or polyunsaturated hydrocarbon monovalent radical having from 3 to 8 carbon atoms, such as for instance cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl and the like, or a C 7-10 polycyclic mono- or polyunsaturated hydrocarbon mono-valent radical having from 7 to 10 carbon atoms such as dicyclopentadienyl, fenchenyl (including all isomers thereof, such as ⁇ -pinolenyl), bicyclo[2.2.1]hept-2-en
- C 2-7 alkynyl defines straight and branched chain hydrocarbon radicals containing one or more triple bonds and optionally at least one double bond and having from 2 to 7 carbon atoms such as, for example, acetylenyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 2-pentynyl, 1-pentynyl, 3-methyl-2-butynyl, 3-hexynyl, 2-hexynyl, 1-penten-4-ynyl, 3-penten-1-ynyl, 1,3-hexadien-1-ynyl and the like.
- arylalkyl As used herein with respect to a substituting radical, and unless otherwise stated, the terms “arylalkyl”, “arylalkenyl” and “heterocyclic-substituted alkyl” refer to an aliphatic saturated or ethylenically unsaturated hydrocarbon monovalent radical (preferably a C 1-7 alkyl or C 2-7 alkenyl radical such as defined above) onto which an aryl or heterocyclic radical (such as defined above) is already bonded via a carbon atom, and wherein the said aliphatic radical and/or the said aryl or heterocyclic radical may be optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, C 1-7 alkyl, C 1-7 alkoxy, trifluoromethyl and nitro, such as but not limited to benzyl, 4-chlorobenzyl, 4-fluorobenzyl, 2-fluorobenzyl
- alkylaryl and alkyl-substituted heterocyclic refer to an aryl or, respectively, heterocyclic radical (such as defined above) onto which are bonded one or more aliphatic saturated or unsaturated hydrocarbon monovalent radicals, preferably one or more C 1-7 alkyl, C 2-7 alkenyl or C 3-10 cycloalkyl radicals as defined above such as, but not limited to, o-toluyl, m-toluyl, p-toluyl, 2,3-xylyl, 2,4-xylyl, 3,4-xylyl, o-cumenyl, m-cumenyl, p-cumenyl, o-cymenyl, m-cymenyl, p-cymenyl, mesityl, tert-butylphenyl, lutidinyl (i.e
- alkoxyaryl refers to an aryl radical (such as defined above) onto which is (are) bonded one or more C 1-7 alkoxy radicals as defined above, preferably one or more methoxy radicals, such as, but not limited to, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, methoxynaphthyl and the like.
- alkylamino As used herein with respect to a substituting radical, and unless otherwise stated, the terms “alkylamino”, “cycloalkylamino”, “alkenylamino” “cyclo-alkenylamino”, “arylamino”, “arylalkylamino”, “heterocyclic-substituted alkyl-amino”, “heterocyclic-substituted arylamino”, “heterocyclic amino”, “hydroxy-alkylamino”, “mercapto-alkylamino” and “alkynylamino” mean that respectively one (thus monosubstituted amino) or even two (thus disubstituted amino) C 1-7 alkyl, C 3-10 cycloalkyl, C 2-7 alkenyl, C 3-10 cycloalkenyl, aryl, arylalkyl, heterocyclic-substituted alkyl, heterocyclic-substituted aryl,
- an alkyl radical and an alkenyl radical or to two different radicals within the same sub-set of radicals, e.g. methylethylamino; among di-substituted amino radicals, symmetrically-substituted amino radicals are more easily accessible and thus usually preferred from a standpoint of ease of preparation.
- the terms “(thio)carboxylic acid ester”, “(thio)carboxylic acid thioester” and “(thio)-carboxylic acid amide” refer to radicals wherein the carboxyl or thiocarboxyl group is bonded to the hydrocarbonyl residue of an alcohol, a thiol, a polyol, a phenol, a thiophenol, a primary or secondary amine, a polyamine, an amino-alcohol or ammonia, the said hydrocarbonyl residue being selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, alkylaryl, alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, arylamino, arylalkylamino,
- sulfonamide refers to a radical represented by the formula —NR x —SO 2 R y , wherein R x hydrogen or a cyclic or non-cyclic hydrocarbyl group and R y is a cyclic or non-cyclic hydrocarbyl group.
- amino-acid refers to a radical derived from a molecule having the chemical formula H 2 N—CHR—COOH, wherein R is the side group of atoms characterising the amino-acid type; said molecule may be one of the 20 naturally-occurring amino-acids or any similar non naturally-occurring amino-acid.
- stereoisomer refers to all possible different isomeric as well as conformational forms which the compounds of the invention may possess, in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the present invention.
- enantiomer means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
- solvate includes any combination which may be formed by a pteridine derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent such as, but not limited to, alcohols, ketones, esters, ethers, nitriles and the like.
- suitable inorganic solvent e.g. hydrates
- organic solvent such as, but not limited to, alcohols, ketones, esters, ethers, nitriles and the like.
- the present invention relates to a group of novel 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives.
- this group includes molecules selected from the group consisting of:
- Each of the substituents present on positions 2, 4 and/or 6 of the pteridine scaffold of these molecules belongs to a broader class of substituents being defined in the section “Definitions ” herein-above. It should be understood that some alternative molecules differing from the molecules of the above list by replacing such a substituent with another similar substituent of the same class, e.g. replacing 4-fluorophenyl with 4-chlorophenyl on position 6, may result in a very similar utility in medical treatment, therefore said alternative molecules are also within the framework of the present invention.
- the present invention relates to a group of pteridine derivative represented by the structural formula:
- X represents an oxygen atom or a group with the formula S(O) m wherein m is an integer from 0 to 2, or a group with the formula NZ and wherein:
- R 1 is a group selected from the group consisting of C 1-7 alkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkenyl, aryl, alkylaryl, arylalkyl, heterocyclic, heterocyclic-substituted alkyl and alkyl-substituted heterocyclic, each of said groups being optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, C 2-7 alkenyl, C 2-7 alkynyl, halo C 1-4 alkyl, C 3-10 cycloalkoxy, aryloxy, arylalkyloxy, oxyheterocyclic, heterocyclic-substituted alkyloxy, thio C 1-7 alkyl, thio C 3-10 cycloalkyl, thioaryl, thioheterocycl
- Z is a group independently defined as R 1 or Z is hydrogen or the group NZ together with R 1 is either hydroxylamino or an optionally substituted heterocyclic group containing at least one nitrogen atom;
- R 2 is selected from the group consisting of amino; alkanoylamino; thioalkanoylamino; carbamoyl; thiocarbamoyl, ureido; thio-ureido, sulfonamido; hydroxylamino; alkoxyamino; thioalkylamino; mercaptoamino, hydrazino; alkylhydrazino; phenyl-hydrazino; optionally substituted heterocyclic radicals; C 3-7 alkylamino; arylamino; arylalkylamino; cycloalkylamino; alkenylamino; cycloalkenylamino; heterocyclic amino; hydroxyalkylamino; mercaptoalkylamino; C 1-7 alkoxy; C 3-10 cycloalkoxy; thio C 1-7 alkyl; arylsulfoxide; arylsulfone; heterocyclic
- R 4 is hydrogen
- R 3 aryl substituted with one or more substituents independently selected from the group consisting of aryl wherein said aryl is optionally substituted with arylcarbonyl; (O,O-dialkylphosphonyl)-alkyl; alkanoyl; halo-C 1-7 alkoxy; hydroxy-C 1-7 alkoxy; hydroxy-C 1-7 alkyl; di-C 1-7 alkylamino C 1-7 alkyl; ⁇ -carboxy-alkanoylamino, mono-(C 3-7 cycloalkyl)aminocarbonyl, di-(C 3-7 cycloalkyl)aminocarbonyl, mono-(C 1-7 alkyl)aminocarbonyl, mono-( ⁇ -dimethylamino-C 1-7 alkyl)aminocarbonyl, di-(C 1-7 alkyl)aminocarbonyl, mono-(hydroxy-C 1-7 alkyl)aminocarbonyl, fomylamin
- suitable aryl-boronic acids include, but are not limited to, the following commercially available materials wherein the aryl group is 3-acetamidophenyl, 4-acetamidophenyl, 4-acetylphenyl, 3-acetylphenyl, 2-acetylphenyl, 5-acetyl-2-chlorophenyl, 4-acetyl-3-fluorophenyl, 5-acetyl-2-fluorophenyl, 4-(4′-allyloxycarbonylpiperazino)phenyl, 3-aminocarbonyl-phenyl, 4-aminocarbonylphenyl, 2-amino-5-chlorophenyl, 4-amino-3-methoxyphenyl, 3-aminophenyl, 2-amino-4-methylphenyl, 2-amino-5-methylphenyl, 4-amino-2-methylphenyl, 5-amino-2-methylphenyl, 4-amino-3-nitro
- suitable heterocyclic-boronic acids or pinacol esters thereof include, but are not limited to, the following commercially available materials wherein the heterocyclic group is 3,4-methylenedioxyphenyl (benzodioxolyl), 2-acetamidopyridin-5-yl, 2-aminopyridin-5-yl, 2-aminopyrimidin-5-yl, 1,4-benzodioxan-6-yl, 2-benzothienyl, 1-benzothien-3-yl, 1-benzo-thien-2-yl, 2-benzyloxypyridin-5-yl, 1-benzyl-1H-pyrazol-4-yl, 2-bromo-3-chloropyridin-4-yl, 5-bromo-2,3-dihydrobenzo[b]furan-7-yl, 2-bromo-3-methylpyridin-5-yl, 3-bromopyridin-5-yl, 2-bromopyridin
- Stereoisomers of the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of the present invention may be formed by using reactants in their single enantiomeric form wherever possible in the manufacturing process, or by resolving a mixture of stereoisomers by conventional methods.
- One such method is liquid chromatography using one or more suitable chiral stationary phases including, for example, polysaccharides, in particular cellulose or amylose derivatives.
- suitable polysaccharide-based chiral stationary phases are ChiralCelTM CA, OA, OB, OC, OD, OF, OG, OJ and OK, and ChiralpakTM AD, AS, OP(+) and OT(+).
- Appropriate eluents or mobile phases for use in combination with said polysaccharide-based chiral stationary phases are hydrocarbons such as hexane and the like, optionally admixed with an alcohol such as ethanol, isopropanol and the like.
- the above mixture of enantiomers may alternatively be separated by making use of microbial resolution or by resolving the diastereoisomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid and the like or with chiral bases such as brucine and the like.
- the resolving agent may be cleaved from the separated diastereoisomers, e.g.
- one particular embodiment of this invention includes the various precursors or “pro-drug” forms of the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of the present invention. It may be desirable to formulate the compounds of the present invention in the form of a chemical species which itself is not significantly biologically-active but which, when delivered to the body of a human being or higher mammal, will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein.
- the term “pro-drug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.
- the pro-drugs of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms.
- the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus.
- a C—C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used.
- the term “therapeutically suitable pro-drug” is defined herein as a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of humans or mammals to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome.
- the present invention provides the use of 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives as defined herein-above for the manufacture of a medicament for treating or preventing a viral infection, and the corresponding method of treatment of a viral infection by administering an effective amount of such a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative to a patient in need thereof.
- said viral infection may be an infection caused by a virus being a member of the Flaviviridae family.
- the Flaviviridae family is a family of positive-strand RNA viruses which includes the following genera:
- Genus Flavivirus type species include yellow fever virus, west nile virus and dengue fever ).
- Genus Hepacivirus type species includes hepatitis C virus
- Genus Pestivirus type species include bovine viral diarrhea virus, classical swine fever and hog cholera ).
- said Flavivirus is the hepatitis C virus (hereinafter referred as HCV).
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising as an active principle at least one 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative as defined above, e.g. in the form of a pharmaceutically acceptable salt.
- the latter include any therapeutically active non-toxic addition salt which the 4,6-disubstituted or 2,4,6-trisubstituted pteridine compounds of the present invention are able to form with a salt-forming agent.
- Such addition salts may conveniently be obtained by treating the pteridine derivatives of the invention with an appropriate salt-forming acid or base.
- 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives having basic properties may be converted into the corresponding therapeutically active, non-toxic acid addition salt form by treating the free base form with a suitable amount of an appropriate acid following conventional procedures.
- appropriate salt-forming acids include, for instance, inorganic acids resulting in forming salts such as, but not limited to, hydrohalides (e.g.
- hydrochloride and hydrobromide sulfate, nitrate, phosphate, diphosphate, carbonate, bicarbonate, and the like; and organic monocarboxylic or dicarboxylic acids resulting in forming salts such as, for example, acetate, propanoate, hydroxyacetate, 2-hydroxypropanoate, 2-oxopropanoate, lactate, pyruvate, oxalate, malonate, succinate, maleate, fumarate, malate, tartrate, citrate, methanesulfonate, ethanesulfonate, benzoate, 2-hydroxybenzoate, 4-amino-2-hydroxy-benzoate, benzenesulfonate, p-toluenesulfonate, salicylate, p-aminosalicylate, pamoate, bitartrate, camphorsulfonate, edetate, 1,2-ethanedisulfonate, fumarate, glucohe
- 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives having acidic properties may be converted in a similar manner into the corresponding therapeutically active, non-toxic base addition salt form.
- appropriate salt-forming bases include, for instance, inorganic bases like metallic hydroxides such as but not limited to those of alkali and alkaline-earth metals like calcium, lithium, magnesium, potassium and sodium, or zinc, resulting in the corresponding metal salt; organic bases such as but not limited to ammonia, alkylamines, benzathine, hydrabamine, arginine, lysine, N,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylene-diamine, N-methyl-glucamine, procaine and the like.
- Reaction conditions for treating the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of this invention with an appropriate salt-forming acid or base are similar to standard conditions involving the same acid or base but different organic compounds with basic or acidic properties, respectively.
- the pharmaceutically acceptable salt will be designed, i.e. the salt-forming acid or base will be selected so as to impart greater water-solubility, lower toxicity, greater stability and/or slower dissolution rate to the substituted pteridine derivative of this invention.
- the present invention further provides the use of a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a stereoisomer thereof or a pro-drug form thereof, as a biologically-active ingredient, i.e. active principle, especially as a medicine or for the manufacture of a medicament for the prevention or treatment of viral infections, especially infections due to Flaviridae, and pathologic conditions associated therewith such as, but not limited to, hepatitis C.
- active principle especially as a medicine or for the manufacture of a medicament for the prevention or treatment of viral infections, especially infections due to Flaviridae, and pathologic conditions associated therewith such as, but not limited to, hepatitis C.
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising:
- this invention provides combinations, preferably synergistic combinations, of one or more 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivatives of this invention with one or more other antiviral agents.
- the evaluation of a synergistic effect in a drug combination may be made by analyzing the quantification of the interactions between individual drugs, using the median effect principle described by Chou et al. in Adv. Enzyme Reg. (1984) 22:27. Briefly, this principle states that interactions (synergism, additivity, antagonism) between two drugs can be quantified using the combination index (hereinafter referred as Cl) defined by the following equation:
- CI x ED x 1 ⁇ ⁇ c ED x 1 ⁇ ⁇ a + ED x 2 ⁇ ⁇ c ED x 2 ⁇ ⁇ a
- ED x is the dose of the first or respectively second drug used alone ( 1 a, 2 a ), or in combination with the second or respectively first drug ( 1 c, 2 c ), which is needed to produce a given effect.
- the present invention further relates to a pharmaceutical composition or combined preparation having synergistic effects against a viral infection, especially a hepatitis C virus infection, and containing:
- Suitable anti-viral agents for inclusion into the synergistic antiviral compositions or combined preparations of this invention include, for instance, retroviral enzyme inhibitors belonging to categories well known in the art, such as HIV-1 IN inhibitors, nucleoside reverse transcriptase inhibitors (e.g. zidovudine, lamivudine, didanosine, stavudine, zalcitabine and the like), non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine, delavirdine and the like), other reverse transcriptase inhibitors (e.g. foscamet sodium and the like), and HIV-1 protease inhibitors (e.g.
- retroviral enzyme inhibitors belonging to categories well known in the art, such as HIV-1 IN inhibitors, nucleoside reverse transcriptase inhibitors (e.g. zidovudine, lamivudine, didanosine, stavudine, zalcitabine and the like), non-nu
- Suitable antiviral agents include for instance acemannan, acyclovir, adefovir, alovudine, alvircept, amantadine, aranotin, arildone, atevirdine, avridine, cidofovir, cipamfylline, cytarabine, desciclovir, disoxaril, edoxudine, enviradene, enviroxime, famciclovir, farnotine, fiacitabine, fialuridine, floxuridine, fosarilate, fosfonet, ganciclovir, idoxuridine, kethoxal, lobucavir, memotine, methisazone, penciclovir, pirodavir, somantadine, sorivudine, tilorone, trifluridine, val
- hepatitis C virus in particular in human beings and other mammals such as primates. Therefore, of particular relevance in the context of HCV prevention or treatment is co-administration with one or more other agents aiming at HCV inhibition well known in the art, such as but not limited to, (pegylated) interferon alpha, ribavirin, an NS3 protease inhibitor (such as telaprivir), or nucleoside- or non-nucleoside-based inhibitors of NS5B polymerase.
- agents aiming at HCV inhibition well known in the art, such as but not limited to, (pegylated) interferon alpha, ribavirin, an NS3 protease inhibitor (such as telaprivir), or nucleoside- or non-nucleoside-based inhibitors of NS5B polymerase.
- Synergistic activity of the pharmaceutical compositions or combined preparations of this invention against viral infection may be readily determined by means of one or more tests such as, but not limited to, the isobologram method, as previously described by Elion et al. in J. Biol. Chem. (1954) 208:477-488 and by Baba et al. in Antimicrob. Agents Chemother. (1984) 25:515-517, using EC 50 for calculating the fractional inhibitory concentration (hereinafter referred as FIC).
- FIC fractional inhibitory concentration
- the combination When the minimum FIC index corresponding to the FIC of combined compounds (e.g., FIC x +FIC y ) is equal to 1.0, the combination is said to be additive; when it is between 1.0 and 0.5, the combination is defined as sub-synergistic, and when it is lower than 0.5, the combination is by defined as synergistic. When the minimum FIC index is between 1.0 and 2.0, the combination is defined as sub-antagonistic and, when it is higher than 2.0, the combination is defined as antagonistic.
- the pharmaceutical composition or combined preparation with synergistic activity against viral infection may contain the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative over a broad content range depending on the contemplated use and the expected effect of the preparation.
- the pteridine derivative content of the combined preparation is within the range of from 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from about 5 to 95% by weight.
- compositions and combined preparations according to the present invention may be administered orally or in any other suitable fashion.
- Oral administration is preferred and the preparation may have the form of a tablet, aqueous dispersion, dispersible powder or granule, emulsion, hard or soft capsule, syrup, elixir or gel.
- the dosing forms may be prepared using any method known in the art for manufacturing these pharmaceutical compositions and may comprise as additives sweeteners, flavoring agents, coloring agents, preservatives and the like.
- Carrier materials and excipients are detailed herein below and may include, inter alia, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, binding agents and the like.
- compositions or combined preparation of this invention may be included in a gelatin capsule mixed with any inert solid diluent or carrier material, or has the form of a soft gelatin capsule, in which the ingredient is mixed with a water or oil medium.
- Aqueous dispersions may comprise the biologically active composition or combined preparation in combination with a suspending agent, dispersing agent or wetting agent.
- Oil dispersions may comprise suspending agents such as a vegetable oil.
- Rectal administration is also applicable, for instance in the form of suppositories or gels.
- Injection e.g. intramuscularly or intraperiteneously
- mode of administration for instance in the form of injectable solutions or dispersions, depending upon the disorder to be treated and the condition of the patient.
- pharmaceutically acceptable carrier or excipient as used herein in relation to pharmaceutical compositions and combined preparations means any material or substance with which the active principle, i.e. the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, and optionally the one or more other antiviral agents, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although, due to the usually low or very low water-solubility of the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivatives of this invention, special attention will be paid to the selection of suitable carrier combinations that can assist in properly formulating them in view of the expected time release profile.
- Suitable pharmaceutical carriers include additives such as, but not limited to, wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals, especially humans.
- additives such as, but not limited to, wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents.
- Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties.
- Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents.
- Suitable soaps include, but are not limited to, alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C 1-10 -C 22 ), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil.
- Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylaryl-sulphonates.
- Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g.
- Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms.
- alkylarylsulphonates are the sodium, calcium or alkanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphthalenesulphonic acid or a naphthalenesulphonic acid/formaldehyde condensation product.
- corresponding phosphates e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and/or propylene oxide, or phospholipids.
- Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g.
- phosphatidylethanolamine phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylphosphatidylcholine, dipalmitoylphoshatidylcholine and their mixtures.
- Suitable non-ionic surfactants include, but are not limited to, poly-ethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to. 18 carbon atoms in the alkyl moiety of the alkylphenol.
- non-ionic surfactants are water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamino-polypropylene glycol preferably containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups.
- Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit.
- non-ionic surfactants include, but are not limited to, nonylphenol-polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxy-polyethoxyethanol.
- Fatty acid esters of polyethylene sorbitan such as polyoxyethylene sorbitan trioleate
- glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants for the purpose of the present invention.
- Suitable cationic surfactants include, but are not limited to, quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C 8 -C 22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-C 1-4 alkyl radicals.
- quaternary ammonium salts preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy
- quaternary ammonium salts containing as N-substituent at least one C 8 -C 22 alkyl radical (e.g
- Structure-forming, thickening or gel-forming agents may be included into the pharmaceutical compositions and combined preparations of the present invention.
- Suitable such agents include in particular, but are not limited to, highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium salts of montmorillonites (e.g., products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).
- Gelling agents which may be included into the pharmaceutical compositions and combined preparations of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof.
- Gelatin and modified celluloses represent a preferred class of gelling agents.
- additives such as, but not limited to, magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.
- additives such as, but not limited to, magnesium oxide; azo dyes; organic and inorganic
- Control release compositions may thus be achieved by selecting appropriate pharmaceutically acceptable polymer carriers such as for example polyesters, polyamino-acids, polyvinyl-pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxymethylcellulose, protamine sulfate and the like.
- the rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethyl-cellulose, polymethyl methacrylate and the other above-described polymers.
- Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on.
- the pharmaceutical composition or combined preparation of the invention may also require protective coatings.
- compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof.
- Typical liquid pharmaceutically acceptable carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof.
- the selected biologically active agent may be administered topically, in an ointment, gel or the like, or transdermally, using a conventional transdermal drug delivery system.
- the said combined preparation may be in the form of a medical kit or package containing the two ingredients in separate but adjacent form.
- each ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g. one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.
- the present invention further relates to a method for treating a viral infection or a pathologic condition associated therewith, including hepatitis C in a patient, preferably a mammal, more preferably a human being.
- the method of this invention consists of administering to the patient in need thereof a therapeutically effective amount of a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, optionally together with an effective amount of one or more other antiviral agents, or a pharmaceutical composition comprising the same, such as disclosed above in extensive details.
- the therapeutically effective amount of the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative to be adiministered according to the present invention is usually in the range of about 0.01 mg to 20 mg, preferably about 0.1 mg to 5 mg, per day per kg body weight for human beings. Depending upon the severity of the pathologic condition to be treated and the patient's condition, the said therapeutically effective amount may be divided into several sub-units per day or may be administered at more than one day intervals.
- the patient to be treated may be any warm-blooded animal, preferably a mammal, more preferably a human being, suffering from an infection by a virus being a member of the Flaviridae family, e.g. HCV, or a pathologic condition associated therewith.
- the synthetic method may be represented schematically as follows:
- the general procedure used for preparing 2-amino-4-alkylamino-6-(4-fluorophenyl)-pteridines was as follows. Sodium methoxide (0.8 mL, 0.5 N solution in methanol) was added to a mixture of 2-acetylamino-4-(1,2,4-triazolyl)-6-(4-fluorophenyl)pteridine (35 mg, 0.1 mmol) and corresponding amines with the general formula NHRR′ (0.2 mL). The resulting mixture was heated at 100° C. for 10 minutes under microwave irradiation.
- the anti HCV activity of specifically substituted pteridine derivatives was tested in a human hepatoma Huh-7 cell line harbouring a HCV replicon.
- the assay comprised the following steps:
- Table 7 shows EC 50 and CC 50 values determined in the above assay for 2-amino-pteridine derivatives synthesized according to the methods described in the examples above. Results are expressed by the following data:
- the 50% effective concentration i.e. the concentration that protects 50% of the cell monolayer from virus-induced cythopathic effect.
- CC 50 50% cytostatic concentration
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
- The present invention relates to a group of novel 4,6-di- and 2,4,6-trisubstituted pteridines and to their use as biologically active ingredients for manufacturing medicaments for the prevention or treatment of viral infections, in particular infections by a virus of the Flaviridae family, more specifically for inhibiting replication of hepatitis C virus. The present invention thus also relates to therapeutic and prophylactic methods comprising administration of said specifically 4,6-di- and 2,4,6-trisubstituted pteridine derivatives, or pro-drugs thereof, to mammals, in particular human beings.
- There is a continuous need in the art for specific and highly therapeutically active compounds for preventing or treating infections due to Flaviridae and pathologic conditions associated therewith, especially hepatitis C. In particular, there is a need in the art to provide drugs which are active against hepatitis C in a minor dose in order to replace existing drugs having significant side effects and to decrease treatment costs.
- Hepatitis is an inflammation of the liver that is most often caused by infection with one of three viruses known as hepatitis A, B or C. Hepatitis A virus (HAV) infection is the most common cause of acute hepatitis, and usually resolves spontaneously after several weeks of acute symptoms. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common viral causes of chronic hepatitis, usually defined as liver inflammation persisting for more than six months. HCV is the second most common cause of viral hepatitis in general and most common cause of chronic hepatitis. The World Health Organization estimates that worldwide 170 million people (3% of the world's population) are chronically infected with HCV. These chronic carriers are at risk of developing cirrhosis and/or liver cancer. In studies with a 10 to 20 year follow-up, cirrhosis developed in 20-30% of the patients, 1-5% of whom may develop liver cancer during the next then years. The 15% to 45% of persons with acute hepatitis C who do recover are not subject to long-term complications and do not need treatment. Since HCV and Pestiviruses belong to the same virus family and share many similarities (such as, but not limited to, organization of the genome, analogous gene products and replication cycle), Pestiviruses may be adopted as a model virus and surrogate for HCV. For example the bovine viral diarrhea virus (BVDV) is closely related to hepatitis C virus (HCV) and may be used as a surrogate virus in drug development for HCV infection.
- HCV is a representative and highly significant member of the Flaviviridae family, a family of positive-strand RNA viruses. This family includes the following genera: Genus Flavivirus (type species yellow fever virus, others include west nile virus and dengue fever), Genus Hepacivirus (type species hepatitis C virus), and Genus Pestivirus (type species bovine viral diarrhea virus (BVDV), others include classical swine fever or hog cholera). Contrary to other families of positive strand RNA viruses such as human immunodeficiency virus (HIV), HCV seems incapable of integrating into the host's genome. The primary immune response to HCV is mounted by cytotoxic T lymphocytes. Unfortunately, this process fails to eradicate infection in most people; in fact, it may contribute to liver inflammation and, ultimately, tissue necrosis. The ability of HCV to escape immune surveillance is the subject of much speculation. One likely means of viral persistence relies on the presence of closely related but heterogeneous populations of viral genomes. Further studies of these quasi-species enable classification of several genotypes and subtypes, which have clinical implications.
- The diagnosis of hepatitis C is rarely made during the acute phase of the disease because the majority of people infected experience no symptoms during this phase of the disease. Those who do experience acute phase symptoms are rarely ill enough to seek medical attention. The diagnosis of chronic phase hepatitis C is also challenging due to the absence or lack of specificity of symptoms until advanced liver disease develops, which may not occur until decades into the disease.
- Hepatitis C testing begins with serological blood tests used to detect antibodies to HCV. Anti-HCV antibodies can be detected in about 80% of patients within 15 weeks after exposure, in more than 90% of patients within 5 months after exposure, and in more than 97% of patients by 6 months after exposure. Overall, HCV antibody tests have a strong positive predictive value for exposure to the hepatitis C virus, but may miss patients who have not yet developed antibodies (seroconversion), or have an insufficient level of antibodies to detect. Anti-HCV antibodies indicate exposure to the virus, but cannot determine if ongoing infection is present. All persons with positive anti-HCV antibody tests must undergo additional testing for the presence of the hepatitis C virus itself to determine whether current infection is present. The presence of HCV may be tested by using molecular nucleic acid testing methods such as, but not limited to, polymerase chain reaction (PCR), transcription mediated amplification (TMA), or branched DNA amplification. All HCV nucleic acid molecular tests have the capacity to detect not only whether the virus is present, but also to measure the amount of virus present in the blood (the HCV viral load). The HCV viral load is an important factor in determining the probability of response to interferon-base therapy, but does not indicate disease severity nor the likelihood of disease progression.
- The goal of treatment is to prevent complications of HCV infection. This is principally achieved by eradication of infection. Accordingly, treatment responses are frequently characterized by the results of HCV RNA testing. Infection is considered eradicated when there is a sustained virologic response (SVR), defined as the absence of HCV RNA in serum by a sensitive test at the end of treatment and 6 months later. Persons who achieve an SVR almost always have a dramatic earlier reduction in the HCV RNA level, referred to as an early virologic response (EVR). Continued absence of detectable virus at termination of treatment is referred to as end of treatment response (ETR). A patient is considered relapsed when HCV RNA becomes undetectable on treatment but is detected again after discontinuation of treatment. Persons in whom HCV RNA levels remain stable on treatment are considered as non-responders, while those whose HCV RNA levels decline but remain detectable are referred to as partial responders.
- Current standard of care for HCV treatment a combination of (pegylated) interferon alpha and the antiviral drug ribavirin for a period of 24 or 48 weeks, depending upon the viral genotype. Should treatment with pegylated ribavirin-interferon not return a viral load reduction after 12 weeks, the chance of treatment success is less than 1% Current indication for treatment includes patients with proven hepatitis C virus infection and persistent abnormal liver function tests. SVR of 75% or better occur in people with genotypes HCV 2 and 3 within 24 weeks of treatment, about 50% in those with genotype 1 within 48 weeks of treatment and 65% for those with genotype 4 within 48 weeks of treatment. About 80% of hepatitis C patients in the United States exhibit genotype 1, whereas genotype 4 is more common in the Middle East and Africa.
- Best results have been achieved with the combination of weekly subcutaneous injections of long-acting peginterferon alpha and oral ribavirin daily. Interferons are substances naturally released by cells in the body after viral invasion. Interferon alfa-2b and peginterferon alfa-2b are synthetic versions of these substances. The protein product is manufactured by recombinant DNA-technology. Second generation interferons are further derivatized by binding to inert polyethylene glycol, thereby altering the pharmacokinetic properties. Ribavirin is a nucleoside analogue, which disrupts viral replication of hepatitis C virus (HCV).
- The most common side effects of HCV treatment with (pegylated) interferon include: a decrease in white blood cells and platelets, anemia, nausea, diarrhea, fever, chills, muscle and joint pain, difficulty in concentrating, thyroid dysfunction, hair loss, sleeplessness, irritability, mild to serious depression, and rarely, suicidal thoughts. Other serious adverse events include bone marrow toxicity, cardiovascular disorders, hypersensitivity, endocrine disorders, pulmonary disorders, colitis, pancreatitis, and ophthalmologic disorders (eye and vision problems). (Pegylated) interferon may also cause or make worse fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients with persistently severe or worsening signs or symptoms of these conditions are advised to stop therapy.
- The most common side effect of HCV treatment with ribavirin is anemia, which can be treated with erythropoietin. Other side effects include mood swings, irritability, anxiety, insomnia, abdominal pain, nervousness, breathlessness, rash, hair loss, dry skin, nausea, diarrhea, loss of appetite, dizziness and weight loss. Ribavirin can also cause birth defects. Ribavirin should not be taken in combination with certain HIV drugs such as, but not limited to, didanosine, since lactic acidosis with fatal hepatic steatosis (fatty liver) may occur. Special attention should be taken for treatment with HIV co-infection.
- Although the liver is the primary target of infection, studies to better define the steps of HCV infection are greatly hampered by the lack of a suitable animal model for such studies. The recent development of sub-genomic HCV RNA replicons capable of autonomous replication in the human hepatoma cell line, Huh-7, has been a significant advance in the study of HCV biology. The sub-genomic HCV RNA replicon system provides a cell-based assay to evaluate inhibitors of HCV enzymes like the protease, helicase, and RNA-dependant RNA polymerase or to evaluate nucleic acid targeting strategies like antisense RNA arid ribozymes.
- Targets for HCV Drug development include HCV-encoded enzymes, namely, NS2-3 and NS3-4A proteases, NS3 helicase, and NS5B RNA dependant RNA polymerase. Alternatively, HCV replication can be inhibited by blocking the conserved RNA elements employing a nucleic acid based approach including antisense oligonucleotides, ribozymes, RNA aptamers, RNA decoys, and RNA interference. A major drawback for such nucleic acid based approach is the size and charge of the nucleic acids, and their usually low physiological stability that do not allow for oral administration. Another target option for therapy is by blocking viral entry into the cell by obstruction of binding to HCV receptors such as, but not limited to, CD 209L and L-SIGN.
- There is a strong need in the art to improve, or to provide alternatives to, the existing prophylactic or therapeutic solutions to infections by a virus of the Flaviridae family, more specifically HCV infection. In particular there is still a need in the art for providing alternative synthetic molecules having significant HCV replication inhibiting activity. There is also a need in the art for providing effective inhibiting molecules which are free from the significant drawbacks of the current drugs like pegylated interferon and ribavirin. Meeting these various needs in the art constitutes the main goal of the present invention.
- The present invention is based on the unexpected finding that a number of novel specifically substituted pteridines, in particular 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines, are capable of exhibiting a significant and selective activity against certain types of viral infections, provided that the substituting pattern of such pteridines is suitably selected. In particular, these selected 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines are capable of selectively inhibiting the replication of the hepatitis C virus. As a consequence, the present invention provides pharmaceutical compositions comprising one or more 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines in combination with one or more pharmaceutically acceptable excipients. The present invention also provides prophylactic and therapeutic methods of treatment of higher mammals, in particular human beings, through the administration of an effective amount of such selected 4,6-disubstituted pteridines and 2,4,6-trisubstituted pteridines.
- Unless otherwise stated herein, the term “tri-substituted” in relation to the pteridine structure means that three of the carbon atoms being in positions 2, 4 and 6 of the pteridine moiety (according to standard atom numbering for the pteridine moiety) are substituted with an atom or group of atoms other than hydrogen. Unless otherwise stated herein, the term “di-substituted” in relation to the pteridine structure means that two of the carbon atoms being in positions 4 and 6 of the pteridine moiety (according to standard atom numbering for the pteridine moiety) are substituted with an atom or group of atoms other than hydrogen.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C1-7 alkyl” means straight and branched chain saturated acyclic hydrocarbon monovalent radicals having from 1 to 7 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methyl-ethyl (isopropyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 2-methyl-butyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, n-heptyl and the like. By analogy, the term “C1-4 alkyl” refers to such radicals having from 1 to 4 carbon atoms, i.e. up to and including butyl, and “C1-12 alkyl” refers to such radicals having from 1 to 12 carbon atoms.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “acyl” broadly refers to a substituent derived from an acid such as an organic monocarboxylic acid, a carbonic acid, a carbamic acid (resulting into a carbamoyl substituent) or the thioacid or imidic acid (resulting into a carbamidoyl substituent) corresponding to said acids, and the term “sulfonyl” refers to a substituent derived from an organic sulfonic acid, wherein said acids comprise an aliphatic, aromatic or heterocyclic group in the molecule. A more specific kind of “acyl” group within the scope of the above definition refers to a carbonyl (oxo) group adjacent to a C1-7 alkyl, a C3-10 cycloalkyl, an aryl, an arylalkyl or a heterocyclic group, all of them being such as herein defined. Suitable examples of acyl groups are to be found below.
- Acyl and sulfonyl groups originating from aliphatic or cycloaliphatic monocarboxylic acids are designated herein as aliphatic or cycloaliphatic acyl and sulfonyl groups and include, but are not limited to, the following:
-
- alkanoyl (for example formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and the like);
- cycloalkanoyl (for example cyclobutanecarbonyl, cyclopentane-carbonyl, cyclo-hexanecarbonyl, 1-adamantanecarbonyl and the like);
- cycloalkyl-alkanoyl (for example cyclohexylacetyl, cyclopentylacetyl and the like);
- alkenoyl (for example acryloyl, methacryloyl, crotonoyl and the like);
- alkylthioalkanoyl (for example methylthioacetyl, ethylthioacetyl and the like);
- alkanesulfonyl (for example mesyl, ethanesulfonyl, propanesulfonyl and the like);
- alkoxycarbonyl (for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl and the like);
- alkylcarbamoyl (for example methylcarbamoyl and the like);
- (N-alkyl)-thiocarbamoyl (for example (N-methyl)-thiocarbamoyl and the like);
- alkylcarbamidoyl (for example methylcarbamidoyl and the like); and
- alkoxyalkyl (for example methoxyalkyl, ethoxyalkyl, propoxyalkyl and the like);
- Acyl and sulfonyl groups may also originate from aromatic monocarboxylic acids and include, but are not limited to, the following:
-
- aroyl (for example benzoyl, toluoyl, xyloyl, 1-naphthoyl, 2-naphthoyl and the like);
- arylalkanoyl (for example phenylacetyl and the like);
- arylalkenoyl (for example cinnamoyl and the like);
- aryloxyalkanoyl (for example phenoxyacetyl and the like)
- arylthioalkanoyl (for example phenylthioacetyl and the like);
- arylaminoalkanoyl (for example N-phenylglycyl, and the like);
- arylsulfonyl (for example benzenesulfonyl, toluenesulfonyl, naphthalenesulfonyl and the like);
- aryloxycarbonyl (for example phenoxycarbonyl, naphthyloxycarbonyl and the like);
- arylalkoxycarbonyl (for example benzyloxycarbonyl and the like);
- arylcarbamoyl (for example phenylcarbamoyl, naphthylcarbamoyl and the like);
- arylglyoxyloyl (for example phenylglyoxyloyl and the like).
- arylthiocarbamoyl (for example phenylthiocarbamoyl and the like); and
- arylcarbamidoyl (for example phenylcarbamidoyl and the like).
- Acyl groups may also originate from an heterocyclic monocarboxylic acids and include, but are not limited to, the following:
-
- heterocyclic-carbonyl, in which said heterocyclic group is as defined herein, preferably an aromatic or non-aromatic 5- to 7-membered heterocyclic ring with one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in said ring (for example thiophenoyl, furoyl, pyrrolecarbonyl, nicotinoyl and the like); and
- heterocyclic-alkanoyl in which said heterocyclic group is as defined herein, preferably an aromatic or non-aromatic 5- to 7-membered heterocyclic ring with one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in said ring (for example thiopheneneacetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2-(2-amino-4-thiazolyl)-2-methoxyiminoacetyl and the like).
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C1-7 alkylene” means the divalent hydrocarbon radical corresponding to the above defined alkyl, such as methylene, bis(methylene), tris(methylene), tetramethylene, hexamethylene and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C3-10 cycloalkyl” means a mono- or polycyclic saturated hydrocarbon monovalent radical having from 3 to 10 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, or a C7-10 polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C3-10 cycloalkyl-alkyl” refers to an aliphatic saturated hydrocarbon monovalent radical (preferably a C1-7 alkyl such as defined above) to which a C3-10 cycloalkyl (such as defined above) is already linked such as, but not limited to, cyclohexylmethyl, cyclopentylmethyl and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C3-10 cycloalkylene” means the divalent hydrocarbon radical corresponding to the above defined C3-10 cycloalkyl.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “aryl” designates any mono- or polycyclic aromatic monovalent hydrocarbon radical having from 6 up to 30 carbon atoms such as but not limited to phenyl, naphthyl, anthracenyl, phenantracyl, fluoranthenyl, chrysenyl, pyrenyl, biphenylyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like, including fused benzo-C4-8 cycloalkyl radicals (the latter being as defined above) such as, for instance, indanyl, tetrahydronaphthyl, fluorenyl and the like, all of the said radicals being optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, trifluoromethyl, hydroxyl, sulfhydryl and nitro, such as for instance 4-fluorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-cyanophenyl, 2,6-dichlorophenyl, 2-fluorophenyl, 3-chlorophenyl, 4-nitrophenyl, 3,5-dichlorophenyl and the like.
- As used herein, e.g. with respect to a substituting radical such as the combination of substituents in certain positions of the pteridine ring together with the carbon atoms in the same positions of said ring, and unless otherwise stated, the term “homocyclic” means a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated hydrocarbon radical having from 4 up to 15 carbon atoms but including no heteroatom in the said ring; for instance said combination of substituents may form a C2-6 alkylene radical, such as tetramethylene, which cyclizes with the carbon atoms in certain positions of the pteridine ring.
- As used herein with respect to a substituting radical (including the combination of substituents in certain positions of the pteridine ring together with the carbon atoms in the same positions of said ring), and unless otherwise stated, the terms “heterocyclic” and “heterocyclyl” mean a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated monovalent hydrocarbon radical having from 2 up to 15 carbon atoms and including one or more heteroatoms in one or more heterocyclic rings, each of said rings having from 3 to 10 atoms (and optionally further including one or more heteroatoms attached to one or more carbon atoms of said ring, for instance in the form of a carbonyl or thiocarbonyl or selenocarbonyl group, and/or to one or more heteroatoms of said ring, for instance in the form of a sulfone, sulfoxide, N-oxide, phosphate, phosphonate or selenium oxide group), each of said heteroatoms being independently selected from the group consisting of nitrogen, oxygen, sulfur, selenium and phosphorus, also including radicals wherein a heterocyclic ring is fused to one or more aromatic hydrocarbon rings for instance in the form of benzo-fused, dibenzo-fused and naphtho-fused heterocyclic radicals; within this definition are included heterocyclic radicals such as, but not limited to, diazepinyl, oxadiazinyl, thiadiazinyl, dithiazinyl, triazolonyl, diazepinonyl, triazepinyl, triazepinonyl, tetrazepinonyl, benzoquinolinyl, benzothiazinyl, benzothiazinonyl, benzoxathiinyl, benzodioxinyl, benzodithiinyl, benzoxazepinyl, benzothiazepinyl, benzodiazepinyl, benzodioxepinyl, benzodithiepinyl, benzoxazocinyl, benzothiazocinyl, benzodiazocinyl, benzoxathiocinyl, benzodioxocinyl, benzotrioxepinyl, benzoxathiazepinyl, benzoxadiazepinyl, benzothiadiazepinyl, benzotriazepinyl, benzoxathiepinyl, benzotriazinonyl, benzoxazolinonyl, azetidinonyl, azaspiroundecyl, dithiaspirodecyl, selenazinyl, selenazolyl, selenophenyl, hypoxanthinyl, azahypo-xanthinyl, bipyrazinyl, bipyridinyl, oxazolidinyl, diselenopyrimidinyl, benzodioxocinyl, benzopyrenyl, benzopyranonyl, benzophenazinyl, benzoquinolizinyl, dibenzocarbazolyl, dibenzoacridinyl, dibenzophenazinyl, dibenzothiepinyl, dibenzoxepinyl, dibenzopyranonyl, dibenzoquinoxalinyl, dibenzothiazepinyl, dibenzisoquinolinyl, tetraazaadamantyl, thiatetraazaadamantyl, oxauracil, oxazinyl, dibenzothiophenyl, dibenzofuranyl, oxazolinyl, oxazolonyl, azaindolyl, azolonyl, thiazolinyl, thiazolonyl, thiazolidinyl, thiazanyl, pyrimidonyl, thiopyrimidonyl, thiamorpholinyl, azlactonyl, naphthindazolyl, naphthindolyl, naphthothiazolyl, naphthothioxolyl, naphthoxindolyl, naphthotriazolyl, naphthopyranyl, oxabicycloheptyl, azabenzimidazolyl, azacycloheptyl, azacyclooctyl, azacyclononyl, azabicyclononyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydropyronyl, tetrahydroquinoleinyl, tetrahydrothienyl and dioxide thereof, dihydrothienyl dioxide, dioxindolyl, dioxinyl, dioxenyl, dioxazinyl, thioxanyl, thioxolyl, thiourazolyl, thiotriazolyl, thiopyronyl, thiopyronyl, coumarinyl, quinoleinyl, oxyquinoleinyl, quinuclidinyl, xanthinyl, dihydropyranyl, benzodihydrofuryl, benzothiopyronyl, benzothiopyranyl, benzoxazinyl, benzoxazolyl, benzodioxolyl, benzodioxanyl, benzothiadiazolyl, benzotriazinyl, benzothiazolyl, benzoxazolyl, phenothioxinyl, phenothiazolyl, phenothienyl (benzothiofuranyl), phenopyronyl, phenoxazolyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, benzotriazolyl, tetrazolyl, imidazolyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, pyrrolyl, furyl, dihydrofuryl, furoyl, hydantoinyl, dioxolanyl, dioxolyl, dithianyl, dithienyl, dithiinyl, thienyl, indolyl, indazolyl, benzofuryl, quinolyl, quinazolinyl, quinoxalinyl, carbazolyl, phenoxazinyl, phenothiazinyl, xanthenyl, purinyl, benzothienyl, naphthothienyl, thianthrenyl, pyranyl, pyronyl, benzopyronyl, isobenzofuranyl, chromenyl, phenoxathiinyl, indolizinyl, quinolizinyl, isoquinolyl, phthalazinyl, naphthiridinyl, cinnolinyl, pteridinyl, carbolinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, imidazolinyl, imidazolidinyl, benzimidazolyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, piperazinyl, uridinyl, thymidinyl, cytidinyl, azirinyl, aziridinyl, diazirinyl, diaziridinyl, oxiranyl, oxaziridinyl, dioxiranyl, thiiranyl, azetyl, dihydroazetyl, azetidinyl, oxetyl, oxetanyl, oxetanonyl, homopiperazinyl, homopiperidinyl, thietyl, thietanyl, diazabicyclooctyl, diazetyl, diaziridinonyl, diaziridinethionyl, chromanyl, chromanonyl, thiochromanyl, thiochromanonyl, thiochromenyl, benzofuranyl, benzisothiazolyl, benzocarbazolyl, benzochromonyl, benzisoalloxazinyl, benzocoumarinyl, thiocoumarinyl, phenometoxazinyl, phenoparoxazinyl, phentriazinyl, thiodiazinyl, thiodiazolyl, indoxyl, thioindoxyl, benzodiazinyl (e.g. phthalazinyl), phthalidyl, phthalimidinyl, phthalazonyl, alloxazinyl, dibenzopyronyl (i.e. xanthonyl), xanthionyl, isatyl, isopyrazolyl, isopyrazolonyl, urazolyl, urazinyl, uretinyl, uretidinyl, succinyl, succinimido, benzylsultimyl, benzylsultamyl and the like, including all possible isomeric forms thereof, wherein each carbon atom of said heterocyclic ring may furthermore be independently substituted with a substituent selected from the group consisting of halogen, nitro, C-1-7 alkyl (optionally containing one or more functions or radicals selected from the group consisting of carbonyl (oxo), alcohol (hydroxyl), ether (alkoxy), acetal, amino, imine, oximino, alkyloximino, amino-acid, cyano, carboxylic acid ester or amide, nitro, thio C1-7 alkyl, thio C3-10 cycloalkyl, C1-7 alkylamino, cyctoalkylamino, alkenylamino, cycloalkenylamino, alkynylamino, arylamino, arylalkylamino, hydroxylalkylamino, mercaptoalkylamino, heterocyclic-substituted alkylamino, heterocyclic amino, heterocyclic-substituted arylamino, hydrazino, alkylhydrazino, phenylhydrazino, sulfonyl, sulfonamido and halogen), C3-7 alkenyl, C2-7 alkynyl, halo C1-7 alkyl, C3-10 cycloalkyl, aryl, arylalkyl, alkylaryl, alkylacyl, arylacyl, hydroxyl, amino, C1-7 alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, alkynylamino, arylamino, arylalkylamino, hydroxyalkylamino, mercaptoalkylamino, heterocyclic-substituted alkylamino, heterocyclic amino, heterocyclic-substituted arylamino, hydrazino, alkylhydrazino, phenylhydrazino, sulfhydryl, C1-7 alkoxy, C3-10 cycloalkoxy, aryloxy, arylalkyloxy, oxyheterocyclic, heterocyclic-substituted alkyloxy, thio C1-7 alkyl, thio C3-10 cycloalkyl, thioaryl, thioheterocyclic, arylalkylthio, heterocyclic-substituted alkylthio, formyl, hydroxylamino, cyano, carboxylic acid or esters or thioesters or amides thereof, thiocarboxylic acid or esters or thioesters or amides thereof; depending upon the number of unsaturations in the 3 to 10 atoms ring, heterocyclic radicals may be sub-divided into heteroaromatic (or “heteroaryl”) radicals and non-aromatic heterocyclic radicals; when a heteroatom of said non-aromatic heterocyclic radical is nitrogen, the latter may be substituted with a substituent selected from the group consisting of C1-7 alkyl, C3-10 cycloalkyl, aryl, arylalkyl and alkylaryl.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “C1-7 alkoxy”, “C3-10 cycloalkoxy”, “aryloxy”, “arylalkoxy”, “oxyheterocyclic”, “heterocyclic-substituted alkoxy”, “thio C1-7 alkyl”, “thio C3-10 cycloalkyl”, “arylthio”, “arylalkylthio” and “thioheterocyclic” refer to substituents wherein a carbon atom of a C1-7 alkyl, respectively a C3-10 cycloalkyl, aryl, arylalkyl, heterocyclic radical or heterocyclic-substituted alkyl (each of them such as defined herein), is attached to an oxygen atom or a divalent sulfur atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, cyclo propyloxy, cyclobutyloxy, cyclopentyloxy, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiocyclopropyl, thiocyclobutyl, thiocyclopentyl, thiophenyl, phenyloxy, benzyloxy, mercaptobenzyl and cresoxy, and various isomers of piperidinoxy, 1-methylpiperidinoxy, pyrrolidinoxy, pyridinoxy, tetrahydrofuranyloxy, morpholino-ethoxy, piperazinoethoxy, piperidinoethoxy, pyridinoethoxy, pyrrolidinoethoxy, piperidinomethoxy, methylpyridinoxy, methylquinolinoxy, pyridinopropoxy and the like.
- As used herein with respect to a substituting atom, and unless otherwise stated, the term halogen means any atom selected from the group consisting of fluorine, chlorine, bromine and iodine.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “halo C1-7 alkyl” means a C1-7 alkyl radical (such as above defined) in which one or more hydrogen atoms are independently replaced by one or more halogens (preferably fluorine, chlorine or bromine), such as but not limited to difluoromethyl, trifluoromethyl, trifluoroethyl, octafluoropentyl, dodecafluoro-heptyl, dichloromethyl and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “C2-7 alkenyl” designate a straight and branched acyclic hydrocarbon monovalent radical having one or more ethylenic unsaturations and having from 2 to 7 carbon atoms such as, for example, vinyl, 1-propenyl, 2-propenyl (allyl), 1-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl, 2-hexenyl, 2-heptenyl, 1,3-butadienyl, pentadienyl, hexadienyl, heptadienyl, heptatrienyl and the like, including all possible isomers thereof.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C3-10 cycloalkenyl” means a monocyclic mono- or polyunsaturated hydrocarbon monovalent radical having from 3 to 8 carbon atoms, such as for instance cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl and the like, or a C7-10 polycyclic mono- or polyunsaturated hydrocarbon mono-valent radical having from 7 to 10 carbon atoms such as dicyclopentadienyl, fenchenyl (including all isomers thereof, such as α-pinolenyl), bicyclo[2.2.1]hept-2-enyl, bicyclo[2.2.1]hepta-2,5-dienyl, cyclo-fenchenyl and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “C2-7 alkynyl” defines straight and branched chain hydrocarbon radicals containing one or more triple bonds and optionally at least one double bond and having from 2 to 7 carbon atoms such as, for example, acetylenyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 2-pentynyl, 1-pentynyl, 3-methyl-2-butynyl, 3-hexynyl, 2-hexynyl, 1-penten-4-ynyl, 3-penten-1-ynyl, 1,3-hexadien-1-ynyl and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “arylalkyl”, “arylalkenyl” and “heterocyclic-substituted alkyl” refer to an aliphatic saturated or ethylenically unsaturated hydrocarbon monovalent radical (preferably a C1-7 alkyl or C2-7 alkenyl radical such as defined above) onto which an aryl or heterocyclic radical (such as defined above) is already bonded via a carbon atom, and wherein the said aliphatic radical and/or the said aryl or heterocyclic radical may be optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, C1-7 alkyl, C1-7 alkoxy, trifluoromethyl and nitro, such as but not limited to benzyl, 4-chlorobenzyl, 4-fluorobenzyl, 2-fluorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-tert-butylbenzyl, phenylpropyl, 1-naphthylmethyl, phenylethyl, 1-amino-2-phenylethyl, 1-amino-2-[4-hydroxy-phenyl]ethyl, 1-amino-2-[indol-2-yl]ethyl, styryl, pyridylmethyl (including all isomers thereof), pyridylethyl, 2-(2-pyridyl)isopropyl, oxazolylbutyl, 2-thienylmethyl, pyrrolylethyl, morpholinylethyl, imidazol-1-yl-ethyl, benzodioxolyl-methyl and 2-furylmethyl.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “alkylaryl” and “alkyl-substituted heterocyclic” refer to an aryl or, respectively, heterocyclic radical (such as defined above) onto which are bonded one or more aliphatic saturated or unsaturated hydrocarbon monovalent radicals, preferably one or more C1-7 alkyl, C2-7 alkenyl or C3-10 cycloalkyl radicals as defined above such as, but not limited to, o-toluyl, m-toluyl, p-toluyl, 2,3-xylyl, 2,4-xylyl, 3,4-xylyl, o-cumenyl, m-cumenyl, p-cumenyl, o-cymenyl, m-cymenyl, p-cymenyl, mesityl, tert-butylphenyl, lutidinyl (i.e. dimethylpyridyl), 2-methylaziridinyl, methylbenzinnidazolyl, methylbenzofuranyl, methylbenzothiazolyl, methylbenzotriazolyl, methylbenzoxazolyl and methylbenzselenazolyl.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “alkoxyaryl” refers to an aryl radical (such as defined above) onto which is (are) bonded one or more C1-7 alkoxy radicals as defined above, preferably one or more methoxy radicals, such as, but not limited to, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, methoxynaphthyl and the like.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “alkylamino”, “cycloalkylamino”, “alkenylamino” “cyclo-alkenylamino”, “arylamino”, “arylalkylamino”, “heterocyclic-substituted alkyl-amino”, “heterocyclic-substituted arylamino”, “heterocyclic amino”, “hydroxy-alkylamino”, “mercapto-alkylamino” and “alkynylamino” mean that respectively one (thus monosubstituted amino) or even two (thus disubstituted amino) C1-7 alkyl, C3-10 cycloalkyl, C2-7 alkenyl, C3-10 cycloalkenyl, aryl, arylalkyl, heterocyclic-substituted alkyl, heterocyclic-substituted aryl, heterocyclic (provided in this case the nitrogen atom is attached to a carbon atom of the heterocyclic ring), mono- or polyhydroxy C1-7 alkyl, mono- or polymercapto C1-7 alkyl, or C2-7 alkynyl radical(s) (each of them as defined herein, respectively, and including the presence of optional substituents independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, C1-7 alkyl, C1-7 alkoxy, trifluoromethyl and nitro) is/are attached to a nitrogen atom through a single bond such as, but not limited to, anilino, 2-bromoanilino, 4-bromoanilino, 2-chloroanilino, 3-chloroanilino, 4-chloroanilino, 3-chloro-4-methoxyanilino, 5-chloro-2-methoxy-anilino, 2,3-dimethylanilino, 2,4-dimethylanilino, 2,5-dimethylanilino, 2,6-dimethylanilino, 3,4-dimethylanilino, 2-fluoroanilino, 3-fluoroanilino, 4-fluoro-anilino, 3-fluoro-2-methoxyanilino, 3-fluoro-4-methoxyanilino, 2-fluoro-4-methylanilino, 2-fluoro-5-methylanilino, 3-fluoro-2-methylanilino, 3-fluoro-4-methylanilino, 4-fluoro-2-methylanilino, 5-fluoro-2-methylanilino, 2-iodoanilino, 3-iodoanilino, 4-iodoanilino, 2-methoxy-5-methylanilino, 4-methoxy-2-methylanilino, 5-methoxy-2-methylanilino, 2-ethoxyanilino, 3-ethoxy-anilino, 4-ethoxyanilino, benzylamino, 2-methoxybenzylamino, 3-methoxybenzylamino, 4-methoxybenzylamino, 2-fluoro-benzylamino, 3-fluorobenzyl-amino, 4-fluorobenzylamino, 2-chlorobenzylamino, 3-chlorobenzylamino, 4-chlorobenzylamino, 2-aminobenzylamino, diphenylmethyl-amino, α-naphthylamino, methylamino, dimethylamino, ethylamino, diethylamino, diethanolamino, isopropylamino, propenylamino, n-butylamino, tert-butylamino, dibutylamino, 1,2-diaminopropyl, 1,3-diaminopropyl, 1,4-diaminobutyl, 1,5-diaminopentyl, 1,6-diaminohexyl, morpholinomethyl-amino, 4-morpholinoanilino, hydroxymethylamino, β-hydroxyethylamino, dicyclohexyl-amino and ethynylamino; this definition also includes mixed disubstituted amino radicals wherein the nitrogen atom is attached to two such radicals belonging to two different sub-sets of radicals, e.g. an alkyl radical and an alkenyl radical, or to two different radicals within the same sub-set of radicals, e.g. methylethylamino; among di-substituted amino radicals, symmetrically-substituted amino radicals are more easily accessible and thus usually preferred from a standpoint of ease of preparation.
- As used herein with respect to a substituting radical, and unless otherwise stated, the terms “(thio)carboxylic acid ester”, “(thio)carboxylic acid thioester” and “(thio)-carboxylic acid amide” refer to radicals wherein the carboxyl or thiocarboxyl group is bonded to the hydrocarbonyl residue of an alcohol, a thiol, a polyol, a phenol, a thiophenol, a primary or secondary amine, a polyamine, an amino-alcohol or ammonia, the said hydrocarbonyl residue being selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, alkylaryl, alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, arylamino, arylalkylamino, heterocyclic-substituted alkylamino, heterocyclic amino, heterocyclic-substituted arylamino, hydroxyalkylamino, mercapto-alkylamino or alkynylamino (such as above defined, respectively).
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “sulfonamide” refers to a radical represented by the formula —NRx—SO2Ry, wherein Rx hydrogen or a cyclic or non-cyclic hydrocarbyl group and Ry is a cyclic or non-cyclic hydrocarbyl group.
- As used herein with respect to a substituting radical, and unless otherwise stated, the term “amino-acid” refers to a radical derived from a molecule having the chemical formula H2N—CHR—COOH, wherein R is the side group of atoms characterising the amino-acid type; said molecule may be one of the 20 naturally-occurring amino-acids or any similar non naturally-occurring amino-acid.
- As used herein and unless otherwise stated, the term “stereoisomer” refers to all possible different isomeric as well as conformational forms which the compounds of the invention may possess, in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the present invention.
- As used herein and unless otherwise stated, the term “enantiomer” means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
- As used herein and unless otherwise stated, the term “solvate” includes any combination which may be formed by a pteridine derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent such as, but not limited to, alcohols, ketones, esters, ethers, nitriles and the like.
- In a first aspect, the present invention relates to a group of novel 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives. Without limitation, this group includes molecules selected from the group consisting of:
- 6-(2,6-dichlorophenyl)-4-ethoxypteridin-2-amine,
- 3-(2-amino-4-ethoxypteridin-6-yl)benzonitrile
- 4-ethoxy-6-(3-fluoro-4-methoxyphenyl)pteridin-2-amine
- 4-ethoxy-6-(4-(trifluoromethoxy)phenyl)pteridin-2-amine
- 6-(3,5-bis(trifluoromethyl)phenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(4-(trifluoromethyl)phenyl)pteridin-2-amine
- 6-(4-chloro-3-fluorophenyl)-4-ethoxypteridin-2-amine
- 6-(3,5-dichlorophenyl)-4-ethoxypteridin-2-amine
- 6-(3,4-difluorophenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(2-fluorophenyl)pteridin-2-amine
- 6-(2,6-difluorophenyl)-4-ethoxypteridin-2-amine
- 6-(3,5-difluorophenyl)-4-ethoxypteridin-2-amine
- 6-(2,3-difluorophenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(3-fluorophenyl)pteridin-2-amine
- dimethyl (4-(2-amino-4-ethoxypteridin-6-yl)phenyl)methylphosphonate
- 6-(2,4-difluorophenyl)-4-ethoxypteridin-2-amine
- 6-(3-chlorophenyl)-4-ethoxypteridin-2-amine
- 6-(2,4-bis(trifluoromethyl)phenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(pyridin-3-yl)pteridin-2-amine
- 4-ethoxy-6-(1H-pyrazol-5-yl)pteridin-2-amine
- 4-ethoxy-6-(pyrimidin-5-yl)pteridin-2-amine
- 4-ethoxy-6-(2-fluoropyridin-3-yl)pteridin-2-amine
- 4-ethoxy-6-(thiophen-3-yl)pteridin-2-amine
- 4-ethoxy-6-(furan-3-yl)pteridin-2-amine
- N-(4-(2-amino-4-ethoxypteridin-6-yl)phenyl)acetamide
- 6-(2,5-difluorophenyl)-4-ethoxypteridin-2-amine
- 6-(4-chlorophenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(2-(trifluoromethyl)phenyl)pteridin-2-amine
- 4-ethoxy-6-(1H-indol-5-yl)pteridin-2-amine
- 4-ethoxy-6-(4-(methylsulfonyl)phenyl)pteridin-2-amine
- 4-ethoxy-6-(pyridin-4-yl)pteridin-2-amine
- 4-ethoxy-6-(1H-pyrazol-4-yl)pteridin-2-amine
- 4-ethoxy-6-(furan-2-yl)pteridin-2-amine
- 6-(2-chlorophenyl)-4-ethoxypteridin-2-amine
- 6-(2,3-dichlorophenyl)-4-ethoxypteridin-2-amine
- 6-(3-chloro-4-fluorophenyl)-4-ethoxypteridin-2-amine
- 6-(2-chloro-4-fluorophenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(3-(trifluoromethyl)phenyl)pteridin-2-amine
- 4-ethoxy-6-(3-(trifluoromethoxy)phenyl)pteridin-2-amine
- 4-(2-amino-4-ethoxypteridin-6-yl)-N-methylbenzamide
- 4-(2-amino-4-ethoxypteridin-6-yl)-N-cyclopropylbenzamide
- 6-(4-(dimethylamino)phenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(4-fluoro-2-methylphenyl)pteridin-2-amine
- 5-(2-amino-4-ethoxypteridin-6-yl)thiophene-2-carbonitrile
- 4-ethoxy-6-(2-(1trifluoromethoxy)phenyl)pteridin-2-amine
- 4-ethoxy-6-(2,3,4-trifluorophenyl)pteridin-2-amine
- 6-(2-chloro-4-(trifluoromethyl)phenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(2,4,6-trifluorephenyl)pteridin-2-amine
- 6-(5-chlorothiophen-2-yl)-4-ethoxypteridin-2-amine
- 2-(2-amino-4-ethoxypteridin-6-yl)phenol
- 6-(2,5-dichlorophenyl)-4-ethoxypteridin-2-amine
- 6-(3,5-dimethylphenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(3-ethoxyphenyl)pteridin-2-amine
- 4-ethoxy-6-p-tolylpteridin-2-amine
- 6-(benzo[b]thiophen-2-yl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(2-ethoxyphenyl)pteridin-2-amine
- 4-(2-amino-4-ethoxypteridin-6-yl)phenol
- 6-(2,4-dichloraphenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(2,4,5-trifluorophenyl)pteridin-2-amine
- 4-ethoxy-6-(2-methylphenyl)pteridin-2-amine
- (4-(2-amino-4-ethoxypteridin-6-yl)phenyl)pyrrolidin-2-one
- 5-(2-amino-4-ethoxypteridin-6-yl)indolin-2-one
- 4-ethoxy-6-(6-methoxypyridin-3-yl)pteridin-2-amine
- 4-ethoxy-6-(isoxazol-4-yl)pteridin-2-amine
- 4-ethoxy-6-(5-fluoro-2-methoxyphenyl)pteridin-2-amine
- methyl 4-(2-amino-4-ethoxypteridin-6-yl)phenylcarbamate
- 6-(benzofuran-2-yl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-morpholinopteridin-2-amine
- 6-(4-aminophenyl)-4-ethoxypteridin-2-amine
- 4-ethoxy-6-(3-methylpyridin-4-yl)pteridin-2-amine
- 4-ethoxy-6-(2-methoxypyridin-4-yl)pteridin-2-amine
- 4-ethoxy-6-(2-methylpyridin-4-yl)pteridin-2-amine
- 4-ethoxy-6-(pyridin-2-yl)pteridin-2-amine
- 6-(2-fluorophenyl)-4-morpholinopteridin-2-amine
- 6-(2-chlorophenyl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(2-(trifluoramethyl)phenyl)pteridin-2-amine
- 6-(2-methoxyphenyl)-4-morpholinopteridin-2-amine
- 6-(3-fluorophenyl)-4-morpholinopteridin-2-amine
- 6-(3-chlorophenyl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(3-(trifluoromethyl)phenyl)pteridin-2-amine
- 4-morpholino-6-(3-(trifluoromethoxy)phenyl)pteridin-2-amine
- 3-(2-amino-4-morpholinopteridin-6-yl)benzonitrile
- 4-morpholino-6-(4-(trifluoromethoxy)phenyl)pteridin-2-amine
- 4-(2-amino-4-morpholinopteridin-6-yl)benzonitrile
- 4-morpholino-6-(4-(morpholinomethyl)phenyl)pteridin-2-amine
- 6-(2,3-difluorophenyl)-4-morpholinopteridin-2-amine
- 6-(2,3-dichlorophenyl)-4-morpholinopteridin-2-amine
- 6-(2-chloro-4-fluorophenyl)-4-morpholinopteridin-2-amine
- 6-(2,4-bis(trifluoromethyl)phenyl)-4-morpholinopteridin-2-amine
- 6-(2,4-difluorophenyl)-4-morpholinopteridin-2-amine
- 6-(2,6-dichlorophenyl)-4-morpholinopteridin-2-amine
- 6-(3,5-bis(trifluoromethyl)phenyl)-4-morpholinopteridin-2-amine
- 6-(4-chloro-3-fluorophenyl)-4-morpholinopteridin-2-amine
- 6-(3,5-difluorophenyl)-4-morpholinopteridin-2-amine
- 6-(3,5-dichlorophenyl)-4-morpholinopteridin-2-amine
- dimethyl (4-(2-amino-4-morpholinopteridin-6-yl)phenyl)methylphosphonate
- 6-(2,6-difluorophenyl)-4-morpholinopteridin-2-amine
- 6-(3,4-dichlorophenyl)-4-morpholinopteridin-2-amine
- 6-(3-chloro-4-fluorophenyl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(4-(trifluoromethyl)phenyl)pteridin-2-amine
- 6-(4-(methylsulfonyl)phenyl)-4-morpholinopteridin-2-amine
- 6-(1H-indol-5-yl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(pyrimidin-5-yl)pteridin-2-amine
- 4-morpholino-6-(pyridin-3-yl)pteridin-2-amine
- 6-(2-fluoropyridin-3-yl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(thiophen-3-yl)pteridin-2-amine
- 6-(furan-3-yl)4-morpholinopteridin-2-amine
- 4-morpholino-6-(1H-pyrazol-5-yl)pteridin-2-amine
- 6-(2,3-difluorophenyl)-4-morpholinopteridin-2-amine
- 4-(2-amino-4-morpholinopteridin-6-yl)-N-methylbenzamide
- 4-(2-amino-4-morpholinopteridin-6-yl)-N-cyclopropylbenzamide
- 6-(2,5-difluorophenyl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(pyridin-4-yl)pteridin-2-amine
- 4-morpholino-6-(1H-pyrazol-4-yl)pteridin-2-amine
- 6-(4-(dimethylamino)phenyl)-4-morpholinopteridin-2-amine
- 6-(4-fluoro-2-methylphenyl)-4-morpholinopteridin-2-amine
- 6-(2-chloro-4-(trifluoromethyl)phenyl)-4-morpholinopteridin-2-amine
- 5-(2-amino-4-morpholinopteridin-6-yl)thiophene-2-carbonitrile
- 6-(benzo[b]thiophen-2-yl)-4-morpholinopteridin-2-amine
- 2-(2-amino-4-morpholinopteridin-6-yl)phenol
- 6-(2-ethoxyphenyl)-4-morpholinopteridin-2-amine
- 6-(3-ethoxyphenyl)-4-morpholinopteridin-2-amine
- 6-(5-chlorothiophen-2-yl)-morpholinopteridin-2-amine
- 1-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)pyrrolidin-2-one
- methyl 4-(2-amino-4-morpholinopteridin-6-yl)phenylcarbamate
- 6-(6-methoxypyridin-3-yl)-4-morpholinopteridin-2-amine
- 6-(isoxazol-4-yl)-4-morpholinopteridin-2-amine
- 6-(2-methylphenyl)-4-morpholinopteridin-2-amine
- 6-(benzofuran-2-yl)-4-morpholinopteridin-2-amine
- 6-(5-fluoro-2-methoxyphenyl)-4-morpholinopteridin-2-amine
- 4-morpholino-6-(3,4,5-trifluorophenyl)pteridin-2-amine
- 5-(2-amino-4-morpholinopteridin-6-yl)indolin-2-one
- N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)isobutyramide
- N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)pivalamide
- (S)-tert-butyl 1-(4-(2-amino-4-morpholinopteridin-6-yl)phenylamino)-3-hydroxy-1-oxopropan-2-yl-carbamate
- (S)-tert-butyl 1-(4-(2-amino-4-morpholinopteridin-6-yl)phenylamino)-1-oxopropan-2-yl-carbamate
- N-[6-(4-amino-phenyl)-4-morpholin-4-yl-pteridin-2-yl]-acetamide
- cyclopropane carboxylic acid [4-(2-amino-4-morpholin-4-yl-pteridin-6-yl)-phenyl]-amide
- 6-(2,3-difluoro-phenyl)-pteridine-2,4-diamine
- (S)-2-amino-N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)-3-hydroxypropanamide
- (S)-2-amino-N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)propanamide
- 6-(4-fluoro-phenyl)-4-methoxy-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-isopropoxy-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-(2-methoxy-ethoxy)-pteridin-2-ylamine
- 4-butoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-(2,2,2-trifluoro-ethoxy)-pteridin-2-ylamine
- 4-[2-amino-6-(4-fluoro-phenyl)-pteridin-4-yloxy]-2-methyl-butan-2-ol
- 6-(4-fluoro-phenyl)-4-(2-morpholin-4-yl-ethoxy)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-(3-morpholin-4-yl-propoxy)-pteridin-2-ylamine
- 4-cyclopropylmethoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- 4-cyclobutylmethoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-propoxy-pteridin-2-ylamine
- 4-sec-butoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-(tetrahydro-furan-3-yloxy)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-isobutoxy-pteridin-2-ylamine
- 4-benzyloxy-6-(4-fluoro-phenyl)pteridin-2-ylamine
- 4-ethylsulfanyl-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- 4-amino-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- 6-(4-fluoro-phenyl)-4-piperidin-1-yl-pteridin-2-ylamine
- N-4-cyclopropyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- 4-(2,6-dimethyl-morpholin-4-yl)-6-(4-fluoro-phenyl)-pteridin-2-ylamine
- N-4-cyclohexyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- N-4-benzyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- N-4-(3-methyl-benzyl)-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- N-4-(3-fluoro-benzyl)-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- 6-(4-fluoro-phenyl)-4-(4-methyl-piperazin-1-yl)-pteridin-2-ylamine
- 6-(4-fluoro-phenyl)-4-piperazin-1-yl-pteridin-2-ylamine
- N-4-cyclopropylmethyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine
- 6-(4-fluoro-phenyl)-4-pyrrolidin-1-yl-pteridin-2-ylamine
- 4-ethoxy-6-(4-fluoro-phenyl)-pteridine
- 4-isopropoxy-6-(4-fluoro-phenyl)-pteridine
- 4-(2-methoxy-ethoxy)-6-(4-fluoro-phenyl)-pteridine
- [6-(4-Fluoro-phenyl)-pteridin-4-yl]-(4-methyl-cyclohexyl)-amine,
- [6-(4-Fluoro-phenyl)-pteridin-4-yl]-(4-methyl-cyclohexyl)-amine,
- 6-(4-fluoro-phenyl)-4-morpholin-4-yl-pteridine, and
- 4-ethylsulfanyl-6-(4-fluoro-phenyl)-pteridine, and/or a pharmaceutically acceptable addition salt thereof and/or a stereoisomer thereof and/or a mono- or a di-N-oxide thereof and/or a solvate thereof and/or a pro-drug form thereof.
- Each of the substituents present on positions 2, 4 and/or 6 of the pteridine scaffold of these molecules belongs to a broader class of substituents being defined in the section “Definitions ” herein-above. It should be understood that some alternative molecules differing from the molecules of the above list by replacing such a substituent with another similar substituent of the same class, e.g. replacing 4-fluorophenyl with 4-chlorophenyl on position 6, may result in a very similar utility in medical treatment, therefore said alternative molecules are also within the framework of the present invention.
- In a second aspect, the present invention relates to a group of pteridine derivative represented by the structural formula:
- wherein X represents an oxygen atom or a group with the formula S(O)m wherein m is an integer from 0 to 2, or a group with the formula NZ and wherein:
- R1 is a group selected from the group consisting of C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, alkylaryl, arylalkyl, heterocyclic, heterocyclic-substituted alkyl and alkyl-substituted heterocyclic, each of said groups being optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, C2-7 alkenyl, C2-7 alkynyl, halo C1-4 alkyl, C3-10 cycloalkoxy, aryloxy, arylalkyloxy, oxyheterocyclic, heterocyclic-substituted alkyloxy, thio C1-7 alkyl, thio C3-10 cycloalkyl, thioaryl, thioheterocyclic, arylalkylthio, heterocyclic-substituted alkylthio, formyl, hydroxyl, sulfhydryl, nitro, hydroxylamino, mercaptoamino, cyano, carboxylic acid or esters or thioesters or amides or thioamides or halides or anhydrides thereof, thiocarboxylic acid or esters or thioesters or amides or thioamides or halides or anhydrides thereof, carbamoyl, thiocarbamoyl, ureido, thio-ureido, amino, alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, alkynylamino, arylamino, arylalkylamino, hydroxyalkylamino, mercaptoalkylamino, heterocyclic amino, hydrazino, alkylhydrazino and phenyl-hydrazino; or R1 is a carboxyalkyl, carboxyaryl, thiocarboxyaryl or thiocarboxyalkyl group;
- Z is a group independently defined as R1 or Z is hydrogen or the group NZ together with R1 is either hydroxylamino or an optionally substituted heterocyclic group containing at least one nitrogen atom;
- R2 is selected from the group consisting of amino; alkanoylamino; thioalkanoylamino; carbamoyl; thiocarbamoyl, ureido; thio-ureido, sulfonamido; hydroxylamino; alkoxyamino; thioalkylamino; mercaptoamino, hydrazino; alkylhydrazino; phenyl-hydrazino; optionally substituted heterocyclic radicals; C3-7 alkylamino; arylamino; arylalkylamino; cycloalkylamino; alkenylamino; cycloalkenylamino; heterocyclic amino; hydroxyalkylamino; mercaptoalkylamino; C1-7 alkoxy; C3-10 cycloalkoxy; thio C1-7 alkyl; arylsulfoxide; arylsulfone; heterocyclic sulfoxide; heterocyclic sulfone; thio C3-10 cycloalkyl; aryloxy; arylthio; arylalkyloxy; arylalkylthio; oxyheterocyclic and thioheterocyclic radicals;
- R4 is hydrogen; and
- R3 aryl substituted with one or more substituents independently selected from the group consisting of aryl wherein said aryl is optionally substituted with arylcarbonyl; (O,O-dialkylphosphonyl)-alkyl; alkanoyl; halo-C1-7 alkoxy; hydroxy-C1-7alkoxy; hydroxy-C1-7 alkyl; di-C1-7 alkylamino C1-7 alkyl; ω-carboxy-alkanoylamino, mono-(C3-7 cycloalkyl)aminocarbonyl, di-(C3-7 cycloalkyl)aminocarbonyl, mono-(C1-7 alkyl)aminocarbonyl, mono-(ω-dimethylamino-C1-7 alkyl)aminocarbonyl, di-(C1-7 alkyl)aminocarbonyl, mono-(hydroxy-C1-7alkyl)aminocarbonyl, fomylamino, sulfamoyl (SO2NH2), arylamino-C1-7 alkyl, C1-7 alkylsulfonyl, heterocyclyl-carbonyl, heterocyclyl-C1-7 alkyl and heterocyclyl, wherein said heterocyclyl is optionally substituted with C3-7 alkenyloxycarbonyl, C1-7 alkyl or C1-7 alkyloxycarbonyl; or R3 is a fused benzo-C5-8 cycloalkyl optionally substituted with oxo; or R3 is heterocyclyl substituted with one or more substituents independently selected from the group consisting of acylamino, C1-7 alkylsulfonyl, arylsulfonyl, heterocyclyl-C1-7 alkyl, heterocyclyl-C1-7 alkylamino, aryl and heterocyclyl, wherein said heterocyclyl is optionally substituted with C1-7 alkyl, arylsulfonyl or (di-C1-7 alkylamino)-C1-7 alkoxy, or said heterocyclyl is non-aromatic and includes a nitrogen atom substituted with heterocyclyl-C1-7 alkyl or a carboxylic acid or a C1-7 alkyl ester thereof,
- and/or a pharmaceutically acceptable addition salt thereof and/or a stereo-isomer thereof and/or a mono- or a di-N-oxide thereof and/or a solvate thereof and/or a pro-drug form thereof.
- A general description of methods for the synthesis of the compounds of the present invention has been provided in WO2005/021003, in particular in FIGS. 1 to 5 thereof and the corresponding description. Most of these methods make use of a boronic acid, or a pinacol ester thereof, for introducing a substituent at position 6 of the pteridine core structure. Processes for preparing such organic boronic acid derivatives have been described for example in EP-B-1,019,414. For the purpose of the present invention, suitable aryl-boronic acids include, but are not limited to, the following commercially available materials wherein the aryl group is 3-acetamidophenyl, 4-acetamidophenyl, 4-acetylphenyl, 3-acetylphenyl, 2-acetylphenyl, 5-acetyl-2-chlorophenyl, 4-acetyl-3-fluorophenyl, 5-acetyl-2-fluorophenyl, 4-(4′-allyloxycarbonylpiperazino)phenyl, 3-aminocarbonyl-phenyl, 4-aminocarbonylphenyl, 2-amino-5-chlorophenyl, 4-amino-3-methoxyphenyl, 3-aminophenyl, 2-amino-4-methylphenyl, 2-amino-5-methylphenyl, 4-amino-2-methylphenyl, 5-amino-2-methylphenyl, 4-amino-3-nitrophenyl, 3-aminophenyl, 2-aminophenyl, 4-aminophenyl, 4-benzyloxyphenyl, 3-benzyloxyphenyl, 2-benzyloxy-phenyl, 4-benzyloxy-2-fluorophenyl, 4-benzyloxy-3-fluorophenyl, 3-benzyloxy-4-methoxy-phenyl, 4-biphenyl, 3,5-bis(trifluoromethyl)benzene, 4-bromophenyl, 3-bromophenyl, 4-bromo-2,5-dimethylphenyl, 2-bromo-5-fluorophenyl, 2-bromo-6-fluorophenyl, 4-n-butylphenyl, 4-isobutylphenyl, 4-carboxyphenyl, 3-carboxyphenyl, 2-carboxyphenyl, 2-carboxy-5-fluorophenyl, 4-carboxy-3-fluorophenyl, 4-carboxy-2-chlorophenyl, 5-carboxy-2-chlorophenyl, 4-carboxy-3-chlorophenyl, 3-carboxyphenyl, 3-(3-carboxypropionyl-amino)phenyl, 4-(3-carboxypropionylamino)phenyl, 2-chloro-5-formylphenyl, 3-chloro-4-fluorophenyl, 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 3-chloro-4-hydroxy-5-methoxyphenyl, 2-chloro-5-hydroxymethylphenyl, 3-chloro-5-methoxyphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-5-trifluoromethoxyphenyl, 3-chloro-5-trifluoromethylphenyl, 4-chloro-2-trifluoromethylphenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-cyanomethoxyphenyl, 3-cyanomethoxyphenyl, 2-cyanomethoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 2-cyanophenyl, 3,5-dibromophenyl, 3-(N-cyclopropylamino-carbonyl)phenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl, 2,3-dichloro-phenyl, 3,5-dichlorophenyl, 3-(N,N-diethylaminocarbonyl)phenyl, 3,5-difluorophenyl, 3,5-difluoro-2-methoxyphenyl, 3,4-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2,4-difluorophenyl, 2,3-difluorophenyl, 4-(N,N-dimethylamino)phenyl, 3-(N,N-dimethylamino)-phenyl, 2-(N,N-dimethylamino)phenyl, 3-(N,N-dimethylaminocarbonyl)phenyl, 3-[(N′,N′-dimethylamino)ethylaminocarbonyl]phenyl, 4-[(N′,N′-dimethylamino)ethyl-aminocarbonyl]-phenyl, 3,5-dimethylphenyl, 3,4-dimethylphenyl, 2,6-dimethylphenyl, 2,6-dimethoxyphenyl, 2, 5-dimethoxyphenyl, 2,4-dimethoxyphenyl, 3-[1,3]dioxolan-2-ylmethoxyphenyl, 4-ethoxyphenyl, 2-ethoxyphenyl, 3-(ethoxycarbonyl)methoxyphenyl, 4-(ethoxycarbonyl)-methoxyphenyl, 4-ethoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 2-ethoxycarbonyl-phenyl, 4-(3-ethoxycarbonylpiperidino)carboxamidophenyl, 4-ethylphenyl, 4-fluorophenyl, 3-fluorophenyl, 2-fluorophenyl, 3-fluoro-4-formylphenyl, 4-fluoro-3-formylphenyl, 4-fluoro-2-methylphenyl, 2-fluoro-5-methylphenyl, 2-fluoro-5-methoxyphenyl, 3-fluoro-4-methoxy-phenyl, 5-fluoro-2-methoxycarbonylphenyl, 2-fluoro-4-trifluoromethylphenyl, 2-formyl-aminophenyl, 3-formylaminophenyl, 4-formylaminophenyl, 2-formyl-5-methoxyphenyl, 3-formyl-4-methoxyphenyl, 5-formyl-2-methoxyphenyl, 2-formyl-5-methylphenyl, 4-formylphenyl, 3-formylphenyl, 2-formylphenyl, 4-hydroxy-3,5-dimethylphenyl, 3-(2-hydroxyethyl)-aminocarbonylphenyl, 4-(2-hydroxyethyl)aminocarbonyl-phenyl, 3-hydroxy-4-methoxycarbonylphenyl, 4-hydroxy-3-methoxyphenyl, 4-(hydroxymethyl)phenyl, 3-(hydroxymethyl)phenyl, 4-hydroxy-3-nitrophenyl, 4-hydroxyphenyl, 3-hydroxyphenyl, 2-hydroxyphenyl, 4-isopropoxyphenyl, 4-(4-isopropylpiperazinyl)phenyl, 4-isopropylphenyl, 4-methanesulfonamido-phenyl, 3-methanesulfonamidophenyl, 2-methanesulfonamido-phenyl, 4-methanesulfonylphenyl, 2-methoxy-5-formylphenyl, 5-methoxy-2-formylphenyl, 4-methoxy-2-formylphenyl, 4-methoxycarbonylphenyl, 3-methoxycarbonylphenyl, 2-methoxycarbonylphenyl, 3-methoxy-4-methoxycarbonylphenyl, 2-methoxy-5-methoxy-carbonylphenyl, 4-methoxy-3-nitrophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 2-methoxy-5-methylphenyl, 4-N-methylcarboxamidophenyl, 4-methyl-phenyl, 3-methylphenyl, 2-methylphenyl, 4-(N-methylamino)phenyl, 3-(4-methyl-piperazine-1-carbonyl)phenyl, 4-(4-methylpiperazine-1-carbonyl)phenyl, 4-(methylthio)-phenyl, 3-(methylthio)phenyl, 2-(methylthio)phenyl, 4-morpholinophenyl, 4-(morpholino-carbonyl)phenyl, 2-morpholinomethyl)phenyl, 4-nitrophenyl, 3-nitrophenyl, 2-nitrophenyl, 4-phenoxyphenyl, 4-(N-phenylaminomethyl)phenyl, 4-(phenylcarbonyl)phenyl, 4-(piperazine-1-carbonyl)phenyl, 4-piperazinylphenyl, 3-succinamidophenyl, 4-succinamidophenyl, sulfamoylphenyl, 2-(toluene-4-sulfonamido)phenyl, 3-(toluene-4-sulfonamido)phenyl, 4-(toluene-4-sulfonamido)phenyl, 4-(tert-butoxycarbonylamino)-3-methoxyphenyl, 2-(tert-A-butoxycarbonyl)phenyl, 3-(tert-butoxycarbonyl)phenyl, 4-(tert-butoxycarbonyl)phenyl, 4-tert-butylphenyl, 4-(tetrahydro-2H-pyran-2-yloxy)phenyl, 4-(2-thienyl)phenyl, 4-trifluoromethoxyphenyl, 4-(trimethylammonium)methylphenyl, 2,4,6-trimethylphenyl, 3,4,5-trifluorophenyl, 2,3,4-trifluorophenyl, 3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 3-trifluoro-methylphenyl, 4-trifluoromethylphenyl, 3,4,5-trimethoxyphenyl, 4-vinylphenyl, 6-benzyloxy-naphth-2-yl, naphth-1-yl, naphth-2-yl, 4-(2-hydroxyethoxy)phenyl, 4′-benzoyl[1,1′-biphenyl]-4-yl, oxoindan-5-yl, (O,O-dimethylphosphonyl)methyl or 1-biphenylyl.
- For the purpose of making the compounds of the present invention, suitable heterocyclic-boronic acids or pinacol esters thereof include, but are not limited to, the following commercially available materials wherein the heterocyclic group is 3,4-methylenedioxyphenyl (benzodioxolyl), 2-acetamidopyridin-5-yl, 2-aminopyridin-5-yl, 2-aminopyrimidin-5-yl, 1,4-benzodioxan-6-yl, 2-benzothienyl, 1-benzothien-3-yl, 1-benzo-thien-2-yl, 2-benzyloxypyridin-5-yl, 1-benzyl-1H-pyrazol-4-yl, 2-bromo-3-chloropyridin-4-yl, 5-bromo-2,3-dihydrobenzo[b]furan-7-yl, 2-bromo-3-methylpyridin-5-yl, 3-bromopyridin-5-yl, 2-bromopyridin-5-yl, 5-bromothien-2-yl, 2-chloro-6-isopropylpyridin-3-yl, 2-chloro-3-methylpyridin-5-yl, 2-[4-(4-chlorophenylsulfonyl)piperazin-1-yl]pyridin-5-yl, 2-chloropyrid-4-yl, 2-chloropyrid-5-yl, 5-chlorothien-2-yl, dibenzo[b,d]furan-4-yl, 2-chloro-3-fluoropyridin-4-yl, dibenzo[b,d]thien-4-yl, 3,4-dihydro-2H-1,5-benzodioxepin-7-yl, 3,6-dihydro-2H-pyridine-1-tert-butoxycarbonyl, 2,5-dibromo-3-pyridinyl, 2,6-dichloro-pyridin-3-yl, 2,3-dihydro-1-benzofuran-5-yl, 2,6-dimethoxypyridin-5-yl, 2,6-dimethoxypyridin-3-yl, 2,4-dimethoxy-pyrimidin-5-yl, 3,5-dimethylisoxazol-4-yl, 2-(3-N,N-dimethylaminopropoxy)pyridin-5-yl, 3,5-dimethylpyrazol-4-yl, 1-[1,3]dioxolan-2-ylmethyl-1H-pyrazol-4-yl, 2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl, 2,4-di(tert-butoxy)pyrimidin-5-yl, 2-ethoxypyridin-3-yl, 2-fluoro-3-methylpyridin-5-yl, 2-fluoropyridin-3-yl, 2-fluoropyridin-5-yl, 5-formyl-2-furyl, 5-formylthien-2-yl, furan-3-yl, furan-2-yl, 2-hydroxypyridin-5-yl, 5-indolyl, 1-isobutyl-1H-pyrazol-4-yl, isoquinolin-4-yl, 2-methoxypyridin-3-yl, 2-methoxypyrimidin-5-yl, 5-methyl-1-benzo-thiophen-2-yl, 1-(3-methylbutyl)-1H-pyrazol-4-yl, 5-methylfuran-2-yl, 1-methylindol-5-yl, 5-methyl-3-phenyl-4-isoxazolyl, 5-(methylthio)thien-2-yl, 2-(4-methylpiperazinyl)pyridin-4-yl, 2-(4-methylpiperazinyl)pyridin-5-yl, 1-methyl-1H-pyrazol-4-yl, 3-methylpyridin-2-yl, 5-methylpyridin-2-yl, 5-methylpyridin-3-yl, 4-methylthien-2-yl, 5-methylthien-2-yl, 2-methoxy-pyridin-5-yl, 2-(2-morpholinoethylamino)-pyridin-5-yl, 2-(2-morpholinoethyl)-1H-pyrazol-4-yl, 2-(morpholin-1-yl)-pyridin-5-yl, 1-(phenylsulfonyl)-1H-indol-3-yl, 5-phenyl-2-thienyl, 2-(piperazin-1-yl)-pyridin-5-yl, 2-(piperazin-1-yl)-pyridin-4-yl, 1-propyl-1H-pyrazol-4-yl, pyrazol-4-yl, pyridin-4-yl, pyridin-3-yl, pyrimidin-5-yl, 4-phenoxathiinyl, quinolin-8-yl, quinolin-3-yl, 2-(4-tert-butoxycarbonylpiperazinyl)-pyrid-4-yl, 1-tert-butoxycarbonyl-1H-pyrazol-4-yl, 1-tert-butoxycarbonyl-2-pyrrolyl, 1-(tert-butoxycarbonyl)-5-bromo-1H-indol-2-yl, 1-(tert-butoxycarbonyl)-1H-indol-5-yl, 1-(tert-butoxycarbonyl)-5-methoxy-1H-indol-2-yl, 1-thianthrenylthien-3-yl, thien-3-yl, thien-2-yl or 1,3,5-trimethyl-1H-pyrazol-4-yl.
- Stereoisomers of the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of the present invention may be formed by using reactants in their single enantiomeric form wherever possible in the manufacturing process, or by resolving a mixture of stereoisomers by conventional methods. One such method is liquid chromatography using one or more suitable chiral stationary phases including, for example, polysaccharides, in particular cellulose or amylose derivatives. Commercially available, but non limiting, suitable polysaccharide-based chiral stationary phases are ChiralCel™ CA, OA, OB, OC, OD, OF, OG, OJ and OK, and Chiralpak™ AD, AS, OP(+) and OT(+). Appropriate eluents or mobile phases for use in combination with said polysaccharide-based chiral stationary phases are hydrocarbons such as hexane and the like, optionally admixed with an alcohol such as ethanol, isopropanol and the like. The above mixture of enantiomers may alternatively be separated by making use of microbial resolution or by resolving the diastereoisomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid and the like or with chiral bases such as brucine and the like. The resolving agent may be cleaved from the separated diastereoisomers, e.g. by treatment with acids or bases, in order to generate the pure enantiomers of the compounds of the invention. Conventional resolution methods were compiled e.g. by Jaques et al. in “Enantiomers, Racemates and Resolution” (Wiley Interscience, 1981).
- As noted above, one particular embodiment of this invention includes the various precursors or “pro-drug” forms of the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of the present invention. It may be desirable to formulate the compounds of the present invention in the form of a chemical species which itself is not significantly biologically-active but which, when delivered to the body of a human being or higher mammal, will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein. The term “pro-drug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.
- The pro-drugs of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C—C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used.
- For the purpose of the present invention the term “therapeutically suitable pro-drug” is defined herein as a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of humans or mammals to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome.
- In another aspect, the present invention provides the use of 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives as defined herein-above for the manufacture of a medicament for treating or preventing a viral infection, and the corresponding method of treatment of a viral infection by administering an effective amount of such a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative to a patient in need thereof. In one embodiment, said viral infection may be an infection caused by a virus being a member of the Flaviviridae family. The Flaviviridae family is a family of positive-strand RNA viruses which includes the following genera:
- Genus Flavivirus (type species include yellow fever virus, west nile virus and dengue fever),
- Genus Hepacivirus (type species includes hepatitis C virus), and
- Genus Pestivirus (type species include bovine viral diarrhea virus, classical swine fever and hog cholera).
- In a more preferred embodiment of this aspect of the present invention, said Flavivirus is the hepatitis C virus (hereinafter referred as HCV).
- In a third aspect, the present invention relates to a pharmaceutical composition comprising as an active principle at least one 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative as defined above, e.g. in the form of a pharmaceutically acceptable salt. The latter include any therapeutically active non-toxic addition salt which the 4,6-disubstituted or 2,4,6-trisubstituted pteridine compounds of the present invention are able to form with a salt-forming agent. Such addition salts may conveniently be obtained by treating the pteridine derivatives of the invention with an appropriate salt-forming acid or base. For instance, 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives having basic properties may be converted into the corresponding therapeutically active, non-toxic acid addition salt form by treating the free base form with a suitable amount of an appropriate acid following conventional procedures. Examples of such appropriate salt-forming acids include, for instance, inorganic acids resulting in forming salts such as, but not limited to, hydrohalides (e.g. hydrochloride and hydrobromide), sulfate, nitrate, phosphate, diphosphate, carbonate, bicarbonate, and the like; and organic monocarboxylic or dicarboxylic acids resulting in forming salts such as, for example, acetate, propanoate, hydroxyacetate, 2-hydroxypropanoate, 2-oxopropanoate, lactate, pyruvate, oxalate, malonate, succinate, maleate, fumarate, malate, tartrate, citrate, methanesulfonate, ethanesulfonate, benzoate, 2-hydroxybenzoate, 4-amino-2-hydroxy-benzoate, benzenesulfonate, p-toluenesulfonate, salicylate, p-aminosalicylate, pamoate, bitartrate, camphorsulfonate, edetate, 1,2-ethanedisulfonate, fumarate, glucoheptonate, gluconate, glutamate, hexylresorcinate, hydroxynaphthoate, hydroxyethanesulfonate, mandelate, methylsulfate, pantothenate, stearate, as well as salts derived from ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)2-butenedioic, 2-hydroxy-butanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic and cyclo-hexanesulfamic acids, and the like.
- 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives having acidic properties may be converted in a similar manner into the corresponding therapeutically active, non-toxic base addition salt form. Examples of appropriate salt-forming bases include, for instance, inorganic bases like metallic hydroxides such as but not limited to those of alkali and alkaline-earth metals like calcium, lithium, magnesium, potassium and sodium, or zinc, resulting in the corresponding metal salt; organic bases such as but not limited to ammonia, alkylamines, benzathine, hydrabamine, arginine, lysine, N,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylene-diamine, N-methyl-glucamine, procaine and the like.
- Reaction conditions for treating the 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivatives of this invention with an appropriate salt-forming acid or base are similar to standard conditions involving the same acid or base but different organic compounds with basic or acidic properties, respectively. Preferably, in view of its use in a pharmaceutical composition or in the manufacture of a medicament for treating specific diseases, the pharmaceutically acceptable salt will be designed, i.e. the salt-forming acid or base will be selected so as to impart greater water-solubility, lower toxicity, greater stability and/or slower dissolution rate to the substituted pteridine derivative of this invention.
- The present invention further provides the use of a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a stereoisomer thereof or a pro-drug form thereof, as a biologically-active ingredient, i.e. active principle, especially as a medicine or for the manufacture of a medicament for the prevention or treatment of viral infections, especially infections due to Flaviridae, and pathologic conditions associated therewith such as, but not limited to, hepatitis C.
- The invention further relates to a pharmaceutical composition comprising:
-
- one or more 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivatives selected from the group as defined above, and
- (b) one or more pharmaceutically acceptable carriers.
- In another embodiment, this invention provides combinations, preferably synergistic combinations, of one or more 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivatives of this invention with one or more other antiviral agents. As is conventional in the art, the evaluation of a synergistic effect in a drug combination may be made by analyzing the quantification of the interactions between individual drugs, using the median effect principle described by Chou et al. in Adv. Enzyme Reg. (1984) 22:27. Briefly, this principle states that interactions (synergism, additivity, antagonism) between two drugs can be quantified using the combination index (hereinafter referred as Cl) defined by the following equation:
-
- wherein EDx is the dose of the first or respectively second drug used alone (1 a, 2 a), or in combination with the second or respectively first drug (1 c, 2 c), which is needed to produce a given effect. The said first and second drug have synergistic or additive or antagonistic effects depending upon Cl<1, Cl=1, or Cl>1, respectively. As will be explained in more detail herein below, this principle may be applied to a number of desirable effects such as, but not limited to, anti-viral activity against HCV.
- The present invention further relates to a pharmaceutical composition or combined preparation having synergistic effects against a viral infection, especially a hepatitis C virus infection, and containing:
-
- (a) at least one 4,6-disubstituted and 2,4,6-trisubstituted pteridine derivative selected from the group as defined above, and
- (b) one or more other anti-viral agents, and
- (c) optionally one or more pharmaceutical excipients or pharmaceutically acceptable carriers,
for simultaneous, separate or sequential use in the treatment of a viral infection, in particular HCV infection.
- Suitable anti-viral agents for inclusion into the synergistic antiviral compositions or combined preparations of this invention include, for instance, retroviral enzyme inhibitors belonging to categories well known in the art, such as HIV-1 IN inhibitors, nucleoside reverse transcriptase inhibitors (e.g. zidovudine, lamivudine, didanosine, stavudine, zalcitabine and the like), non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine, delavirdine and the like), other reverse transcriptase inhibitors (e.g. foscamet sodium and the like), and HIV-1 protease inhibitors (e.g. saquinavir, ritonavir, indinavir, nelfinavir and the like). Other suitable antiviral agents include for instance acemannan, acyclovir, adefovir, alovudine, alvircept, amantadine, aranotin, arildone, atevirdine, avridine, cidofovir, cipamfylline, cytarabine, desciclovir, disoxaril, edoxudine, enviradene, enviroxime, famciclovir, farnotine, fiacitabine, fialuridine, floxuridine, fosarilate, fosfonet, ganciclovir, idoxuridine, kethoxal, lobucavir, memotine, methisazone, penciclovir, pirodavir, somantadine, sorivudine, tilorone, trifluridine, valaciclovir, vidarabine, viroxime, zinviroxime, moroxydine, podophyllotoxin, ribavirine, rimantadine, stallimycine, statolon, tromantadine and xenazoic acid, and their pharmaceutically acceptable salts.
- Especially relevant to this aspect of the invention is the inhibition of the replication of hepatitis C virus, in particular in human beings and other mammals such as primates. Therefore, of particular relevance in the context of HCV prevention or treatment is co-administration with one or more other agents aiming at HCV inhibition well known in the art, such as but not limited to, (pegylated) interferon alpha, ribavirin, an NS3 protease inhibitor (such as telaprivir), or nucleoside- or non-nucleoside-based inhibitors of NS5B polymerase. Synergistic activity of the pharmaceutical compositions or combined preparations of this invention against viral infection may be readily determined by means of one or more tests such as, but not limited to, the isobologram method, as previously described by Elion et al. in J. Biol. Chem. (1954) 208:477-488 and by Baba et al. in Antimicrob. Agents Chemother. (1984) 25:515-517, using EC50 for calculating the fractional inhibitory concentration (hereinafter referred as FIC). When the minimum FIC index corresponding to the FIC of combined compounds (e.g., FICx+FICy) is equal to 1.0, the combination is said to be additive; when it is between 1.0 and 0.5, the combination is defined as sub-synergistic, and when it is lower than 0.5, the combination is by defined as synergistic. When the minimum FIC index is between 1.0 and 2.0, the combination is defined as sub-antagonistic and, when it is higher than 2.0, the combination is defined as antagonistic.
- The pharmaceutical composition or combined preparation with synergistic activity against viral infection according to this invention may contain the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative over a broad content range depending on the contemplated use and the expected effect of the preparation. Generally, the pteridine derivative content of the combined preparation is within the range of from 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from about 5 to 95% by weight.
- The pharmaceutical compositions and combined preparations according to the present invention may be administered orally or in any other suitable fashion. Oral administration is preferred and the preparation may have the form of a tablet, aqueous dispersion, dispersible powder or granule, emulsion, hard or soft capsule, syrup, elixir or gel. The dosing forms may be prepared using any method known in the art for manufacturing these pharmaceutical compositions and may comprise as additives sweeteners, flavoring agents, coloring agents, preservatives and the like. Carrier materials and excipients are detailed herein below and may include, inter alia, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, binding agents and the like. The pharmaceutical composition or combined preparation of this invention may be included in a gelatin capsule mixed with any inert solid diluent or carrier material, or has the form of a soft gelatin capsule, in which the ingredient is mixed with a water or oil medium. Aqueous dispersions may comprise the biologically active composition or combined preparation in combination with a suspending agent, dispersing agent or wetting agent. Oil dispersions may comprise suspending agents such as a vegetable oil. Rectal administration is also applicable, for instance in the form of suppositories or gels. Injection (e.g. intramuscularly or intraperiteneously) is also applicable as a mode of administration, for instance in the form of injectable solutions or dispersions, depending upon the disorder to be treated and the condition of the patient.
- The term “pharmaceutically acceptable carrier or excipient” as used herein in relation to pharmaceutical compositions and combined preparations means any material or substance with which the active principle, i.e. the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, and optionally the one or more other antiviral agents, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although, due to the usually low or very low water-solubility of the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivatives of this invention, special attention will be paid to the selection of suitable carrier combinations that can assist in properly formulating them in view of the expected time release profile. Suitable pharmaceutical carriers include additives such as, but not limited to, wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals, especially humans.
- The pharmaceutical compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 μm, namely for the manufacture of microcapsules for controlled or sustained release of the biologically active ingredient(s).
- Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties. Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents. Suitable soaps include, but are not limited to, alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C1-10-C22), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil. Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylaryl-sulphonates. Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g. the sodium or calcium salt of lignosulphonic acid or dodecylsulphonic acid or a mixture of fatty alcohol sulphates obtained from natural fatty acids, alkaline or alkaline-earth metal salts of sulphuric or sulphonic acid esters (such as sodium lauryl sulphate) and sulphonic acids of fatty alcohol/ethylene oxide adducts. Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms. Examples of alkylarylsulphonates are the sodium, calcium or alkanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphthalenesulphonic acid or a naphthalenesulphonic acid/formaldehyde condensation product. Also suitable are the corresponding phosphates, e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and/or propylene oxide, or phospholipids. Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g. phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylphosphatidylcholine, dipalmitoylphoshatidylcholine and their mixtures.
- Suitable non-ionic surfactants include, but are not limited to, poly-ethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to. 18 carbon atoms in the alkyl moiety of the alkylphenol. Further suitable non-ionic surfactants are water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamino-polypropylene glycol preferably containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups. Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit. Representative examples of non-ionic surfactants include, but are not limited to, nonylphenol-polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxy-polyethoxyethanol. Fatty acid esters of polyethylene sorbitan (such as polyoxyethylene sorbitan trioleate), glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants for the purpose of the present invention.
- Suitable cationic surfactants include, but are not limited to, quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C8-C22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-C1-4 alkyl radicals.
- A more detailed description of surface-active agents suitable for this purpose may be found for instance in “McCutcheon's Detergents and Emulsifiers Annual” (MC Publishing Crop., Ridgewood, N.J., 1981), “Tensid-Taschenbuch”, 2nd ed. (Hanser Verlag, Vienna, 1981) and “Encyclopaedia of Surfactants (Chemical Publishing Co., New York, 1981).
- Structure-forming, thickening or gel-forming agents may be included into the pharmaceutical compositions and combined preparations of the present invention. Suitable such agents include in particular, but are not limited to, highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium salts of montmorillonites (e.g., products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).
- Gelling agents which may be included into the pharmaceutical compositions and combined preparations of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof. Gelatin and modified celluloses represent a preferred class of gelling agents.
- Other optional excipients which may be included in the pharmaceutical compositions and combined preparations of the present invention include additives such as, but not limited to, magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.
- Additional ingredients may be included in order to control the duration of action of the biologically-active ingredient in the compositions and combined preparations of the invention. Control release compositions may thus be achieved by selecting appropriate pharmaceutically acceptable polymer carriers such as for example polyesters, polyamino-acids, polyvinyl-pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxymethylcellulose, protamine sulfate and the like. The rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethyl-cellulose, polymethyl methacrylate and the other above-described polymers. Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on. Depending on the route of administration, the pharmaceutical composition or combined preparation of the invention may also require protective coatings.
- Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof. Typical liquid pharmaceutically acceptable carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof.
- Other modes of local drug administration can also be used. For example, the selected biologically active agent may be administered topically, in an ointment, gel or the like, or transdermally, using a conventional transdermal drug delivery system.
- Since, in the case of combined preparations including the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention and one or more other antiviral agents, both ingredients do not necessarily bring out their synergistic therapeutic effect directly at the same time in the patient to be treated, the said combined preparation may be in the form of a medical kit or package containing the two ingredients in separate but adjacent form. In the latter context, each ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g. one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.
- The present invention further relates to a method for treating a viral infection or a pathologic condition associated therewith, including hepatitis C in a patient, preferably a mammal, more preferably a human being. The method of this invention consists of administering to the patient in need thereof a therapeutically effective amount of a 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative of the present invention, optionally together with an effective amount of one or more other antiviral agents, or a pharmaceutical composition comprising the same, such as disclosed above in extensive details.
- The therapeutically effective amount of the 4,6-disubstituted or 2,4,6-trisubstituted pteridine derivative to be adiministered according to the present invention is usually in the range of about 0.01 mg to 20 mg, preferably about 0.1 mg to 5 mg, per day per kg body weight for human beings. Depending upon the severity of the pathologic condition to be treated and the patient's condition, the said therapeutically effective amount may be divided into several sub-units per day or may be administered at more than one day intervals. The patient to be treated may be any warm-blooded animal, preferably a mammal, more preferably a human being, suffering from an infection by a virus being a member of the Flaviridae family, e.g. HCV, or a pathologic condition associated therewith.
- The present invention will be further described with reference to certain more specific embodiments and examples, but the present invention is not limited thereto. The following examples are given by way of illustration only.
- The synthetic method may be represented schematically as follows:
- The general procedure used for preparing 2-amino-6-aryl-4-ethoxy-pteridines and 2-amino-6-heteroaryl-4-ethoxy-pteridines starts from the common intermediate 2-amino-6-chloro-4-ethoxypteridine (described in WO 2005/025574) as follows. A mixture of 2-amino-6-chloro-4-ethoxypteridine (23 mg, 0.1 mmol), potassium carbonate (27 mg, 0.2 mmol), tetrakis(triphenylphosphine) palladium (8 mg, 0.007 mmol) and a suitable arylboronic or heteroarylboronic acid, or a pinacol ester thereof, (0.12 mmol) in dimethylether (1.5 mL) and water (1 mL) was heated to 100° C. for 10 minutes under microwave irradiation. Solvents were concentrated in vacuo and the residue was purified by high performance liquid chromatography (hereinafter referred as HPLC) onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile, in order to afford the pure desired product. This procedure provided, with yield ranging from 5% to 65%, depending upon the aryl or heteroaryl group R introduced at position 6 of the pteridine ring, the pure compounds shown in the table 1, which were characterized by their mass spectrum MS.
-
TABLE 1 Example R Compound name M + H 1 6-(2,6-dichlorophenyl)-4-ethoxypteridin-2- ylamine 336.1 2 3-(2-amino-4-ethoxypteridin-6- yl)benzonitrile 293.3 3 4-ethoxy-6-(3-fluoro-4-methoxyphenyl) pteridin-2-ylamine 316.1 4 4-ethoxy-6-(4-(trifluoromethoxy)phenyl) pteridin-2-ylamine 352.5 5 6-(3,5-bis(trifluoromethyl)phenyl)-4- ethoxypteridin-2-ylamine 404.5 6 4-ethoxy-6-(4-(trifluoromethyl)phenyl) pteridin-2-ylamine 336.5 7 6-(4-chloro-3-fluorophenyl)-4- ethoxypteridin-2-ylamine 320.3 8 6-(3,5-dichlorophenyl)-4-ethoxypteridin- 2-ylamine 336.3 9 6-(3,4-difluorphenyl)-4-ethoxypteridin-2- ylamine 304.3 10 4-ethoxy-6-(2-fluorophenyl)pteridin-2- ylamine 286.3 11 6-(2,6-difluorophenyl)-4-ethoxypteridin-2- ylamine 304.1 12 6-(3,5-difluorophenyl)-4-ethoxypteridin-2- ylamine 304.1 13 6-(2,3-difluorophenyl)-4-ethoxypteridin-2- ylamine 304.3 14 4-ethoxy-6-(3-fluorophenyl)pteridin-2- ylamine 286.2 15 dimethyl (4-(2-amino-4-ethoxypteridin-6- yl)phenyl)methylphosphonate 390.0 16 6-(2,4-difluorophenyl)-4-ethoxypteridin-2- ylamine 304.3 17 6-(3-chlorophenyl)-4-ethoxypteridin-2- ylamine 302.3 18 6-(2,4-bis(trifluoromethyl)phenyl)-4- ethoxypteridin-2-ylamine 404.5 19 4-ethoxy-6-(pyridin-3-yl)pteridin-2-ylamine 269.3 20 4-ethoxy-6-(1H-pyrazol-5-yl)pteridin-2- ylamine 258.3 21 4-ethoxy-6-(pyrimidin-5-yl)pteridin-2- ylamine 270.2 22 4-ethoxy-6-(2-fluoropyridin-3-yl)pteridin-2- ylamine 287.1 23 4-ethoxy-6-(thiophen-3-yl)pteridin-2- ylamine 274.3 24 4-ethoxy-6-(furan-3-yl)pteridin-2-ylamine 258.1 25 N-(4-(2-amino-4-ethoxypteridin-6- yl)phenyl)acetamide 325.2 26 6-(2,5-difluorophenyl)-4-ethoxypteridin-2- ylamine 304.3 27 6-(4-chlorophenyl)-4-ethoxypteridin-2- ylamine 302.3 28 4-ethoxy-6-(2-(trifluoromethyl)phenyl) pteridin-2-ylamine 336.3 29 4-ethoxy-6-(1H-indol-5-yl)pteridin-2- ylamine 307.3 30 4-ethoxy-(4-(methylsulfonyl)phenyl) pteridin-2-ylamine 346.3 31 4-ethoxy-6-(pyridin-4-yl)pteridin-2-ylamine 269.3 32 4-ethoxy-6-(1H-pyrazol-4-yl)pteridin-2- ylamine 258.3 33 4-ethoxy-6-(furan-2-yl)pteridin-2-ylamine 258.3 34 6-(2-chlorophenyl)-4-ethoxypteridin-2- ylamine 302.1 35 6-(2,3-diclorophenyl)-4-ethoxypteridin-2- ylamine 336.1 36 6-(3-chloro-4-fluorophenyl)-4- ethoxypteridin-2-ylamine 320.1 37 6-(2-chloro-4-fluorophenyl)-4- ethoxypteridin-2-ylamine 320.1 38 4-ethoxy-6-(3-(trifluoromethyl)phenyl) pteridin-2-ylamine 336.2 39 4-ethoxy-6-(3-(trifluoromethoxy) phenyl)pteridin-2-ylamine 352.1 40 4-(2-amino-4-ethoxypteridin-6-yl)-N- ethylbenzamide 325.2 41 4-(2-amino-4-ethoxypteridin-6-yl)-N- cyclopropylbenzamide 351.2 42 6-(4-(dimethylamino)phenyl)-4- ethoxypteridin-2-ylamine 311.2 43 4-ethoxy-6-(4-fluoro-2- methylphenyl)pteridin-2-ylamine 300.2 44 5-(2-amino-4-ethoxypteridin-6- yl)thiophene-2-carbonitrile 299.1 45 4-ethoxy-6-(2-(trifluoromethoxy) phenyl)pteridin-2-ylamine 352.1 46 4-ethoxy-6-(2,3,4-trifluorophenyl)pteridin- 2-ylamine 322.0 47 6-(2-chloro-4-(trifluoromethyl)phenyl)-4- ethoxypteridin-2-ylamine 369.9 48 4-ethoxy-6-(2,4,6-trifluorophenyl)pteridin- 2-ylamine 322.0 49 6-(5-chlorothiophen-2-yl)-4-ethoxypteridin- 2-ylamine 308.1 50 2-(2-amino-4-ethoxypteridin-6-yl)phenol 284.3 51 6-(2,5-dichlorophenyl)-4-ethoxypteridin-2- ylamine 336.1 52 6-(3,5-dimethylphenyl)-4-ethoxypteridin-2- ylamine 296.5 53 4-ethoxy-6-(3-ethoxyphenyl)pteridin-2- ylamine 312.3 54 4-ethoxy-6-p-tolylpteridin-2-ylamine 282.3 55 6-(benzo[b]thiophen-2-yl)-4-ethoxypteridin- 2-ylamine 324.5 56 4-ethoxy-6-(2-ethoxyphenyl)pteridin-2- ylamine 312.3 57 4-(2-amino-4-ethoxypteridin-6-yl)phenol 284.3 58 6-(2,4-dichlorophenyl)-4-ethoxypteridin-2- ylamine 336.1 59 4-ethoxy-6-(2,4,5-trifluorophenyl)pteridin- 2-ylamine 322.3 60 4-ethoxy-6-(2-methylphenyl)pteridin-2- ylamine 282.3 61 1-(4-(2-amino-4-ethoxypteridin-6- yl)phenyl)pyrrolidin-2-one 351.0 62 5-(2-amino-4-ethoxypteridin-6-yl)indolin- 2-one 323.4 63 4-ethoxy-6-(6-methoxypyridin-3- yl)pteridin-2-ylamine 299.3 64 4-ethoxy-6-(isoxazol-4-yl)pteridin-2- ylamine 259.2 65 4-ethoxy-6-(5-fluoro-2- methoxyphenyl)pteridin-2-ylamine 316.1 66 methyl4-(2-amino-4-ethoxypteridin-6- yl)phenylcarbamate 341.3 67 6-(benzofuran-2-yl)-4-ethoxypteridin-2- ylamine 308.2 68 4-ethoxy-6-morpholinopteridin-2-ylamine 277.2 69 6-(4-aminophenyl)-4-ethoxypteridin-2- ylamine 283.1 70 4-ethoxy-6-(3-methylpyridin-4-yl)pteridin- 2-ylamine 283.0 71 4-ethoxy-6-(2-methoxypyridin-4-yl)pteridin-2-ylamine 299.0 72 4-ethoxy-6-(2-methoxypyridin-4-pteridin- 2-ylamine 283 73 4-ethoxy-6-(pyridin-2-yl)pteridin-2-ylamine 269.3 (end of table 1) - The scheme below shows a general procedure for the synthesis of 2-amino-4-morpholin-4-yl-6-substituted-pteridines.
- To a solution of 2,5,6-triamino-4-morpholino-pyrimidine dihydrochloride (7.08 g, 25 mmol) in ethanol (60 mL) was added glyoxal (405 solution in water, 2.9 mi., 25 mmol). The reaction mixture was refluxed for one hour. After cooling, the solvent was removed under reduced pressure. The residue was purified by flash chromatography (using 7% MeOH/DCM as the eluent), providing the pure title compound in 80% yield (4.6 g), which was characterized by mass spectrometry as follows: MS (m/z) 233.3 [M+H]+.
- To a cooled (0° C.) solution of 4-morpholin-4-yl-pteridin-2-ylamine (4.6 g, 20 mmol) in trifluroroacetic acid (80 mL) was added dropwise 5.1 mL of a 35% aqueous H2O2 solution. The reaction mixture was kept at 4° C. overnight. The solution was concentrated to dryness, providing crude product (4.9 g, 98% yield) as a yellow powder. The crude material was used without further purification, but was characterized by mass spectrometry as follows: MS (m/z) 249.3 [M+H]+.
- A suspension of 4-morpholin-4-yl-8-oxy-pteridin-2-ylamine. (2.3 g) in acetyl chloride (25 mL) was stirred at −40° C. Trifluoroacetic acid (12 mL) was then added dropwise. The resulting solution was slowly warmed up to room temperature and stirred for one day. Reaction was carefully quenched with ice, followed by neutralization with ammonium hydroxide solution. The aqueous phase was extracted with DCM repeatedly. The combined organic layers were concentrated in vacuo and the residue was purified by flash chromatography providing the pure title compound as a yellow solid (1.2 g, 43% yield) was characterized by mass spectrometry as follows: MS (m/z) 309.2 [M+H]+.
- The general procedure used for preparing 2-amino-6-aryl-4-morpholino-pteridines and 2-amino-6-heteroaryl-4-morpholino-pteridines was as follows. A mixture of 2-amino-6-chloro-4-morpholine-pteridine (31 mg, 0.1 mmol), potassium carbonate (42 mg, 0.4 mmol), tetrakis(triphenylphosphine) palladium (8 mg, 0.007 mmol) and a suitable arylboronic or heteroarylboronic acid, or a pinacol ester thereof (0.12 mmol), in dimethylether (2 mL) and water (1 mL) was heated to 110° C. for 30 minutes under microwave irradiation. Solvents were concentrated in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile. This procedure provided, with yields ranging from 10% to 70%, depending upon the aryl or heteroaryl group R introduced at position 6 of the pteridine ring, the pure compounds which were characterized by their mass spectrum MS as indicated in Table 2 below.
-
TABLE 2 Example R Compound name M + H 77 6-(2-fluorophenyl)-4-morphoinopteridin-2- ylamine 327.2 78 6-(2-chlorophenyl)-4-morpholinopteridin-2- ylamine 343.2 79 4-morpholino-6-(2-(trifluoromethyl)phenyl) pteridin-2-ylamine 377.1 80 6-(2-methoxyphenyl)-4-morpholinopteridin-2- ylamine 339.2 81 6-(3-fluorophenyl)-4-morpholinopteridin-2- ylamine 327.2 82 6-(3-chlorophenyl)-4-morpholinopteridin-2- ylamine 343.2 83 4-morpholino-6-(3-(trifluoromethyl)phenyl)- pteridin-2-ylamine 377.1 84 4-morpholino-6-(3-(trifluoromethoxy)phenyl)- pteridin-2-ylamine 393.1 85 3-(2-amino-4-morpholinopteridin-6- yl)benzonitrile 334.3 86 4-morpholino-6-(4-(trifluoromethoxy- phenyl)pteridin-2-ylamine 393.1 87 4-(2-amino-4-morpholinopteridin-6- yl)benzonitrile 334.2 89 4-morpholino-6-(4-(morpholino- methyl)phenyl)pteridin-2-ylamine 408.1 90 6-(2,3-difluorophenyl)-4-morpholinopteridin-2- ylamine 345.2 91 6-(2,3-dichlorophenyl)-4-morpholinopteridin-2- amine 377 92 6-(2-chloro-4-fluorophenyl)-4- morpholinopteridin-2-ylamine 361.1 93 6-(2,4-bis(trifluoromethyl)phenyl)-4- morpholinopteridin-2-ylamine 444.9 94 6-(2,4-difluorophenyl)-4-morpholinopteridin-2- ylamine 345.2 95 5-(2,6-dichlorophenyl)-4-morpholinopteridin-2- ylamine 377 96 6-(3,5-bis(trifluoromothyl)phenyl)-4- morpholinopteridin-2-ylamine 445.5 97 6-(4-chloro-3-fluorophenyl)-4- morpholinopteridin-2-ylamine 361.3 98 6-(3,5-difluorophenyl)-4-morpholinopteridin-2- ylamine 345.3 99 6-(3,5-dichlorophenyl)-4-morpholinopteridin-2- ylamine 377.3 100 dimethyl(4-(2-amino-4-morpholinopteridin-6- yl)phenyl)methylphosphonate 431 101 6-(2,6-difluorophenyl)-4-morpholinopteridin-2- ylamine 345.2 102 6-(3,4-dichlorophenyl)-4-morpholinopteridin-2- ylamine 377 103 6-(3-chloro-4-fluorophenyl)-4- morpholinopteridin-2-ylamine 361.1 104 4-morpholino-6-(4-(trifluoromethyl)phenyl) pteridin-2-ylamine 377.5 105 6-(4-(methylsulfonyl)phenyl)-4- morpholinopteridin-2-ylamine 387.3 106 6-(1H-indol-5-yl)-4-morpholinopteridin-2- ylamine 348.5 107 4-morpholino-6-(pyrimidin-5-yl)pteridin-2- ylamine 311.5 108 4-morpholino-6-(pyridin-3-yl)pteridin-2-ylamine 310.5 109 6-(2-fluoropyridin-3-yl)-4-morpholino-pteridin- 2-ylamine 328.3 110 4-morpholino-6-(thiophen-3-yl)pteridin-2- ylamine 315.3 111 6-(furan-3-yl)4-morpholinopteridin-2-ylamine 299.5 112 4-morpholino-6-(1H-pyrazol-5-yl)pteridin-2- ylamine 299.5 113 6-(2,3-difluorophenyl)-4-morpholino-pteridin-2- ylamine 345.3 114 4-(2-amino-4-morpholinopteridin-6-yl)-N- methylbenzamide 366.2 115 4-(2-amino-4-morpholinopteridin-6-yl)-N- cyclopropylbenzamide 392.1 116 6-(2,5-difluorophenyl)-4-morpholinopteridin-2- ylamine 345.2 117 4-morpholino-6-(pyridin-4-yl)pteridin-2-ylamine 310.2 118 4-morpholino-6-(1H-pyrazol-4-yl)pteridin-2- ylamine 299.2 119 6-(4-(dimethylamino)phenyl)-4- morpholinopteridin-2-ylamine 352.5 120 6-(4-fluoro-2-methylphenyl)-4- morpholinopteridin-2-ylamine 341.3 121 6-(2-chloro-4-(trifluoromethyl)phenyl)-4- morpholinopteridin-2-ylamine 411.5 122 5-(2-amino-4-morpholinopteridin-6- yl)thiophene-2-carbonitrile 340.2 123 6-(benzo[b]thiophen-2-yl)-4- morpholinopteridin-2-ylamine 365.3 124 2-(2-amino-4-morpholinopteridin-6-yl)phenol 325.5 125 6-(2-ethoxyphenyl)-4-morpholinopteridin-2- ylamine 353.5 126 6-(3-ethoxyphenyl)-4-morpholinopteridin-2- ylamine 353.5 127 6-(5-chiorothiophen-2-yl)-morpholinopteridin- 2-ylamine 349 128 1-(4-(2-amino-4-morpholinopteridin-6- yl)phenyl)pyrrolidin-2-one 392.1 129 methyl 4-(2-amino-4-morpholinopteridm-6- yl)phenylcarbamate 382.2 130 6-(6-methoxypyridin-3-yl)-4- morpholinopteridin-2-ylamine 340.3 131 6-(isoxazol-4-yl)-4-morpholinopteridin-2- ylamine 300.2 132 6-(2-methylphenyl)-4-morpholinopteridin-2- ylamine 323.5 133 6-(benzofuran-2-yl)-4-morpholinopteridin-2- ylamine 349.3 134 6-(5-fluoro-2-methoxyphenyl)-4- morpholinopteridin-2-ylamine 357.2 135 4-morpholino-6-(3,4,5-trifluorophenyl)pteridin- 2-ylamine 263.3 136 5-(2-amino-4-morpholinopteridin-6-yl)indolin-2- one 364.7 137 N-(4-(2-amino-4-morpholinopteridin-6- yl)phenyl)isobutyramide 394.3 138 N-(4-(2-amino-4-morpholinopteridin-6- yl)phenyl)pivalamide 409 139 (S)-tert-butyl 1-(4-(2-amino-4- morpholinopteridin-6-yl)phenylamino)-3- hydroxy-1-oxopropan-2-ylcarbamate 511.5 140 (S)-tert-butyl 1-(4-(2-amino-4- morpholinopteridin-6-yl)phenylamino)-1- oxopropan-2-ylcarbamate 496 (end of Table 2) - Synthesis Proceeds According to the Following Scheme:
- A mixture of 2-amino-6-chloro-4-morpholino-pteridine (600 mg, 1.9 mmol), potassium carbonate (394 mg, 66 mmol), tetrakis(triphenylphosphine) palladium (66 mg, 0.057 mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (511 mg, 2.3 mmol) in dimethylether (6 mL) and water (3 mL) was heated to 110° C. for 4 minutes under microwave irradiation. Solvents were concentrated in vacuo and the resulting solid was washed with water, methanol, and dichloromethane to provide 502 mg (yield: 72%) of the desired product as an orange solid, which was characterized by its mass spectrum as follows: MS (m/z) 366.8 [M+H]+.
- Synthesis Proceeds According to the Following Scheme:
- To a mixture of N-[6-(4-Amino-phenyl)-4-morpholin-4-yl-pteridin-2-yl]-acetamide (55 mg, 0.15 mmol) and diisopropylethylamine (78 μL, 0.15 mmol) in dimethylformamide (3 mL) was added cyclopropanecarbonyl chloride (14 μL, 0.15 mmol). The resulting mixture was stirred at room temperature for 4 hours. Chloroform was then added to the reaction mixture and extracted with saturated aqueous sodium bicarbonate solution and brine. The organic layer was dried over sodium sulfate and concentrated to dryness to provide 12 mg of solid as crude product. This material was dissolved in methanol (2 mL) and added NaOMe (0.1 mL, 0.5 N in methanol). The mixture was then heated to 100° C. for 10 minutes under microwave irradiation. Solvents were concentrated in vacuo and the residue was purified by flash chromatography (using 10% MeOH/DCM as the eluent), providing 4 mg of the desired product as a yellow solid, which was characterized by its mass spectrum as follows: MS (m/z) 393.0 [M+H]+.
- Synthesis Proceeds According to the Following Scheme:
- To a solution of 6-(2,3-difluoro-phenyl)-4-ethoxy-pteridin-2-ylamine (10 mg, 0.03 mmol) in MeOH (1 mL) was added 10 mL of a 30% aqueous ammonia solution. The mixture was microwave at 130° C. for 20 minutes. The precipitate formed was collected by filtration and washed with water and small amount of MeOH to provide 5 mg of the title compound as a yellow solid (62% yield), which characterized by mass spectrometry as follows: MS (m/z) 275.7 [M+H]+.
-
- The compound of example 139 (12 mg, 0.023 mmol) was stirred in 20% TFA/DCM (2 mL) solution for 20 minutes. The solvent was removed in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile, to provide the desired product which was characterized by mass spectrometry as follows: MS (m/z) 411.8 [M+H]+.
-
- This product was prepared using the method of example 144 but starting from the compound of example 140. The resulting compound was characterized by mass spectrometry as follows: MS (m/z) 395.8 [M+H]+.
- The scheme below shows a general procedure for the synthesis of 2-amino-4-alkoxy-6-(4-fluorophenyl)-pteridines.
- To a boiling solution of 2,5,6-triamino-4-hydroxypyrimidine dihydrochloride (2.75 g, 12.9 mmol) in methanol (80 mL) was added a solution of 4-fluorophenylglyoxal monooxime (2.58 g, 15.5 mmol) in methanol (20 mL). The reaction mixture was heated under reflux for 5 hours. The precipitate formed was filtered off, washed with water, then ethanol and diethyl ether, and dried under vacuum, providing the title compound as a yellow powder in 45% yield (1.5 g), which was characterized by mass spectrometry as follows: MS (m/z) 258.1 [M+H]+.
- A suspension of 2-amino-6-(4-fluorophenyl)pteridine (1 g, 3.9 mmol) in acetic anhydride (60 mL) and acetic acid (20 mL) was refluxed for 90 minutes until a clear solution was formed. By cooling down the reaction mixture in the refrigerator, the precipitate formed was filtered off, washed with ethyl acetate and diethyl ether, and dried under vacuum, providing the title compound as a yellow powder in 87% yield (1.01 g), which was characterized by mass spectrometry as follows: MS (m/z) 300.1 [M+H]+.
- To a suspension solution of 2-acetylamino-6-(4-fluorophenyl)pteridine (517 mg, 1.73 mmol), 1,2,4-triazole (1.19 g, 17.3 mmol), diisopropylethylamine (1.5 mL, 8.65 mmol) in acetonitrile (20 mL) was added dropwise phosphorus oxychloride (0.32 mL, 3.46 mmol). The suspension was stirred at room temperature for 3 days. The precipitated was filtered off, washed with large amount of acetonitrile and diethyl ether. The resulting solid was dried under vacuum, providing the title compound as a yellow powder in 80% yield (480 mg), which was characterized by mass spectrometry as follows: MS (m/z) 351.2 [M+H]+.
- The general procedure used for preparing 2-amino-4-alkoxy-6-(4-fluorophenyl)-pteridines was as follows: Potassium t-butoxide (0.1 mL, 1.0 M solution in THF) was added to a solution of 2-acetylamino-4-(1,2,4-triazolyl)-6-(4-fluorophenyl)pteridine (35 mg, 0.1 mmol) in a suitable alcohol (0.5 mL). The resulting mixture was heated at 100° C. for 10 minutes under microwave irradiation. After cooling, the solution was concentrated in vacuo and the residue was purified by HPLC onto C18 column with a gradient of H2O, 0.1% TFA-acetonitrile. This procedure provided, with yields ranging from 5% to 50%, depending upon the alkoxy group introduced at position 4 of the pteridine ring, the pure compounds, which were characterized by their mass spectrum as indicated in the following table 3.
-
TABLE 3 Example R Compound name M + H 149 methyl 6-(4-Fluorophenyl)-4-methoxy-pteridin-2- ylamine 272.2 150 isopropyl 6-(4-Fluorophenyl)-4-isopropoxy-pteridin-2- ylamine 300.1 151 CH2CH2OMe 6-(4-Fluorophenyl)-4-(2-methoxy-ethoxy)- pteridin-2-ylamine 316.6 152 n-butyl 4-Butoxy-6-(4-fluorophenyl)-pteridin-2-ylamine 314.2 153 CH2CF3 6-(4-Fluorophenyl)-4-(2,2,2-trifluoro-ethoxy)- pteridin-2-ylamine 340.1 154 4-[2-Amino-6-(4-fluorophenyl)-pteridin-4-yloxy]- 2-methyl-butan-2-ol 344.2 155 6-(4-Fluorophenyl)-4-(2-morpholin-4-yl-ethoxy)- pteridin-2-ylamine 370.9 156 6-(4-Fluorophenyl)-4-(3-morpholin-4-yl- propoxy)-pteridin-2-ylamine 385 157 4-Cyclopropylmethoxy-6-(4-fluorophenyl)- pteridin-2-ylamine 312.3 158 4-Cyclobutylmethoxy-6-(4-fluorophenyl)- pteridin-2-ylamine 326.2 159 n-propyl 6-(4-Fluorophenyl)-4-propoxy-pteridin-2-ylamine 300.1 160 sec-butyl 4-sec-butoxy-(4-fluorophenyl)-pteridin-2- ylamine 314.4 161 6-(4-Fluorophenyl)-4-(tetrahydro-furan-3-yloxy)- pteridin-2-ylamine 328.2 162 isobutyl 6-(4-Fluorophenyl)-4-isobutoxy-pteridin-2- ylamine 314.1 163 benzyl 4-Benzyloxy-6-(4-fluorophenyl)-pteridin-2- ylamine 348.2 (end of table 3) -
- This product, which was prepared according to a method similar to that of example 149, except for using sodium ethane-thiolate as reagent and ethanol, was characterized by mass spectrometry as follows: MS (m/z) 30.26 [M+H]+.
- The Synthesis Proceeds as Follows:
- The general procedure used for preparing 2-amino-4-alkylamino-6-(4-fluorophenyl)-pteridines was as follows. Sodium methoxide (0.8 mL, 0.5 N solution in methanol) was added to a mixture of 2-acetylamino-4-(1,2,4-triazolyl)-6-(4-fluorophenyl)pteridine (35 mg, 0.1 mmol) and corresponding amines with the general formula NHRR′ (0.2 mL). The resulting mixture was heated at 100° C. for 10 minutes under microwave irradiation. After cooling, the solution was concentrated in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile. This procedure provided, with yields ranging from 25% to 60%, depending upon the amino group introduced at position 4 of the pteridine ring, the pure compounds which were characterized by their mass spectrum MS as indicated in table 4 below.
-
TABLE 4 Example R Compound name M + H 165 NH2 4-amino-6-(4-fluorophenyl)-pteridine-2,4- diamine 257.2 166 6-(4-Fluorophenyl)-4-piperidin-1-yl-pteridin-2- ylamine 325.2 167 NH-cyclo-propyl N-4-Cyclopropyl-6-(4-fluorophenyl)-pteridine- 2,4-diamine 297.1 168 4-(2,6-Dimethylmorpholin-4-yl)-6-(4-fluoro- phenyl)-pteridin-2-ylamine 355.1 169 N-4-Cyclohexyl-6-(4-fluorophenyl)-pteridine- 2,4-diamine 339.2 170 N-4-Benzyl-6-(4-fluorophenyl)-pteridine-2,4- diamine 347.2 171 N-4-(3-Methyl-benzyl)-6-(4-fluorophenyl)- pteridine-2,4-diamine 347.2 172 N-4-(3-Fluorobenzyl)-6-(4-fluorophenyl)- pteridine-2,4-diamine 351.2 173 6-(4-Fluorophenyl)-4-(4-methylpiperazin-1-yl)- pteridin-2-ylamine 340.2 174 6-(4-Fluorophenyl)-4-piperazin-1-yl-pteridin-2- ylamine 326.2 175 N-4-Cyclopropylmethyl-6-(4-fluorophenyl)- pteridine-2,4-diamine 311.2 176 6-(4-Fluorophenyl)-4-pyrrolidin-1-yl-pteridin-2- ylamine 311.2 (end of table 4) - Synthesis Proceeded in Two Steps as Shown in the Following Scheme:
- To a boiling solution of 4,5-Diamino-6-hydroxy-pyrimidine hydrochloride (1.5 g, 9.23 mmol) in methanol (60 mL) was added a solution of 4-fluoropheynlglyoxal monooximie (2.0 g, 12 mmol) in methanol (20 mL). The reaction mixture was heated under reflux for 1 hour. After cooling, the precipitate formed was filtered off, washed with diethyl ether, and dried under vacuum, providing the title compound as a yellow powder in 68% yield (1.51 g) which was characterized by its mass spectrum as follows: MS (m/z) 243.4 [M+H]+.
- To a solution of the compound of example 177 (250 mg, 1.03 mmol), 1,2,4-triazole (285 mg, 4.13 mmol) and diisopropylethylamine (0.72 mL, 4.13 mmol) in acetonitrile (8 mL) phosphorus oxychloride (0.24 mL, 2.58 mmol) was added dropwise. The suspension was stirred at room temperature for 3 days. The precipitated was filtered off, washed with large amount of acetonitrile and diethyl ether. The resulting solid was dried under vacuum, providing the title compound as a yellow powder in 99% yield (300 mg), which was characterized by mass spectrometry as follows: MS (m/z) 294.0 [M+H]+.
- Synthesis Proceeded as Follows:
- The general procedure used for preparing 4-alkoxy-6-(4-fluorophenyl)-pteridines was as follows. Potassium t-butoxide (0.1 mL, 1.0 M solution in THF) was added to a solution of 6-(4-fluorophenyl)-4-[1,2,41]triazol-1-yl-pteridine (30 mg, 0.1 mmol) in a suitable alcohol (0.5 mL). The resulting mixture was heated at 70° C. for 5 minutes under microwave irradiation. After cooling, the solution was concentrated in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile. This procedure provided, with yields ranging from 25% to 70%, depending upon the alkoxy group introduced at position 4 of the pteridine ring, the pure compounds which were characterized by their mass spectrum MS as indicated in the following table 5.
-
TABLE 5 Example R Compound name M + H 179 ethyl 4-ethoxy-6-(4fluorophenyl)pteridine 271.2 180 isopropyl 4-isopropoxy-6-(4-fluorophenyl)- 285.2 pteridine 181 CH2CH2OMe 4--(2-methoxy-ethoxy)-6-(4-fluoro- 301.1 phenyl)-pteridine -
- The general procedure used for preparing 4-amino-6-(4-fluorophenyl)-pteridines was as follows. A mixture of (4-fluorophenyl)-4-[1,2,4]triazol-1-yl-pteridine (30 mg, 0.1 mmol) and a suitable amine (0.1 mL) in dioxane (0.5 mL) was heated at 100° C. for 7 minutes under microwave irradiation. After cooling, the solution was concentrated in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile. This procedure provided, with yields ranging from 50% to 60%, depending upon the amino group introduced at position 4 of the pteridine ring, the pure compounds which were characterized by their mass spectrum as indicated in table 6.
-
- Sodium ethane thiolate (9 mg, 0.11 mmol) was added to a solution of (4-Fluoro-phenyl)-4-[1,2,4]triazol-1-yl-pteridine (30 mg, 0.1 mmol) in ethanol (0.5 mL). The resulting mixture was heated at 70° C. for 5 minutes under microwave irradiation. After cooling, the solution was concentrated in vacuo and the residue was purified by HPLC onto a C18 column with a gradient of H2O, 0.1% TFA-acetonitrile, to provide 3.8 mg (yield 13%) of the desired product which was characterized by mass spectrometry as follows: MS (rn/z) 287.2 [M+H]+.
- The anti HCV activity of specifically substituted pteridine derivatives was tested in a human hepatoma Huh-7 cell line harbouring a HCV replicon. The assay comprised the following steps:
- Step 1: compound preparation and serial dilution involved the following alternatives, depending upon the water solubility of pteridine derivative being tested:
- 1. with respect to water soluble pteridine derivatives, 500 μL of solution in cell media (DMEM, 10% FBS, P/S, L-Glutamine) was prepared with a concentration that is twice the concentration of the starting final serial dilution concentration. 150 μL of the solution was added to the pre-specified wells in column 1 of a 96-well cell culture plate (PerkinElmer, white plate, cat. #6005181, for EC50 assay; black plate, cat. #6005182 for CC50 assay). The rest of the plate, i.e. columns 2-12, was filled with 100 μL of cell media. The plate was then placed on a Precision 2000 Workstation in order to start serial dilution. Pteridine compounds were diluted three times each step from column 1 to column 10. Column 11 was used as a blank control (no pteridine compound added).
- 2. With respect to poorly water soluble pteridine derivatives, DMSO was used as a solvent, and serial dilution was performed in 50% DMSO in water, in a 384-well plate. A solution containing the relevant compound at 100-fold the concentration of the starting final serial dilution concentration was prepared in 50% DMSO in water and added to the pre-specified wells in column 1 of a polypropylene 384-well plate. This plate was then placed on a Precision 2000 Workstation in order to start serial dilution. After serial dilution, 2 μL of the solution was transferred from the 384-well plate to a 96-well cell culture plate containing 100 μL of cell media on a Biomek FX Workstation. The DMSO concentration in the final assay condition was 0.5% after cells have been added to the plate and the total volume in each well was brought to 200 μL.
- Step 2: to each well of the serial dilution plate prepared in step 1, 100 μL of cell media containing 6000 suspended Huh-7 HCV replicon cells was added with a Multidrop workstation. Plates were incubated for 3 days at 37° C. with 5% CO2.
- Step 3: detection:
- 1) with respect to the EC5 assay, the media in a 96-well cell culture plate was aspirated with a Biotek EL405 plate-washer. A volume of 200 μL of a solution containing a 1:1 mixture Of a cell-lysis buffer (commercially available from Promega, Luciferase Cell Culture Lysis 5X Reagent, cat. #E1531) and a luciferase substrate solution (commercially available from Promega, Luciferase Assay, cat.#E4550) was added to each well of the plate with Multidrop. The plate was incubated for 30 minutes at room temperature before the luminescence signal was measured with a TopCount plate-reader.
- 2) with respect to the CC50 assay, 100 μL of a pre-mixed CellTiter-Glo (commercially available from Promega, cat.#G7572) solution was added directly to the cell culture in each well of the plate and the luminescence signal was measured with a TopCount plate-reader after 10 minutes of incubation at room temperature.
- Table 7 shows EC50 and CC50 values determined in the above assay for 2-amino-pteridine derivatives synthesized according to the methods described in the examples above. Results are expressed by the following data:
- the 50% effective concentration (EC50), i.e. the concentration that protects 50% of the cell monolayer from virus-induced cythopathic effect.
- the 50% cytostatic concentration (CC50), i.e. the concentration that results in 50% inhibition of cell growth.
-
TABLE 7 EC50 CC50 (A < 0.3 μM; 0.3 (A < 10 μM; μM < B < 1 μM; B 10 − 20 μM; Example 1 μM < C < 10 μM) C > 20 μM) 3 C C 27 B A 30 C C 31 B A 54 C C 57 C C 69 C C 78 B A 79 B A 80 B C 82 B C 84 A A 85 C C 86 B B 89 C C 90 B C 91 B C 92 B B 93 C B 95 C B 108 B B 109 C B 110 C C 111 C C 112 C C 113 C C 114 C C 120 C B 121 C B 123 B A 126 C B 127 B A 129 A A 130 C C 133 B C 136 C B 137 A B 138 C B 140 C A 142 B A 143 C B 144 C C 145 B C 149 B C 150 A C 152 C C 154 C C 157 C C 159 C C 164 B C (end of table 7) - The experimental procedure of example 77 is repeated, except that other arylboronic adds or heteroarylboronic acids, or esters thereof, are used instead of 2-fluorophenylboronic acid. In this way the following compounds are obtained in similar yields:
- 4-morpholino-6-(4-(4′-allyloxycarbonylpiperazino)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-amino-5-chlorophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-amino-3-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-amino-4-methylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-amino-5-methylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-amino-2-methyl phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(5-amino-2-methyl phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-amino-3-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-benzyloxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-benzyloxy-4-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-biphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-n-butyl phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-isobutylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-carboxy-3-fluorophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(3-carboxypropionylamino)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(3-carboxypropionylamino)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-chloro-4-hydroxy-5-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloro-5-hydroxymethylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-cyanophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-cyanophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-cyanophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(N-cyclopropylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(N,N-diethylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(N,N-dimethylamino)phenyl)pteridin-2-ylamine,
- 4-morpholine-6-(2-(N,N-dimethylamino)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(N,N-dimethylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-[(N′,N′-dimethylamino)ethylaminocarbonyl]phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-[(N′,N′-dimethylamino)ethylaminocarbonyl]phenyl)-pteridin-2-ylamine,
- 4-morpholino-6-(3-[1,3]dioxolan-2-ylmethoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(ethoxycarbonyl)methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(ethoxycarbonyl)methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(3-ethoxycarbonylpiperidino)carboxamidophenyl)-pteridin-2-ylamine,
- 4-morpholino-6-(4-formylaminophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-formylaminophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-formylaminophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-formyl-5-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-formyl-4-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(5-formyl-2-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-formyl-5-methylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-formylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-formylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-formylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-hydroxy-3,5-dimethylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(2-hydroxyethyl)-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(2-hydroxyethyl)aminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-hydroxy-4-methoxycarbonyl phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-hydroxy-3-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(hydroxymethyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(hydroxymethyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-hydroxy-3-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-isopropoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(4-isopropylpiperazinyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-isopropylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-methanesulfonamidophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-methanesulfonamidophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methanesulfonamido phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-methoxy-4-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methoxy-5-methylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-methoxy-3-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-N-methylcarboxamidophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(N-methylamino)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(4-methylpiperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(4-methylpiperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(methylthio)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(methylthio)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(methylthio)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(morpholinocarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-morpholinophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(morpholinomethyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-nitrophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-phenoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(N-phenylaminomethyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(phenylcarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(piperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-piperazinylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-succinamidophenyl)pteridin-2-ylamine,
- 4-morpholine-6-(3-succinamidophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(sulfamoylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(toluene-4-sulfonamido)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(toluene-4-sulfonamido)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(tert-butoxycarbonylamino)-3-methoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2,3,4-trifluorophenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-tert-butylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(2-thienyl)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(2,4,6-trimethylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(3,4,5-trimethoxyphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-vinylphenyl)pteridin-2-ylamine,
- 4-morpholino-6-(4-(2-hydroxyethoxy)phenyl)pteridin-2-ylamine,
- 4-morpholino-6-(6-benzyloxynaphth-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(naphth-1-yl)pteridin-2-ylamine,
- 4-morpholino-6-(naphth-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(4′-benzoyl[1,1′-biphenyl]-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-biphenylyl)pteridin-2-ylamine,
- 4-morpholino-6-(oxoindan-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(benzodioxolyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-acetamidopyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-aminopyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-aminopyrimidin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1,4-benzodioxan-6-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-benzothien-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-benzyloxypyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-benzyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-bromo-3-chloropyridin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-bromo-2,3-dihydrobenzo[b]furan-7-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-bromo-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-bromopyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3-bromopyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-bromothien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloro-6-isopropylpyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloro-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-[4-(4-chlorophenylsulfonyl)piperazin-1-yl]pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloropyrid-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloropyrid-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(dibenzo[b,d]furan-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-chloro-3-fluoropyridin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(dibenzo[b,d]thien-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3,6-dihydro-2H-pyridine-1-tert-butoxycarbonyl)pteridin-2-ylamine,
- 4-morpholino-6-(2,5-dibromopyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,6-dichloropyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,3-dihydro-1-benzofuran-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,6-dimethoxypyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,6-dimethoxypyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,4-dimethoxypyrimidin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3,5-dimethylisoxazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(3-N,N-dimethylaminopropoxy)pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3,5-dimethylpyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-[1,3]dioxolan-2-ylmethyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)pteridin-2-ylamine,
- 4-morpholino-6-(2,4-di(tert-butoxy)pyrimidin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-ethoxypyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-8-(2-fluoro-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-fluoropyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-formyl-2-furyl)pteridin-2-ylamine,
- 4-morpholino-6-(5-formylthien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(furan-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-hydroxypyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-isobutyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(isoquinolin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methoxypyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methoxypyrimidin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methyl-1-benzothien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-(3-methylbutyl)-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methylfuran-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-methylindol-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methyl-3-phenyl-4-isoxazolyl)pteridin-2-ylamine,
- 4-morpholino-6-(5-(methylthio)thien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(4-methylpiperazinyl)pyridin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(4-methylpiperazinyl)pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-methyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(3-methylpyridin-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methylpyridin-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methylpyridin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-methoxypyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(4-methylthien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-methylthien-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(2-morpholinoethylamino)-pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(2-morpholinoethyl)-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(morpholin-1-yl)-pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-(phenylsulfonyl)-1H-indol-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(5-phenyl-2-thienyl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(Piperazin-1-yl)-pyridin-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(piperazin-1-yl)-pyridin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-propyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(pyridin-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(4-phenoxathiinyl)pteridin-2-ylamine,
- 4-morpholino-6-(quinolin-8-yl)pteridin-2-ylamine,
- 4-morpholino-6-(quinolin-3-yl)pteridin-2-ylamine,
- 4-morpholino-6-(2-(4-tert-butoxycarbonylpiperazinyl)-pyrid-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-tert-butoxycarbonyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-tert-butoxycarbonyl-2-pyrrolyl)pteridin-2-ylamine,
- 4-morpholino-6-(1-(tert-butoxycarbonyl)-5-bromo-1H-indol-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-(tert-butoxycarbonyl)-1H-indol-5-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-(tert-butoxycarbonyl)-5-methoxy-1H-indol-2-yl)pteridin-2-ylamine,
- 4-morpholino-6-(1-thianthrenylthien-3-yl)pteridin-2-ylamine, and
- 4-morpholino-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- The experimental procedure of example 10 is repeated, except that other arylboronic acids or heteroarylboronic acids, or esters thereof, are used instead of 2-fluorophenylboronic acid. In this way the following compounds are obtained in similar yields:
- 4-ethoxy-6-(4-(4′-allyloxycarbonylpiperazino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-amino-5-chlorophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-amino-3-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-amino-4-methylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-amino-5-methylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-amino-2-methyl phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-amino-2-methyl phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-amino-3-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-benzyloxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-benzyloxy-4-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-biphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-n-butyl phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-isobutylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-carboxy-3-fluorophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(3-carboxypropionylamino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(3-carboxypropionylamino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-chloro-4-hydroxy-5-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloro-5-hydroxymethylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-cyanomethoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-cyanophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-cyanophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-cyanophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(N-cyclopropylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(N,N-diethylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(N,N-dimethylamino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(N,N-dimethylamino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(N,N-dimethylaminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-[(N′,N′-dimethylamino)ethylaminocarbonyl]phenyl)-pteridin-2-ylamine,
- 4-ethoxy-6-(4-[(N′,N′-dimethylamino)ethylaminocarbonyl]phenyl)-pteridin-2-ylamine,
- 4-ethoxy-6-(3-[1,3]dioxolan-2-ylmethoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(ethoxycarbonyl)methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(ethoxycarbonyl)methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-ethoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(3-ethoxycarbonylpiperidino)carboxamidophenyl)-pteridin-2-ylamine,
- 4-ethoxy-6-(4-formylaminophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-formylaminophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-formylaminophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-formyl-5-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-formyl-4-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-formyl-2-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-formyl-5-methylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-formylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-formylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-formylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-hydroxy-3,5-dimethylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(2-hydroxyethyl)-aminocarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(2-hydroxyethyl)aminocarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-hydroxy-4-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-hydroxy-3-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(hydroxymethyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(hydroxymethyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-hydroxy-3-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-isopropoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(4-isopropylpiperazinyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-isopropylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-methanesulfonamidophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-methanesulfonamidophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methanesulfonamido phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-methoxy-4-methoxycarbonylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methoxy-5-methylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-methoxy-3-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-N-methylcarboxamidophenyl)pteridin-2-ylamine.
- 4-ethoxy-6-(4-(N-methylamino)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(4-methylpiperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(4-methylpiperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(methylthio)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(methylthio)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(methylthio)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(morpholinocarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-morpholinophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(morpholinomethyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-nitrophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-phenoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(N-phenylaminomethyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(phenylcarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(piperazine-1-carbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-piperazinylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-succinamidophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-succinamidophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(sulfamoylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(toluene-4-sulfonamido)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(toluene-4-sulfonamido)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(tert-butoxycarbonylamino)-3-methoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(tert-butoxycarbonyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,3,4-trifluorophenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-tert-butylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(2-thienyl)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,4,6-trimethylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(3,4,5-trimethoxyphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-vinylphenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-(2-hydroxyethoxy)phenyl)pteridin-2-ylamine,
- 4-ethoxy-6-(6-benzyloxynaphth-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(naphth-1-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(naphth-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(4′-benzoyl[1,1′-biphenyl]-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-biphenylyl)pteridin-2-ylamine,
- 4-ethoxy-6-(oxoindan-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(benzodioxolyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-acetamidopyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-aminopyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-aminopyrimidin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1,4-benzodioxan-6-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-benzothien-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-benzyloxypyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-benzyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-bromo-3-chloropyridin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-bromo-2,3-dihydrobenzo[b]furan-7-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-bromo-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-bromopyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-bromopyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-bromothien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloro-6-isopropylpyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloro-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-[4-(4-chlorophenylsulfonyl)piperazin-1-yl]pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloropyrid-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloropyrid-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(dibenzo[b,d]furan-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-chloro-3-fluoropyridin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(dibenzo[b,d]thien-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3,6-dihydro-2H-pyridine-1-tert-butoxycarbonyl)pteridin-2-ylamine,
- 4-ethoxy-6(2,5-dibromopyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,6-dichloropyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6(2,3-dihydro-1-benzofuran-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,6-dimethoxypyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,6-dimethoxypyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,4-dimethoxypyrimidin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3,5-dimethylisoxazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(3-N,N-dimethylaminopropoxy)pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3,5-dimethylpyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-[1,3]dioxolan-2-ylmethyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2,4-di(tert-butoxy)pyrimidin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-ethoxypyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-fluoro-3-methylpyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6(2-fluoropyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-formyl-2-furyl)pteridin-2-ylamine,
- 4-ethoxy-6(5-formylthien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(furan-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-hydroxypyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-isobutyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(isoquinolin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methoxypyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methoxypyrimidin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methyl-1-benzothien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-(3-methylbutyl)-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methylfuran-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-methylindol-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methyl-3-phenyl-4-isoxazolyl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-(methylthio)thien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2(4-methylpiperazinyl)pyridin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(4-methylpiperazinyl)pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-methyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(3-methylpyridin-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methylpyridin-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methylpyridin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-methoxypyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-methylthien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-methylthien-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(2-morpholinoethylamino)-pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(2-morpholinoethyl)-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(morpholin-1-yl)-pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-(phenylsulfonyl)-1H-indol-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(5-phenyl-2-thienyl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(piperazin-1-yl)-pyridin-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(piperazin-1-yl)-pyridin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-propyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(pyridin-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(4-phenoxathiinyl)pteridin-2-ylamine,
- 4-ethoxy-6-(quinolin-8-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(quinolin-3-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(2-(4-tert-butoxycarbonylpiperazinyl)-pyrid-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-tert-butoxycarbonyl-1H-pyrazol-4-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-tert-butoxycarbonyl-2-pyrrolyl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-(tert-butoxycarbonyl)-5-bromo-1H-indol-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-(tert-butoxycarbonyl)-1H-indol-5-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-(tert-butoxycarbonyl)-5-methoxy-1H-indol-2-yl)pteridin-2-ylamine,
- 4-ethoxy-6-(1-thianthrenylthien-3-yl)pteridin-2-ylamine, and
- 4-ethoxy-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pteridin-2-ylamine.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/162,887 US20190152974A1 (en) | 2006-07-20 | 2018-10-17 | Substituted pteridines useful for the treatment and prevention of viral infections |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80792506P | 2006-07-20 | 2006-07-20 | |
PCT/BE2007/000092 WO2008009079A2 (en) | 2006-07-20 | 2007-07-20 | Substituted pteridines useful for the treatment and prevention of viral infections |
US37445709A | 2009-01-20 | 2009-01-20 | |
US16/162,887 US20190152974A1 (en) | 2006-07-20 | 2018-10-17 | Substituted pteridines useful for the treatment and prevention of viral infections |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/374,457 Division US10144736B2 (en) | 2006-07-20 | 2007-07-20 | Substituted pteridines useful for the treatment and prevention of viral infections |
PCT/BE2007/000092 Division WO2008009079A2 (en) | 2006-07-20 | 2007-07-20 | Substituted pteridines useful for the treatment and prevention of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190152974A1 true US20190152974A1 (en) | 2019-05-23 |
Family
ID=38872028
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/374,457 Active 2029-10-07 US10144736B2 (en) | 2006-07-20 | 2007-07-20 | Substituted pteridines useful for the treatment and prevention of viral infections |
US16/162,887 Abandoned US20190152974A1 (en) | 2006-07-20 | 2018-10-17 | Substituted pteridines useful for the treatment and prevention of viral infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/374,457 Active 2029-10-07 US10144736B2 (en) | 2006-07-20 | 2007-07-20 | Substituted pteridines useful for the treatment and prevention of viral infections |
Country Status (2)
Country | Link |
---|---|
US (2) | US10144736B2 (en) |
WO (1) | WO2008009079A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11124487B2 (en) | 2016-09-02 | 2021-09-21 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US11286257B2 (en) | 2019-06-28 | 2022-03-29 | Gilead Sciences, Inc. | Processes for preparing toll-like receptor modulator compounds |
US11396509B2 (en) | 2019-04-17 | 2022-07-26 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
US11583531B2 (en) | 2019-04-17 | 2023-02-21 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
US12049461B2 (en) | 2006-07-20 | 2024-07-30 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006135993A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
US20090318456A1 (en) * | 2006-07-06 | 2009-12-24 | Gilead Sciences, Inc. | Substituted pteridines for the treatment and prevention of viral infections |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
WO2008009077A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
AU2010234650A1 (en) * | 2009-04-06 | 2011-11-03 | Ptc Therapeutics, Inc | Indole derivatives and methods for antiviral treatment |
US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011081918A1 (en) * | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
MX2012008658A (en) | 2010-01-25 | 2012-12-05 | Enanta Pharm Inc | Hepatitis c virus inhibitors. |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
BR112012022311A2 (en) * | 2010-03-04 | 2016-08-23 | Enanta Pharm Inc | combination pharmaceutical agents as inhibitors of hcv replication. |
EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
EP2571882A1 (en) | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
JP5669984B2 (en) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Process for producing 5-azaspiro [2.4] heptane-6-carboxylic acid and derivatives thereof |
CA2837227C (en) * | 2011-06-01 | 2022-05-10 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
JP6367204B2 (en) * | 2012-10-12 | 2018-08-01 | メドイミューン・リミテッドMedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
GB201416186D0 (en) | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
AU2015370004B2 (en) | 2014-12-26 | 2021-03-11 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
SI3321265T1 (en) | 2015-03-04 | 2020-07-31 | Gilead Sciences, Inc. | 4,6-diamino-pyrido(3,2-d)pyrimidine compounds and their utilisation as modulators of toll-like receptors |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
JP2023535790A (en) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | Fused bicyclic RAF inhibitors and methods of use thereof |
WO2023150684A2 (en) * | 2022-02-03 | 2023-08-10 | University Of Connecticut | Nanomaterial and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077859A1 (en) * | 1998-12-28 | 2004-04-22 | Albert Waer Mark Jozef | Immunosuppressive effects of pteridine derivatives |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2512572A (en) | 1950-06-20 | Substituted pteridines and method | ||
DE267495C (en) | 1913-09-07 | 1913-11-20 | Max Schreiber | SECURITY LOCK FOR JEWELRY |
CH231852A (en) | 1940-08-09 | 1944-04-15 | Ig Farbenindustrie Ag | Process for the production of a condensation product. |
US2581889A (en) | 1948-07-07 | 1952-01-08 | Burroughs Wellcome Co | Method of preparing pyrimidopyrazines |
US2665275A (en) | 1948-12-22 | 1954-01-05 | Allen & Hanburys Ltd | 2, 4-diamino-7, 8-disubstituted pteridines |
GB677342A (en) | 1949-08-19 | 1952-08-13 | Ici Ltd | New pyrimidine derivatives and their use in the manufacture of pteridin derivatives |
US2667486A (en) | 1951-05-24 | 1954-01-26 | Research Corp | 2,4-diamino pteridine and derivatives |
GB763044A (en) | 1952-04-18 | 1956-12-05 | Ici Ltd | Pteridin derivatives |
GB785353A (en) | 1953-01-30 | 1957-10-30 | Merck & Co Inc | Substituted pteridine derivatives |
US2740784A (en) | 1954-05-03 | 1956-04-03 | Merck & Co Inc | Process for preparing pteridines |
US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
US2939882A (en) | 1958-07-21 | 1960-06-07 | Shell Oil Co | Stabilized alpha, beta-unsaturated aldehydes |
US3081230A (en) | 1960-09-08 | 1963-03-12 | Smith Kline French Lab | Diuretic and antihypertensive triaminoarylpteridines |
US3071587A (en) | 1961-07-25 | 1963-01-01 | American Cyanamid Co | Cyanoethyl-pteridines |
US3159628A (en) | 1962-05-28 | 1964-12-01 | Smith Kline French Lab | Pteridine-5-oxide derivatives |
US3122546A (en) | 1962-12-03 | 1964-02-25 | American Home Prod | 4, 7-diamino-2-(substituted)-n-substituted-6-pteridinecarboxamides |
US3162635A (en) | 1962-08-06 | 1964-12-22 | Searle & Co | 1, 2, 3, 4-tetrahydro-2, 4-pteridinediones and intermediates |
NL131481C (en) | 1965-04-15 | |||
DE1921308A1 (en) | 1969-04-25 | 1971-01-07 | Boehringer Sohn Ingelheim | Pharmaceutical prepns. containing one or more of cpds. of general formula (I):- ArOCH2 - CHOH - CH2 - NHR (I) Ar= opt. mono-or polysubstd. iso-, hom |
US3859287A (en) | 1971-05-05 | 1975-01-07 | Walter Wesley Parish | Thiopteridines and process for producing same |
DE3378634D1 (en) | 1982-09-20 | 1989-01-12 | Wellcome Found | Pharmaceutically active pteridine derivatives |
DE3323932A1 (en) | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW 2-PIPERAZINO-PTERIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND |
DE3445298A1 (en) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW PTERIDINE, METHOD FOR THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS OR AS A MEDICINAL PRODUCT |
US5149705A (en) * | 1987-03-13 | 1992-09-22 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity |
IT1204612B (en) | 1987-05-14 | 1989-03-10 | Bioresearch Spa | PTERIDINS SUITABLE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR ANTI-MAGNESIC ACTIVITIES |
DD267495A1 (en) | 1987-11-11 | 1989-05-03 | Akad Wissenschaften Ddr | PROCESS FOR PREPARING A NEW METHOTREXATE DERIVATIVITY WITH REDUCED TOXICITY |
DE3833393A1 (en) | 1988-10-01 | 1990-04-05 | Thomae Gmbh Dr K | USE OF PTERIDINES TO PREVENT PRIMARY AND SECONDARY RESISTANCE IN CHEMOTHERAPY AND MEDICINES CONTAINING THESE COMPOUNDS |
DE4009941A1 (en) | 1990-03-28 | 1991-10-02 | Thomae Gmbh Dr K | Use of pteridine(s) to sensitise resistant plasmodia - in combination with conventional di:hydro:folate reductase inhibitors and di:hydro-pteroate synthase inhibitors |
GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
DE69330639T2 (en) | 1992-01-27 | 2002-07-04 | Chugai Seiyaku K.K., Tokio/Tokyo | METHOTREXATE DERIVATIVES |
AU4535893A (en) | 1992-06-15 | 1994-01-04 | Regents Of The University Of California, The | Screening assay for the identification of immunosuppressive drugs |
HU214331B (en) | 1992-06-17 | 1998-03-02 | Gyógyszerkutató Intézet Kft. | Methods for producing piperazine and homopiperazine derivatives and pharmaceutical compositions containing them |
CA2145192A1 (en) | 1992-09-22 | 1994-03-31 | Gail Underiner | Novel epoxide-containing compounds |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
WO1994014065A1 (en) | 1992-12-14 | 1994-06-23 | Dana-Farber Cancer Institute, Inc. | Methods for identifying and using immunosuppressant compounds |
US5641783A (en) | 1993-11-12 | 1997-06-24 | Cell Therapeutics, Inc. | Substituted amino alcohol compounds |
US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
US6043228A (en) | 1993-06-08 | 2000-03-28 | Cancer Research Campaign Technology Limited | O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells |
EP0728003A1 (en) | 1993-11-12 | 1996-08-28 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
DE4418097A1 (en) | 1994-05-24 | 1995-11-30 | Cassella Ag | Use of tetrahydropteridine derivatives as inhibitors of NO synthase |
DE4418096A1 (en) | 1994-05-24 | 1995-11-30 | Cassella Ag | Use of pteridine derivatives as inhibitors of NO synthase |
US5929046A (en) | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
US5607936A (en) | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
US5843943A (en) | 1994-12-29 | 1998-12-01 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
AU717243B2 (en) | 1994-12-29 | 2000-03-23 | Regents Of The University Of California, The | Compounds for inhibition of ceramide-mediated signal transduction |
WO1997023616A1 (en) | 1995-12-22 | 1997-07-03 | BUNDESREPUBLIK DEUTSCHLAND, vertreten durch den BUNDESMINISTER FÜR GESUNDHEIT | Polypeptides with interleukin 16 activity, process for the preparation and use thereof |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
US5663335A (en) | 1996-03-01 | 1997-09-02 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
WO1997039358A1 (en) | 1996-04-15 | 1997-10-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | In vitro prognostic test for progressors and non-progressors after hiv infection |
AU739069B2 (en) | 1996-07-31 | 2001-10-04 | Cmic Co., Ltd. | Active oxygen scavengers containing pterin derivatives |
DE69725721T3 (en) | 1996-08-30 | 2007-10-31 | Daiichi Asubio Pharma Co., Ltd. | PREVENTIVE OR HEALING MEDICINE FOR DISEASES CAUSED BY LACK OF STAIN OXIDE SYNTHASE (NOS) |
EP0956855B1 (en) | 1998-04-24 | 2003-03-12 | K.U. Leuven Research & Development | Immunosuppressive effects of 8 substituted xanthine derivatives |
US5992713A (en) | 1998-10-23 | 1999-11-30 | Manabat; Gregorio S. | Clothes hanger with slidable side attachments |
JP2002533464A (en) | 1998-12-28 | 2002-10-08 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | Immunosuppressive effects of pteridine derivatives |
US6946465B2 (en) | 1999-02-02 | 2005-09-20 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
WO2000045800A2 (en) | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Immunosurpressive effects of pteridine derivatives |
US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
EA005287B1 (en) | 1999-09-15 | 2004-12-30 | Уорнер-Ламберт Компани | Pteridinones as kinase inhibitors |
DE19944767A1 (en) | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituted 4-aminopteridines, process for their preparation and their use as medicines |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
SE0003828D0 (en) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
DE10059864A1 (en) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Substituted amino-furan-2-yl-acetic acid and amino-thien-2-yl-acetic acid derivatives |
DE10202468A1 (en) | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridine derivatives, process for their preparation and their use |
PL1658081T3 (en) * | 2003-08-29 | 2008-03-31 | 4 Aza Ip Nv | Immunosuppressive effects of pteridine derivatives |
WO2005025574A2 (en) | 2003-09-12 | 2005-03-24 | 4 Aza Bioscience Nv | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
GB2405793A (en) | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
US20070032477A1 (en) | 2003-10-17 | 2007-02-08 | Waer Mark J A | Pteridine derivatives useful for making pharmaceutical compositions |
AU2004283479A1 (en) | 2003-10-17 | 2005-05-06 | 4 Aza Bioscience Nv | Heterocycle-substituted pteridine derivatives and their use in therapy |
KR101123429B1 (en) | 2003-12-30 | 2012-06-29 | 바조팜 게엠베하 | 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level |
ATE476428T1 (en) * | 2004-01-22 | 2010-08-15 | Lilly Co Eli | SELECTIVE MODULATORS OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF VASOMOTOR SYMPTOMS |
CN1583747A (en) | 2004-05-26 | 2005-02-23 | 中国药科大学 | Pterin mononitrogen monoxide synthase inhibitor |
DE102004057645A1 (en) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia |
DE102004057595A1 (en) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted pteridines for the treatment of inflammatory diseases |
US20090264415A2 (en) | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
GB0428475D0 (en) | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
AR056347A1 (en) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS |
WO2006135993A1 (en) | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
ATE549338T1 (en) | 2006-05-24 | 2012-03-15 | Boehringer Ingelheim Int | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBER HETEROCYCLE |
WO2007135026A2 (en) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituted pteridines as therapeutic agents |
US20090318456A1 (en) * | 2006-07-06 | 2009-12-24 | Gilead Sciences, Inc. | Substituted pteridines for the treatment and prevention of viral infections |
WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
WO2008009077A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
-
2007
- 2007-07-20 WO PCT/BE2007/000092 patent/WO2008009079A2/en active Application Filing
- 2007-07-20 US US12/374,457 patent/US10144736B2/en active Active
-
2018
- 2018-10-17 US US16/162,887 patent/US20190152974A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077859A1 (en) * | 1998-12-28 | 2004-04-22 | Albert Waer Mark Jozef | Immunosuppressive effects of pteridine derivatives |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12049461B2 (en) | 2006-07-20 | 2024-07-30 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
US11124487B2 (en) | 2016-09-02 | 2021-09-21 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US11827609B2 (en) | 2016-09-02 | 2023-11-28 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US11396509B2 (en) | 2019-04-17 | 2022-07-26 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
US11583531B2 (en) | 2019-04-17 | 2023-02-21 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
US11286257B2 (en) | 2019-06-28 | 2022-03-29 | Gilead Sciences, Inc. | Processes for preparing toll-like receptor modulator compounds |
Also Published As
Publication number | Publication date |
---|---|
US20100305117A1 (en) | 2010-12-02 |
WO2008009079A2 (en) | 2008-01-24 |
WO2008009079A3 (en) | 2009-05-07 |
US10144736B2 (en) | 2018-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10144736B2 (en) | Substituted pteridines useful for the treatment and prevention of viral infections | |
US12049461B2 (en) | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | |
US8338435B2 (en) | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | |
US8673929B2 (en) | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | |
US8232278B2 (en) | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | |
US20090318456A1 (en) | Substituted pteridines for the treatment and prevention of viral infections | |
US8637531B2 (en) | Pyrido(3,2-d)pyridmidines useful for treating viral infections | |
US8143394B2 (en) | Pyrido(3,2-d)pyrimidines useful for treating viral infections | |
US20080182870A1 (en) | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | |
US20090036430A1 (en) | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment | |
US20080004285A1 (en) | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment | |
US9573966B2 (en) | Anti-cancer activity of novel bicyclic heterocycles | |
EP1663244B1 (en) | Pteridine derivatives for the treatment of tnf-alpha-related diseases. | |
US9822127B2 (en) | GAK modulators as antivirals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GILEAD SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HERDEWIJN, PIET ANDRE MAURITS MARIA;DE JONGHE, STEVEN CESAR ALFONS;WATKINS, WILLIAM JOHN;AND OTHERS;SIGNING DATES FROM 20090224 TO 20090311;REEL/FRAME:048304/0286 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |